Center Announcements

Center Publications/Bibliography

Journal Articles, including Editorials, Reports and Reviews

  1. Baginski, S. G., D. C. Pevear, M. Seipel, S. C. Sun, C. A. Benetatos, S. K. Chunduru, C. M. Rice, and M. S. Collett. 2000. Mechanism of action of a pestivirus antiviral compound. Proc Natl Acad Sci U S A 97:7981-6.
  2. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-4.
  3. Helm, J. F., M. W. Russo, A. K. Biddle, K. N. Simpson, D. F. Ransohoff, and R. S. Sandler. 2000. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol 95:3250-8.
  4. Kolykhalov, A. A., K. Mihalik, S. M. Feinstone, and C. M. Rice. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol 74:2046-51.
  5. Landzberg, B. R., and I. M. Jacobson. 2000. An unusual case of acute colitis. Lancet 355:1786.
  6. Lee, E., C. E. Stocks, S. M. Amberg, C. M. Rice, and M. Lobigs. 2000. Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production. J Virol 74:24-32.
  7. Reed, K. E., and C. M. Rice. 2000. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242:55-84.
  8. Russo, M. W., S. L. Zacks, R. S. Sandler, and R. S. Brown. 2000. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 31:358-63.
  9. Talal, A. H., C. L. Moe, A. A. Lima, K. A. Weigle, L. Barrett, S. I. Bangdiwala, M. K. Estes, and R. L. Guerrant. 2000. Seroprevalence and seroincidence of Norwalk-like virus infection among Brazilian infants and children. J Med Virol 61:117-24.
  10. Talon, J., C. M. Horvath, R. Polley, C. F. Basler, T. Muster, P. Palese, and A. Garcia-Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 74:7989-96.
  11. Tellinghuisen, T. L., and R. J. Kuhn. 2000. Nucleic acid-dependent cross-linking of the nucleocapsid protein of Sindbis virus. J Virol 74:4302-9.
  12. Wolk, B., D. Sansonno, H. G. Krausslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 74:2293-304.
  13. Bergqvist, A., and C. M. Rice. 2001. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J Virol 75:772-81.
  14. Canchis, P. W., and A. H. Talal. 2001. Editorial Comment: Nevirapine and hepatitis-tread cautiously. AIDS Read 11:380-381.
  15. Cheng, W. F., C. F. Hung, C. Y. Chai, K. F. Hsu, L. He, C. M. Rice, M. Ling, and T. C. Wu. 2001. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166:6218-26.
  16. Dustin, L. B. 2001. Ratiometric analysis of calcium mobilization. Clinical and Applied Immunology Reviews 1:5-15.
  17. Dustin, M. L., and L. B. Dustin. 2001. The immunological relay race: B cells take antigen by synapse. Nat Immunol 2:480-2.
  18. Flint, M., E. R. Quinn, and S. Levy. 2001. In search of hepatitis C virus receptor(s). Clin Liver Dis 5:873-93.
  19. Frolov, I., R. Hardy, and C. M. Rice. 2001. Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA 7:1638-51.
  20. Geddes, S., P. Holst, J. Grotzinger, R. Gill, P. Nugent, P. De Meyts, A. Wollmer, S. Wood, and J. Pitts. 2001. Structure-function studies of an IGF-I analogue that can be chemically cleaved to a two-chain mini-IGF-I. Protein Eng 14:61-5.
  21. Grakoui, A., H. L. Hanson, and C. M. Rice. 2001. Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology 33:489-95.
  22. Hammond, A. L., J. Lewis, J. May, J. Albert, P. Balfe, and J. A. McKeating. 2001. Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization. J Virol 75:5593-603.
  23. Hugle, T., F. Fehrmann, E. Bieck, M. Kohara, H. G. Krausslich, C. M. Rice, H. E. Blum, and D. Moradpour. 2001. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284:70-81.
  24. Jacobson, I. M. 2001. Managing chronic hepatitis C virus infection. Hospital Physician January:34-41.
  25. Kersh, G. J., M. J. Miley, C. A. Nelson, A. Grakoui, S. Horvath, D. L. Donermeyer, J. Kappler, P. M. Allen, and D. H. Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 166:3345-54.
  26. Kost, R. G., A. Hurley, L. Zhang, M. Vesanen, A. Talal, S. Furlan, P. Caldwell, J. Johnson, L. Smiley, D. Ho, and M. Markowitz. 2001. Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients. J Acquir Immune Defic Syndr 26:332-9.
  27. Lindsay, K. L., C. Trepo, T. Heintges, M. L. Shiffman, S. C. Gordon, J. C. Hoefs, E. R. Schiff, Z. D. Goodman, M. Laughlin, R. Yao, J. K. Albrecht, and (Jacobson). 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
  28. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, J. K. Albrecht, and (Jacobson). 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-65.
  29. Min, A. D., J. L. Jones, S. Esposito, E. Lebovics, I. M. Jacobson, F. M. Klion, I. S. Goldman, J. M. Geders, H. Tobias, C. Bodian, and H. C. Bodenheimer, Jr. 2001. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroenterol 96:1143-9.
  30. Moriya, O., M. Matsui, M. Osorio, H. Miyazawa, C. M. Rice, S. M. Feinstone, S. H. Leppla, J. M. Keith, and T. Akatsuka. 2001. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20:789-96.
  31. Myers, T. M., V. G. Kolupaeva, E. Mendez, S. G. Baginski, I. Frolov, C. U. Hellen, and C. M. Rice. 2001. Efficient translation initiation is required for replication of bovine viral diarrhea virus subgenomic replicons. J Virol 75:4226-38.
  32. Owsianka, A., R. F. Clayton, L. D. Loomis-Price, J. A. McKeating, and A. H. Patel. 2001. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82:1877-83.
  33. Paragas, J., J. Talon, R. E. O'Neill, D. K. Anderson, A. Garcia-Sastre, and P. Palese. 2001. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. J Virol 75:7375-83.
  34. Qu, L., L. K. McMullan, and C. M. Rice. 2001. Isolation and characterization of noncytopathic pestivirus mutants reveals a role for nonstructural protein NS4B in viral cytopathogenicity. J Virol 75:10651-62.
  35. Quinn, E. R., C. H. Chan, K. G. Hadlock, S. K. Foung, M. Flint, and S. Levy. 2001. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98:3745-9.
  36. Randall, G., and C. M. Rice. 2001. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies. Curr Opin Infect Dis 14:743-7.
  37. Russo, M. W., and R. S. Brown, Jr. 2001. Should patients with chronic hepatitis C who have normal ALT levels be treated? Curr Gastroenterol Rep 3:49-53.
  38. Schmidt-Mende, J., E. Bieck, T. Hugle, F. Penin, C. M. Rice, H. E. Blum, and D. Moradpour. 2001. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 276:44052-63.
  39. Talal, A. H., C. E. Irwin, D. T. Dieterich, H. Yee, and L. Zhang. 2001. Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue. J Acquir Immune Defic Syndr 26:208-17.
  40. Talal, A. H., S. Monard, M. Vesanen, Z. Zheng, A. Hurley, Y. Cao, F. Fang, L. Smiley, J. Johnson, R. Kost, and M. H. Markowitz. 2001. Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue. J Acquir Immune Defic Syndr 26:1-7.
  41. Talal, A. H., K. Weisz, T. Hau, S. Kreiswirth, and D. T. Dieterich. 2001. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 96:2802-4.
  42. Tellinghuisen, T. L., R. Perera, and R. J. Kuhn. 2001. In vitro assembly of Sindbis virus core-like particles from cross-linked dimers of truncated and mutant capsid proteins. J Virol 75:2810-7.
  43. Tellinghuisen, T. L., R. Perera, and R. J. Kuhn. 2001. Genetic and biochemical studies on the assembly of an enveloped virus. Genet Eng (N Y) 23:83-112.
  44. You, S., B. Falgout, L. Markoff, and R. Padmanabhan. 2001. In vitro RNA synthesis from exogenous dengue viral RNA templates requires long range interactions between 5'- and 3'-terminal regions that influence RNA structure. J Biol Chem 276:15581-91.
  45. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:13001-14.
  46. Buonocore, L., K. J. Blight, C. M. Rice, and J. K. Rose. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 76:6865-72.
  47. Catalano, M. F., J. E. Geenen, G. A. Lehman, J. H. Siegel, L. Jacob, M. J. McKinley, I. Raijman, P. Meier, I. M. Jacobson, R. Kozarek, F. H. Al-Kawas, S. K. Lo, K. S. Dua, J. Baille, G. G. Ginsberg, W. Parsons, S. M. Meyerson, S. Cohen, D. B. Nelson, J. D. McHattie, and D. L. Carr-Locke. 2002. "Tannenbaum" Teflon stents versus traditional polyethylene stents for treatment of malignant biliary stricture. Gastrointest Endosc 55:354-8.
  48. Di Bisceglie, A. M., J. McHutchison, and C. M. Rice. 2002. New therapeutic strategies for hepatitis C. Hepatology 35:224-31.
  49. Frolova, E. I., R. Z. Fayzulin, S. H. Cook, D. E. Griffin, C. M. Rice, and I. Frolov. 2002. Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol 76:11254-64.
  50. Herrine, S. K., I. M. Jacobson, and R. S. Koff. 2002. Progress against hepatitis C infection. Patient Care 3:11-20.
  51. Jeffs, S. A., C. Shotton, P. Balfe, and J. A. McKeating. 2002. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J Gen Virol 83:2723-32.
  52. Kuemmerer, B. M., and C. M. Rice. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol 76:4773-84.
  53. Kumar, K. S., J. Lefkowitch, M. W. Russo, C. Hesdorffer, M. Kinkhabwala, S. Kapur, J. C. Emond, and R. S. Brown, Jr. 2002. Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology 122:2026-31.
  54. Kumar, K. S., M. W. Russo, A. C. Borczuk, M. Brown, S. P. Esposito, S. J. Lobritto, I. M. Jacobson, and R. S. Brown, Jr. 2002. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 97:2432-40.
  55. Lindenbach, B. D., and C. M. Rice. 2002. RNAi targeting an animal virus: news from the front. Mol Cell 9:925-7.
  56. Lindenbach, B. D., J. Y. Sgro, and P. Ahlquist. 2002. Long-distance base pairing in flock house virus RNA1 regulates subgenomic RNA3 synthesis and RNA2 replication. J Virol 76:3905-19.
  57. Lorenz, I. C., S. L. Allison, F. X. Heinz, and A. Helenius. 2002. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 76:5480-91.
  58. Major, M. E., K. Mihalik, M. Puig, B. Rehermann, M. Nascimbeni, C. M. Rice, and S. M. Feinstone. 2002. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76:6586-95.
  59. Marcotrigiano, J., and S. K. Burley. 2002. Structural biology of eIF4F: mRNA recognition and preparation in eukaryotic translation initiation. Adv Protein Chem 61:269-97.
  60. Mizukoshi, E., M. Nascimbeni, J. B. Blaustein, K. Mihalik, C. M. Rice, T. J. Liang, S. M. Feinstone, and B. Rehermann. 2002. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol 76:6093-103.
  61. Moriya, O., M. Matsui, M. Osorio, H. Miyazawa, C. M. Rice, S. M. Feinstone, S. H. Leppla, J. M. Keith, and T. Akatsuka. 2002. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20:789-96.
  62. Mueller, A., N. G. Mahmoud, M. C. Goedecke, J. A. McKeating, and P. G. Strange. 2002. Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 135:1033-43.
  63. Niedzwiecka, A., J. Marcotrigiano, J. Stepinski, M. Jankowska-Anyszka, A. Wyslouch-Cieszynska, M. Dadlez, A. C. Gingras, P. Mak, E. Darzynkiewicz, N. Sonenberg, S. K. Burley, and R. Stolarski. 2002. Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol 319:615-35.
  64. Paulson, M., C. Press, E. Smith, N. Tanese, and D. E. Levy. 2002. IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol 4:140-7.
  65. Russo, M. W., and I. M. Jacobson. 2002. Nonalcoholic fatty liver disease. Hospital Physician November:26-41.
  66. Russo, M. W., P. F. Jacques, M. Mauro, P. Odell, and R. S. Brown, Jr. 2002. Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl 8:271-7.
  67. Talal, A. 2002. Opportunistic infections in HIV-infected individuals: hepatitis C virus. Lancet 360:584-6.
  68. Talal, A. H. 2002. Hepatitis C virus in people with HIV infection. Lancet 360:2089.
  69. Talal, A. H., P. W. Canchis, and I. Jacobson. 2002. The HCV and HIV coinfected patient: what have we learned about pathophysiology? Curr Gastroenterol Rep 4:15-22.
  70. Tellinghuisen, T. L., and C. M. Rice. 2002. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 5:419-27.
  71. Zhang, L., L. Rowe, T. He, C. Chung, J. Yu, W. Yu, A. Talal, M. Markowitz, and D. D. Ho. 2002. Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection. J Virol 76:9465-73.
  72. Ahmed, F., and A. H. Talal. 2003. Proactive management of hematologic adverse effects in HIV/HCV co-infected patients under treatment with pegylated interferon and ribavirin. HIV/HCV Coinfection Monthly 2:1-9.
  73. Atkinson, J., B. R. Edlin, E. A. Engels, A. H. Kral, K. Seal, C. J. Gamache, D. Whitby, and T. R. O'Brien. 2003. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 187:974-81.
  74. Bick, M. J., J. W. Carroll, G. Gao, S. P. Goff, C. M. Rice, and M. R. MacDonald. 2003. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77:11555-62.
  75. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77:3181-90.
  76. Bouamr, F., J. A. Melillo, M. Q. Wang, K. Nagashima, M. de Los Santos, A. Rein, and S. P. Goff. 2003. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101. J Virol 77:11882-95.
  77. Bredenbeek, P. J., E. A. Kooi, B. Lindenbach, N. Huijkman, C. M. Rice, and W. J. Spaan. 2003. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol 84:1261-8.
  78. Cannon, M. J., S. C. Dollard, J. B. Black, B. R. Edlin, C. Hannah, S. E. Hogan, M. M. Patel, H. W. Jaffe, M. K. Offermann, T. J. Spira, P. E. Pellett, and C. J. Gunthel. 2003. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. Aids 17:215-22.
  79. Cocquerel, L., E. R. Quinn, M. Flint, K. G. Hadlock, S. K. Foung, and S. Levy. 2003. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol 77:1604-9.
  80. Concha, L. B., H. E. Carlson, A. Heimann, G. V. Lake-Bakaar, and A. F. Paal. 2003. Interferon-induced hypopituitarism. Am J Med 114:161-3.
  81. Davidson, P. J., R. L. McLean, A. H. Kral, A. A. Gleghorn, B. R. Edlin, and A. R. Moss. 2003. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health 80:261-73.
  82. De Francesco, R., and C. M. Rice. 2003. New therapies on the horizon for hepatitis C: are we close? Clin Liver Dis 7:211-42, xi.
  83. DiMichele, D. M., G. Mirani, P. W. Canchis, D. W. Trost, and A. H. Talal. 2003. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 9:613-8.
  84. Dustin, L. B. 2003. Literature review: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Hepatitis Index and Reviews 1:12.
  85. Dustin, L. B. 2003. Literature review: Does a betaretrovirus infection trigger primary biliary cirrhosis? Hepatitis Index and Reviews 1:10.
  86. Edlin, B. R. 2003. Literature review: The tattooing paradox: Are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Hepatitis Index and Reviews 1:14.
  87. Edlin, B. R. 2003. Literature review: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Hepatitis Index and Reviews 1:11.
  88. Edlin, B. R. 2003. Literature review: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Hepatitis Index and Reviews 1:11.
  89. Edlin, B. R. 2003. Literature review: Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anesthetic ampoules and A survey of doctor's and nurses' knowledge, attitudes and compliance withinfection control guidelines in Birmingham teaching hospitals. Hepatitis Index and Reviews 1:10.
  90. Elazar, M., K. H. Cheong, P. Liu, H. B. Greenberg, C. M. Rice, and J. S. Glenn. 2003. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 77:6055-61.
  91. Evans, M. J., and C. M. Rice. 2003. Hepatitis C virus replicons finally get to second base. Gastroenterology 125:1892-5.
  92. Gauthier, A., and B. B. Finlay. 2003. Translocated intimin receptor and its chaperone interact with ATPase of the type III secretion apparatus of enteropathogenic Escherichia coli. J Bacteriol 185:6747-55.
  93. Golia, P., and A. Talal. 2003. Literature Review: Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatitis Index and Reviews 1:13.
  94. Golia, P., and A. Talal. 2003. Literature review: A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. Hepatitis Index and Reviews 1:10.
  95. Golia, P., and A. Talal. 2003. Literature review: Occult HBV infection with YMDD variants in hemodialysis patients with chronic HCV infection. Hepatitis Index and Reviews 1:12.
  96. Golia, P., and A. Talal. 2003. Editorial comment: Diagnosis of acute HIV infection in hepatitis C treatment nonresponders--is extra vigilance required? AIDS Read 13:288-90.
  97. Gonzalez, S., and A. Talal. 2003. Hepatitis C Virus in HIV-infected Individuals: An Emerging Comorbidity with Significant Implications. Sem Liver Disease 23:149-166.
  98. Gonzalez, S. A., and I. M. Jacobson. 2003. Literature review: Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatitis Index and Reviews 1:11.
  99. Gonzalez, S. A., and I. M. Jacobson. 2003. Literature review: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Hepatitis Index and Reviews 1:12.
  100. Grakoui, A., N. H. Shoukry, D. J. Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy, C. M. Rice, and C. M. Walker. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-62.
  101. Hardy, R. W., J. Marcotrigiano, K. J. Blight, J. E. Majors, and C. M. Rice. 2003. Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol 77:2029-37.
  102. Hsu, M., J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C. M. Rice, and J. A. McKeating. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100:7271-6.
  103. Jacobson, I. M. 2003. Literature review: Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatitis Index and Reviews 1:12.
  104. Jacobson, I. M. 2003. Literature review: Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Hepatitis Index and Reviews 1:9.
  105. Jacobson, I. M. 2003. Literature review: The prevalence and etiology of elevated aminotransferase levels in the United States. Hepatitis Index and Reviews 1:14.
  106. Jacobson, I. M. 2003. Literature review: Long-term suppression of hepatitis B e antigen negative chronic hepatitis B by 24-month interferon therapy. Hepatitis Index and Reviews 1:12.
  107. Jacobson, I. M. 2003. Literature review: Interferon-alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Hepatitis Index and Reviews 1:11.
  108. Kral, A. H., J. Lorvick, L. Gee, P. Bacchetti, B. Rawal, M. Busch, and B. R. Edlin. 2003. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol 157:915-22.
  109. Kushner, D. B., B. D. Lindenbach, V. Z. Grdzelishvili, A. O. Noueiry, S. M. Paul, and P. Ahlquist. 2003. Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc Natl Acad Sci U S A 100:15764-9.
  110. Lake-Bakaar, G. 2003. Literature review: Zoonotic transmission of hepatitis E virus from deer to human beings. Hepatitis Index and Reviews 1:15.
  111. Lake-Bakaar, G. 2003. Literature review: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin and Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatitis Index and Reviews 1:15.
  112. Lake-Bakaar, G. 2003. Literature review: L-Sign (CD209L) is a liver-specific capture receptor for hepatitis C virus. Hepatitis Index and Reviews 1:11.
  113. Lake-Bakaar, G. 2003. Current and future therapy for chronic hepatitis C virus liver disease. Curr Drug Targets Infect Disord 3:247-53.
  114. Lake-Bakaar, G., and S. D. Frost. 2003. Viral kinetics and hepatitis C. Hepatology 38:1588; author reply 1588-1590.
  115. Lake-Bakaar, G., L. Ruffini, and P. Kuzmic. 2003. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 48:126-39.
  116. Lindenbach, B. D., and C. M. Rice. 2003. Evasive maneuvers by hepatitis C virus. Hepatology 38:769-71.
  117. Lindenbach, B. D., and C. M. Rice. 2003. Molecular biology of flaviviruses. Adv Virus Res 59:23-61.
  118. Liu, L. U., T. D. Schiano, N. Lau, M. O'Rourke, A. D. Min, S. H. Sigal, M. Drooker, and H. C. Bodenheimer, Jr. 2003. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 3:1273-7.
  119. Lorenz, I. C., J. Kartenbeck, A. Mezzacasa, S. L. Allison, F. X. Heinz, and A. Helenius. 2003. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 77:4370-82.
  120. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, C. L. Brosgart, and The Adefovir Dipivoxil 437 Study Group (Jacobson). 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-16.
  121. Nascimbeni, M., E. Mizukoshi, M. Bosmann, M. E. Major, K. Mihalik, C. M. Rice, S. M. Feinstone, and B. Rehermann. 2003. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77:4781-93.
  122. Nelson, D., R. Schuch, S. Zhu, D. M. Tscherne, and V. A. Fischetti. 2003. Genomic sequence of C1, the first streptococcal phage. J Bacteriol 185:3325-32.
  123. Ni, J., E. Hembrador, A. M. Di Bisceglie, I. M. Jacobson, A. H. Talal, D. Butera, C. M. Rice, T. J. Chambers, and L. B. Dustin. 2003. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 170:3429-39.
  124. Nomaguchi, M., M. Ackermann, C. Yon, S. You, R. Padmanabhan, and R. Padmanbhan. 2003. De novo synthesis of negative-strand RNA by Dengue virus RNA-dependent RNA polymerase in vitro: nucleotide, primer, and template parameters. J Virol 77:8831-42.
  125. Pfeiffer, R. M., Y. Tanaka, A. E. Yeo, T. Umemura, K. H. Seal, J. W. Shih, H. J. Alter, B. R. Edlin, and T. R. O'Brien. 2003. Prevalence of SEN viruses among injection drug users in the San Francisco Bay area. J Infect Dis 188:13-8.
  126. Pohlmann, S., J. Zhang, F. Baribaud, Z. Chen, G. J. Leslie, G. Lin, A. Granelli-Piperno, R. W. Doms, C. M. Rice, and J. A. McKeating. 2003. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77:4070-80.
  127. Poles, M. A., S. Barsoum, W. Yu, J. Yu, P. Sun, J. Daly, T. He, S. Mehandru, A. Talal, M. Markowitz, A. Hurley, D. Ho, and L. Zhang. 2003. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy. J Virol 77:10456-67.
  128. Powers, K. A., N. M. Dixit, R. M. Ribeiro, P. Golia, A. H. Talal, and A. S. Perelson. 2003. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 23 Suppl 1:13-8.
  129. Purow, D. B., and I. M. Jacobson. 2003. Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications. Postgrad Med 114:65-8, 73-6.
  130. Randall, G., A. Grakoui, and C. M. Rice. 2003. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A 100:235-40.
  131. Rice, C. M. 2003. Virology: fresh assault on hepatitis C. Nature 426:129-31.
  132. Rivadeneira, D. E., M. Pochapin, S. R. Grobmyer, M. D. Lieberman, P. J. Christos, I. Jacobson, and J. M. Daly. 2003. Comparison of linear array endoscopic ultrasound and helical computed tomography for the staging of periampullary malignancies. Ann Surg Oncol 10:890-7.
  133. Roccasecca, R., H. Ansuini, A. Vitelli, A. Meola, E. Scarselli, S. Acali, M. Pezzanera, B. B. Ercole, J. McKeating, A. Yagnik, A. Lahm, A. Tramontano, R. Cortese, and A. Nicosia. 2003. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77:1856-67.
  134. Russo, M. W., C. D. Goldsweig, I. M. Jacobson, and R. S. Brown, Jr. 2003. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 98:1610-5.
  135. Russo, M. W., A. Sood, I. M. Jacobson, and R. S. Brown, Jr. 2003. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 98:2521-7.
  136. Schiff, E. R., J. L. Dienstag, S. Karayalcin, I. S. Grimm, R. P. Perrillo, P. Husa, R. A. de Man, Z. Goodman, L. D. Condreay, L. M. Crowther, M. A. Woessner, P. J. McPhillips, N. A. Brown, and The International Lamivudine Investigator Group (Jacobson). 2003. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 38:818-26.
  137. Seal, K. H., M. Downing, A. H. Kral, S. Singleton-Banks, J. P. Hammond, J. Lorvick, D. Ciccarone, and B. R. Edlin. 2003. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health 80:291-301.
  138. Seal, K. H., A. H. Kral, J. Lorvick, A. McNees, L. Gee, and B. R. Edlin. 2003. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 71:127-31.
  139. Shata, M. T., M. M. Shan, N. Tricoche, A. Talal, M. Perkus, and A. Prince. 2003. Optimization of recombinant vaccinia-based ELISPOT assay. J Immunol Methods 283:281-9.
  140. Shoukry, N. H., A. Grakoui, M. Houghton, D. Y. Chien, J. Ghrayeb, K. A. Reimann, and C. M. Walker. 2003. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197:1645-55.
  141. Snead, J., M. Downing, J. Lorvick, B. Garcia, R. Thawley, S. Kegeles, and B. R. Edlin. 2003. Secondary syringe exchange among injection drug users. J Urban Health 80:330-48.
  142. Urso, B., M. M. Ilondo, P. A. Holst, C. T. Christoffersen, M. Ouwens, S. Giorgetti, E. Van Obberghen, D. Naor, H. Tornqvist, and P. De Meyts. 2003. IRS-4 mediated mitogenic signalling by insulin and growth hormone in LB cells, a murine T-cell lymphoma devoid of IGF-I receptors. Cell Signal 15:385-94.
  143. Wang, M. Q., W. Kim, G. Gao, T. A. Torrey, H. C. Morse, 3rd, P. De Camilli, and S. P. Goff. 2003. Endophilins interact with Moloney murine leukemia virus Gag and modulate virion production. J Biol 3:4.
  144. Woollard, D. J., A. Grakoui, N. H. Shoukry, K. K. Murthy, K. J. Campbell, and C. M. Walker. 2003. Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. Hepatology 38:1297-306.
  145. Yun, S. I., S. Y. Kim, C. M. Rice, and Y. M. Lee. 2003. Development and application of a reverse genetics system for Japanese encephalitis virus. J Virol 77:6450-65.
  146. Agapov, E. V., C. L. Murray, I. Frolov, L. Qu, T. M. Myers, and C. M. Rice. 2004. Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus. J Virol 78:2414-25.
  147. Ahmed, F., and I. M. Jacobson. 2004. Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterol Clin North Am 33:513-26, viii.
  148. Ala, A., and M. L. Schilsky. 2004. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis 8:787-805, viii.
  149. Backmund, M., K. Meyer, and B. R. Edlin. 2004. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39:1540-3.
  150. Canchis, P. W., S. A. Gonzalez, M. I. Fiel, L. Chiriboga, H. Yee, B. R. Edlin, I. M. Jacobson, and A. H. Talal. 2004. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver Int 24:198-203.
  151. Canchis, P. W., H. T. Yee, M. I. Fiel, D. T. Dieterich, R. C. Liu, L. Chiriboga, I. M. Jacobson, B. R. Edlin, and A. H. Talal. 2004. Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV-Coinfected Patients. J Acquir Immune Defic Syndr 37:1125-1131.
  152. Chang, H. M., M. Paulson, M. Holko, C. M. Rice, B. R. Williams, I. Marie, and D. E. Levy. 2004. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A 101:9578-83.
  153. Charlebois, E. D., F. Perdreau-Remington, B. Kreiswirth, D. R. Bangsberg, D. Ciccarone, B. A. Diep, V. L. Ng, K. Chansky, B. R. Edlin, and H. F. Chambers. 2004. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 39:47-54.
  154. Dustin, L. B. 2004. Reexamining the role of the humoral immune response in control of hepatitis C virus infection. Hepatology 40:756-8.
  155. Edlin, B. R. 2004. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy 15:81-91.
  156. Elazar, M., P. Liu, C. M. Rice, and J. S. Glenn. 2004. An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication. J Virol 78:11393-400.
  157. Engler, O. B., R. A. Schwendener, W. J. Dai, B. Wolk, W. Pichler, D. Moradpour, T. Brunner, and A. Cerny. 2004. A liposomal peptide vaccine inducing CD8(+) T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23:58-68.
  158. Evans, M. J., E. Bacharach, and S. P. Goff. 2004. RNA sequences in the Moloney murine leukemia virus genome bound by the Gag precursor protein in the yeast three-hybrid system. J Virol 78:7677-84.
  159. Evans, M. J., C. M. Rice, and S. P. Goff. 2004. Genetic interactions between hepatitis C virus replicons. J Virol 78:12085-9.
  160. Evans, M. J., C. M. Rice, and S. P. Goff. 2004. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 101:13038-43.
  161. Fernandez, J., D. Taylor, D. R. Morhardt, K. Mihalik, M. Puig, C. M. Rice, S. M. Feinstone, and M. E. Major. 2004. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 78:9782-9.
  162. Flint, M., C. Logvinoff, C. M. Rice, and J. A. McKeating. 2004. Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol 78:6875-82.
  163. Gauthier, A., and C. M. Rice. 2004. Molecular Virology of Hepatitis C: Consorting of Proteins. Hepatitis Index and Reviews II:3-4, 14.
  164. Gonzalez, S. A., and I. M. Jacobson. 2004. The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation. Cleveland Clinic Journal of Medicine 71:S22-S26.
  165. Gorchakov, R., E. Frolova, B. R. Williams, C. M. Rice, and I. Frolov. 2004. PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol 78:8455-67.
  166. Gorchakov, R., R. Hardy, C. M. Rice, and I. Frolov. 2004. Selection of functional 5' cis-acting elements promoting efficient sindbis virus genome replication. J Virol 78:61-75.
  167. Gremion, C., B. Grabscheid, B. Wolk, D. Moradpour, J. Reichen, W. Pichler, and A. Cerny. 2004. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 78:2152-7.
  168. Guo, X., J. W. Carroll, M. R. MacDonald, S. P. Goff, and G. Gao. 2004. The Zinc Finger Antiviral Protein Directly Binds to Specific Viral mRNAs through the CCCH Zinc Finger Motifs. J Virol 78:12781-7.
  169. Jacobson, I. M. 2004. Literature review: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Hepatitis Index and Reviews 2:11.
  170. Jacobson, I. M., F. Ahmed, M. W. Russo, E. Lebovics, D. T. Dieterich, S. P. Esposito, N. Bach, F. Klion, H. Tobias, L. Antignano, R. S. Brown, Jr., D. Gabbaizadeh, J. Geders, and H. Levendoglu. 2004. Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 99:1700-5.
  171. Jacobson, I. M., and J. McHutchison. 2004. Response to article by Formann et Al. (2003). J Viral Hepat 11:187; author reply 189-90.
  172. Keeffe, E. B., D. T. Dieterich, S. H. Han, I. M. Jacobson, P. Martin, E. R. Schiff, H. Tobias, and T. L. Wright. 2004. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2:87-106.
  173. Kral, A. H., K. Page-Shafer, B. R. Edlin, T. Kellogg, E. Riley, L. Gee, A. Moss, M. Busch, J. D. Klausner, J. Dilley, and W. McFarland. 2004. Persistent HIV incidence among injection drug users in San Francisco during the 1990s: results of five studies. J Acquir Immune Defic Syndr 37:1667-9.
  174. Larsson, M., E. Babcock, A. Grakoui, N. Shoukry, G. Lauer, C. Rice, C. Walker, and N. Bhardwaj. 2004. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 78:6151-61.
  175. Lin, A. W., S. A. Gonzalez, S. Cunningham-Rundles, G. Dorante, S. Marshall, A. Tignor, C. Ha, I. M. Jacobson, and A. H. Talal. 2004. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 137:408-16.
  176. Liu, L. U., H. A. Haddadin, C. A. Bodian, S. H. Sigal, J. D. Korman, H. C. Bodenheimer, Jr., and T. D. Schiano. 2004. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 126:142-8.
  177. Logvinoff, C., M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, and J. A. McKeating. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101:10149-54.
  178. Longman, R. S., A. H. Talal, I. M. Jacobson, M. L. Albert, and C. M. Rice. 2004. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103:1026-9.
  179. Major, M. E., H. Dahari, K. Mihalik, M. Puig, C. M. Rice, A. U. Neumann, and S. M. Feinstone. 2004. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39:1709-20.
  180. Manigold, T., C. Piccirillo, E.-C. Shin, K. Mihalik, C. M. Rice, and B. Rehermann. 2004. CD4+ regulatory T cells control effector functions of hepatitis C virus-specific memory CD8+ T cells. J Exp Med In revision.
  181. Matto, M., C. M. Rice, B. Aroeti, and J. S. Glenn. 2004. Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. J Virol 78:12047-53.
  182. McKeating, J. A., L. Q. Zhang, C. Logvinoff, M. Flint, J. Zhang, J. Yu, D. Butera, D. D. Ho, L. B. Dustin, C. M. Rice, and P. Balfe. 2004. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 78:8496-505.
  183. Moradpour, D., M. J. Evans, R. Gosert, Z. Yuan, H. E. Blum, S. P. Goff, B. D. Lindenbach, and C. M. Rice. 2004. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 78:7400-9.
  184. Neimark, E., M. L. Schilsky, and B. L. Shneider. 2004. Wilson's disease and hemochromatosis. Adolesc Med Clin 15:175-94, xi.
  185. Randall, G., and C. M. Rice. 2004. Interfering with hepatitis C virus RNA replication. Virus Res 102:19-25.
  186. Russo, M. W., and I. M. Jacobson. 2004. How to use statins in patients with chronic liver disease. Cleve Clin J Med 71:58-62.
  187. Schilsky, M. L., and M. Kinkhabwala. 2004. Hepatitis C and liver transplantation. Hepatitis Index and Reviews 2:5-6.
  188. Syder, A. J., S. M. Karam, J. C. Mills, J. E. Ippolito, H. R. Ansari, V. Farook, and J. I. Gordon. 2004. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci U S A 101:4471-6.
  189. Talal, A. H., M. T. Shata, M. Markatou, G. Dorante, A. Chadburn, R. Koch, A. U. Neumann, R. M. Ribeiro, and A. S. Perelson. 2004. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 35:103-13.
  190. Tanaka, Y., R. Pfeiffer, A. E. Yeo, M. Mizokami, B. R. Edlin, P. Castle, T. R. O'Brien, H. J. Alter, and J. W. Shih. 2004. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. J Med Virol 73:123-30.
  191. Tellinghuisen, T. L., J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice. 2004. The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein. J Biol Chem 279:48576-87.
  192. Tsui, R., B. L. Herring, J. D. Barbour, R. M. Grant, P. Bacchetti, A. Kral, B. R. Edlin, and E. L. Delwart. 2004. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 78:94-103.
  193. Warabi, K., W. T. Zimmerman, J. Shen, A. Gauthier, M. Robertson, B. B. Finlay, R. van Soest, and R. J. Andersen. 2004. Pacymoside A, a novel antimicrobial glycolipid isolated from the marine sponge Pachymatisma johnstonia. Canadian Journal of Chemistry 82:101-112.
  194. You, S., D. D. Stump, A. D. Branch, and C. M. Rice. 2004. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78:1352-66.
  195. Zhang, J., G. Randall, A. Higginbottom, P. Monk, C. M. Rice, and J. A. McKeating. 2004. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78:1448-55.
  196. Ahmed, F., and I. M. Jacobson. 2005. Management of hematologic side effects: impact on compliance and efficacy. Hepatitis Reports 4:56-60.
  197. Ahmed, F., L. Petrovic, E. Rosen, R. Gonzalez, and I. M. Jacobson. 2005. Fenofibrate-induced cirrhosis. Dig Dis Sci 50:312-3.
  198. Ala, A., J. Borjigin, A. Rochwarger, and M. Schilsky. 2005. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology 41:668-70.
  199. Alcon-LePoder, S., M. T. Drouet, P. Roux, M. P. Frenkiel, M. Arborio, A. M. Durand-Schneider, M. Maurice, I. Le Blanc, J. Gruenberg, and M. Flamand. 2005. The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity. J Virol 79:11403-11.
  200. Barba-Spaeth, G., R. S. Longman, M. L. Albert, and C. M. Rice. 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202:1179-84.
  201. Beatch, M. D., J. C. Everitt, L. J. Law, and T. C. Hobman. 2005. Interactions between rubella virus capsid and host protein p32 are important for virus replication. J Virol 79:10807-20.
  202. Brown, R. S. 2005. Hepatitis C and liver transplantation. Nature 436:973-8.
  203. Brown, R. S., Jr. 2005. MARS preconditioning for living donor liver transplantation: panacea or placebo? Liver Int 25:692-5.
  204. Brown, R. S., Jr., and J. R. Lake. 2005. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 5:203-4.
  205. Butera, D., S. Marukian, A. E. Iwamaye, E. Hembrador, T. J. Chambers, A. M. Di Bisceglie, E. D. Charles, A. H. Talal, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106:1175-82.
  206. Butt, A. S., and I. M. Jacobson. 2005. Hepatitis C: Latest treatment guidelines. Consultant 45:960-962.
  207. Butt, A. S., and I. M. Jacobson. 2005. Hepatitis C: Making the diagnosis. Consultant 45:955-959.
  208. Chambers, T. J., X. Fan, D. A. Droll, E. Hembrador, T. Slater, M. W. Nickells, L. B. Dustin, and A. M. Dibisceglie. 2005. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79:3071-83.
  209. Dahari, H., M. Major, X. Zhang, K. Mihalik, C. M. Rice, A. S. Perelson, S. M. Feinstone, and A. U. Neumann. 2005. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128:1056-66.
  210. Downing, M., T. H. Riess, K. Vernon, N. Mulia, M. Hollinquest, C. McKnight, D. C. Jarlais, and B. R. Edlin. 2005. What's community got to do with it? Implementation models of syringe exchange programs. AIDS Educ Prev 17:68-78.
  211. Edlin, B. R., and M. R. Carden. 2005. Written in response to Scott LD: treating hepatitis C in active injection drug users. Am J Gastroenterol 100:2131-2; author reply 2132.
  212. Edlin, B. R., T. F. Kresina, D. B. Raymond, M. R. Carden, M. N. Gourevitch, J. D. Rich, L. W. Cheever, and V. A. Cargill. 2005. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 40 Suppl 5:S276-85.
  213. Gauthier, A., M. L. Robertson, M. Lowden, J. A. Ibarra, J. L. Puente, and B. B. Finlay. 2005. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 49:4101-9.
  214. Gonzalez, S. A., and I. M. Jacobson. 2005. Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging. Am J Gastroenterol 100:977-8.
  215. Hardy, R. W., and C. M. Rice. 2005. Requirements at the 3' end of the sindbis virus genome for efficient synthesis of minus-strand RNA. J Virol 79:4630-9.
  216. Herrine, S. K., R. S. Brown, Jr., D. E. Bernstein, M. S. Ondovik, E. Lentz, and H. Te. 2005. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 50:719-26.
  217. Jacobson, I. M., S. A. Gonzalez, F. Ahmed, E. Lebovics, A. D. Min, H. C. Bodenheimer, Jr., S. P. Esposito, R. S. Brown, Jr., N. Brau, F. M. Klion, H. Tobias, E. J. Bini, N. Brodsky, M. A. Cerulli, A. Aytaman, P. W. Gardner, J. M. Geders, J. E. Spivack, M. G. Rahmin, D. H. Berman, J. Ehrlich, M. W. Russo, M. Chait, D. Rovner, and B. R. Edlin. 2005. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 100:2453-62.
  218. Jones, C. T., C. G. Patkar, and R. J. Kuhn. 2005. Construction and applications of yellow fever virus replicons. Virology 331:247-59.
  219. Klupp, B. G., S. Bottcher, H. Granzow, M. Kopp, and T. C. Mettenleiter. 2005. Complex formation between the UL16 and UL21 tegument proteins of pseudorabies virus. J Virol 79:1510-22.
  220. Klupp, B. G., H. Granzow, R. Klopfleisch, W. Fuchs, M. Kopp, M. Lenk, and T. C. Mettenleiter. 2005. Functional analysis of the pseudorabies virus UL51 protein. J Virol 79:3831-40.
  221. Kowdley, K. V., D. J. Brandhagen, R. G. Gish, N. M. Bass, J. Weinstein, M. L. Schilsky, R. J. Fontana, T. McCashland, S. J. Cotler, B. R. Bacon, E. B. Keeffe, F. Gordon, and N. Polissar. 2005. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129:494-503.
  222. Kral, A. H., J. Lorvick, D. Ciccarone, L. Wenger, L. Gee, A. Martinez, and B. R. Edlin. 2005. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health 82:i43-50.
  223. Lee, Y. M., D. M. Tscherne, S. I. Yun, I. Frolov, and C. M. Rice. 2005. Dual mechanisms of pestiviral superinfection exclusion at entry and RNA replication. J Virol 79:3231-42.
  224. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-6.
  225. Lindenbach, B. D., and C. M. Rice. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436:933-8.
  226. Longman, R. S., A. H. Talal, I. M. Jacobson, C. M. Rice, and M. L. Albert. 2005. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 192:497-503.
  227. Mark-Danieli, M., N. Laham, M. Kenan-Eichler, A. Castiel, D. Melamed, M. Landau, N. M. Bouvier, M. J. Evans, and E. Bacharach. 2005. Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity. J Virol 79:7756-67.
  228. Marks, K. M., L. M. Petrovic, A. H. Talal, M. P. Murray, R. M. Gulick, and M. J. Glesby. 2005. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 192:1943-9.
  229. Moss, J., D. Lapointe-Rudow, J. F. Renz, M. Kinkhabwala, L. M. Dove, P. J. Gaglio, J. C. Emond, and R. S. Brown, Jr. 2005. Select utilization of obese donors in living donor liver transplantation: implications for the donor pool. Am J Transplant 5:2974-81.
  230. Olson, S. H., S. Iyer, J. Scott, O. Erez, S. Samuel, T. Markovits, M. Schwartz, C. Toro, M. Gambarin-Gelwan, and R. C. Kurtz. 2005. Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes 3:39.
  231. Pfeffer, S., A. Sewer, M. Lagos-Quintana, R. Sheridan, C. Sander, F. A. Grasser, L. F. van Dyk, C. K. Ho, S. Shuman, M. Chien, J. J. Russo, J. Ju, G. Randall, B. D. Lindenbach, C. M. Rice, V. Simon, D. D. Ho, M. Zavolan, and T. Tuschl. 2005. Identification of microRNAs of the herpesvirus family. Nat Methods 2:269-76.
  232. Ploss, A., I. Leiner, and E. G. Pamer. 2005. Distinct regulation of H2-M3-restricted memory T cell responses in lymph node and spleen. J Immunol 175:5998-6005.
  233. Ploss, A., A. Tran, E. Menet, I. Leiner, and E. G. Pamer. 2005. Cross-recognition of N-formylmethionine peptides is a general characteristic of H2-M3-restricted CD8+ T cells. Infect Immun 73:4423-6.
  234. Raison, C. L., A. S. Borisov, S. D. Broadwell, L. Capuron, B. J. Woolwine, I. M. Jacobson, C. B. Nemeroff, and A. H. Miller. 2005. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66:41-8.
  235. Raison, C. L., S. D. Broadwell, A. S. Borisov, A. K. Manatunga, L. Capuron, B. J. Woolwine, I. M. Jacobson, C. B. Nemeroff, and A. H. Miller. 2005. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19:23-7.
  236. Rice, C. M., and S. You. 2005. Treating hepatitis C: can you teach old dogs new tricks? Hepatology 42:1455-8.
  237. Rudow, D. L., and R. S. Brown, Jr. 2005. Role of the independent donor advocacy team in ethical decision making. Prog Transplant 15:298-302.
  238. Rudow, D. L., M. Chariton, C. Sanchez, S. Chang, D. Serur, and R. S. Brown, Jr. 2005. Kidney and liver living donors: a comparison of experiences. Prog Transplant 15:185-91.
  239. Ryman, K. D., K. C. Meier, E. M. Nangle, S. L. Ragsdale, N. L. Korneeva, R. E. Rhoads, M. R. MacDonald, and W. B. Klimstra. 2005. Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells. J Virol 79:1487-99.
  240. Schilsky, M. L. 2005. Wilson disease: new insights into pathogenesis, diagnosis, and future therapy. Curr Gastroenterol Rep 7:26-31.
  241. Schilsky, M. L., and I. Oikonomou. 2005. Inherited metabolic liver disease. Curr Opin Gastroenterol 21:275-82.
  242. Seal, K. H., R. Thawley, L. Gee, J. Bamberger, A. H. Kral, D. Ciccarone, M. Downing, and B. R. Edlin. 2005. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 82:303-11.
  243. Shin, E. C., U. Protzer, A. Untergasser, S. M. Feinstone, C. M. Rice, D. Hasselschwert, and B. Rehermann. 2005. Liver-directed gamma interferon gene delivery in chronic hepatitis C. J Virol 79:13412-20.
  244. Sigal, S. H., A. Ala, K. Ivanov, S. Hossain, C. Bodian, T. D. Schiano, A. D. Min, H. C. Bodenheimer, Jr., and S. N. Thung. 2005. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: a possible mechanism to explain the response to antiviral therapy. Liver Transpl 11:82-8.
  245. Sterling, R. K., R. S. Brown, Jr., C. M. Hofmann, V. A. Luketic, R. T. Stravitz, A. J. Sanyal, M. J. Contos, A. S. Mills, V. Smith, and M. L. Shiffman. 2005. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol 100:313-21.
  246. Tao, D., G. Barba-Spaeth, U. Rai, V. Nussenzweig, C. M. Rice, and R. S. Nussenzweig. 2005. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 201:201-9.
  247. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-9.
  248. Verna, E. C., K. H. Hunt, J. F. Renz, D. L. Rudow, S. Hafliger, L. M. Dove, M. Kinkhabwala, J. C. Emond, and R. S. Brown, Jr. 2005. Predictors of candidate maturation among potential living donors. Am J Transplant 5:2549-54.
  249. Weitzman, G., and I. Jacobson. 2005. Cost-effectiveness in hepatitis B. Ann Intern Med 143:757-8; author reply 758-9.
  250. Wolk, B., C. Gremion, N. Ivashkina, O. B. Engler, B. Grabscheid, E. Bieck, H. E. Blum, A. Cerny, and D. Moradpour. 2005. Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins. J Gen Virol 86:1737-46.
  251. Zeremski, M., and A. H. Talal. 2005. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol 43:2-5.
  252. Ahmed, F., and I. M. Jacobson. 2006. Treatment of relapsers after combination therapy for chronic hepatitis C. Infect Dis Clin North Am 20:137-53.
  253. Alkofer, B., B. Samstein, J. V. Guarrera, C. Kin, D. Jan, S. Bellemare, M. Kinkhabwala, R. Brown, Jr., J. C. Emond, and J. F. Renz. 2006. Extended-donor criteria liver allografts. Semin Liver Dis 26:221-33.
  254. Berro, R., K. Kehn, C. de la Fuente, A. Pumfery, R. Adair, J. Wade, A. M. Colberg-Poley, J. Hiscott, and F. Kashanchi. 2006. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol 80:3189-204.
  255. Bourgois, P., A. Martinez, A. Kral, B. R. Edlin, J. Schonberg, and D. Ciccarone. 2006. Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach. PLoS Med 3:e452.
  256. Brewer, G. J., F. Askari, M. T. Lorincz, M. Carlson, M. Schilsky, K. J. Kluin, P. Hedera, P. Moretti, J. K. Fink, R. Tankanow, R. B. Dick, and J. Sitterly. 2006. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:521-7.
  257. Brown Jr, R. S. 2006. Advances in Hepatology: The current state of liver transplantation. Gastroenterol & Hepatology 2:244-246.
  258. Brown, R. S., Jr. 2006. Asymptomatic liver mass. Gastroenterology 131:619-23.
  259. Brown, R. S., Jr. 2006. Evaluating the evidence from clinical trials in chronic hepatitis C. J Viral Hepat 13 Suppl 1:15-25.
  260. Conjeevaram, H. S., M. W. Fried, L. J. Jeffers, N. A. Terrault, T. E. Wiley-Lucas, N. Afdhal, R. S. Brown, S. H. Belle, J. H. Hoofnagle, D. E. Kleiner, and C. D. Howell. 2006. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470-7.
  261. Cristea, I. M., J. W. Carroll, M. P. Rout, C. M. Rice, B. T. Chait, and M. R. MacDonald. 2006. Tracking and elucidating alphavirus-host protein interactions. J Biol Chem 281:30269-78.
  262. de la Fuente, C., M. V. Gupta, Z. Klase, K. Strouss, P. Cahan, T. McCaffery, A. Galante, P. Soteropoulos, A. Pumfery, M. Fujii, and F. Kashanchi. 2006. Involvement of HTLV-I Tax and CREB in aneuploidy: a bioinformatics approach. Retrovirology 3:43.
  263. Dickson, R. C., N. A. Terrault, M. Ishitani, K. R. Reddy, P. Sheiner, V. Luketic, C. Soldevila-Pico, M. Fried, D. Jensen, R. S. Brown, Jr., G. Horwith, R. Brundage, and A. Lok. 2006. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 12:124-33.
  264. Edlin, B. R., and M. R. Carden. 2006. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 42:673-6.
  265. Fink, S. A., and R. S. Brown Jr. 2006. Statistic for Clinicians: Survival Analysis. Gastroenterology & Hepatology 2:380-383.
  266. Fink, S. A., and R. S. Brown Jr. 2006. Pantoprazole reduces size, but not number, of postendoscopic variceal banding-related ulcers. Evidence-Based Gastroenterology 7:19-20.
  267. Flint, M., T. von Hahn, J. Zhang, M. Farquhar, C. T. Jones, P. Balfe, C. M. Rice, and J. A. McKeating. 2006. Diverse CD81 proteins support hepatitis C virus infection. J Virol 80:11331-42.
  268. Gaglio, P. J., and R. S. Brown, Jr. 2006. Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: the transplant hepatologist. J Hepatol 44:655-7.
  269. Gambarin-Gelwan, M., and I. M. Jacobson. 2006. Treatment of nonresponders to standard hepatitis C therapy. Current Hepatitis Reports 5:108-113.
  270. Gambarin-Gelwan, M., and I. M. Jacobson. 2006. Treatment of chronic hepatitis B infection. Gastroenterology and Hepatology Annual Review 1:77-83.
  271. Gonzalez, S. A., R. C. Liu, B. R. Edlin, I. M. Jacobson, and A. H. Talal. 2006. HIV/Hepatitis C Virus-Coinfected Patients With Normal Alanine Aminotransferase Levels. J Acquir Immune Defic Syndr 41:582-589.
  272. Jacobson, I. M. 2006. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol 101 Suppl 1:S13-8.
  273. Keeffe, E. B., D. T. Dieterich, S. H. Han, I. M. Jacobson, P. Martin, E. R. Schiff, H. Tobias, and T. L. Wright. 2006. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4:936-62.
  274. Kichina, J. V., M. Zeremski, L. Aris, K. V. Gurova, E. Walker, R. Franks, A. Y. Nikitin, H. Kiyokawa, and A. V. Gudkov. 2006. Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 25:857-66.
  275. Klopfleisch, R., B. G. Klupp, W. Fuchs, M. Kopp, J. P. Teifke, and T. C. Mettenleiter. 2006. Influence of pseudorabies virus proteins on neuroinvasion and neurovirulence in mice. J Virol 80:5571-6.
  276. Lai, W. K., P. J. Sun, J. Zhang, A. Jennings, P. F. Lalor, S. Hubscher, J. A. McKeating, and D. H. Adams. 2006. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol 169:200-8.
  277. Law, L. J., C. S. Ilkow, W. P. Tzeng, M. Rawluk, D. T. Stuart, T. K. Frey, and T. C. Hobman. 2006. Analyses of phosphorylation events in the rubella virus capsid protein: role in early replication events. J Virol 80:6917-25.
  278. Lefkowitch, J. H., S. J. Lobritto, R. S. Brown, Jr., J. C. Emond, M. L. Schilsky, L. A. Rosenthal, D. M. George, and M. S. Cairo. 2006. Ground-glass, polyglucosan-like hepatocellular inclusions: A "new" diagnostic entity. Gastroenterology 131:713-8.
  279. Lindenbach, B. D., P. Meuleman, A. Ploss, T. Vanwolleghem, A. J. Syder, J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-Roels, and C. M. Rice. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103:3805-9.
  280. Lorenz, I. C., J. Marcotrigiano, T. G. Dentzer, and C. M. Rice. 2006. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442:831-5.
  281. Manigold, T., E. C. Shin, E. Mizukoshi, K. Mihalik, K. K. Murthy, C. M. Rice, C. A. Piccirillo, and B. Rehermann. 2006. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107:4424-32.
  282. Manigold, T., E. C. Shin, E. Mizukoshi, K. Mihalik, K. K. Murthy, C. M. Rice, C. A. Piccirillo, and B. Rehermann. 2006. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees recovered from Hepatitis C. Blood 10:1182.
  283. Marcello, T., A. Grakoui, G. Barba-Spaeth, E. S. Machlin, S. V. Kotenko, M. R. MacDonald, and C. M. Rice. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887-98.
  284. Olsen, S. K., and R. S. Brown, Jr. 2006. Hepatitis B treatment: Lessons for the nephrologist. Kidney Int 70:1897-904.
  285. Pumfery, A., C. de la Fuente, R. Berro, S. Nekhai, F. Kashanchi, and S. H. Chao. 2006. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 12:1949-61.
  286. Pumfery, A., C. de la Fuente, and F. Kashanchi. 2006. HTLV-1 Tax: centrosome amplification and cancer. Retrovirology 3:50.
  287. Randall, G., L. Chen, M. Panis, A. K. Fischer, B. D. Lindenbach, J. Sun, J. Heathcote, C. M. Rice, A. M. Edwards, and I. D. McGilvray. 2006. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131:1584-91.
  288. Russo, M. W., R. Ghalib, S. Sigal, and V. Joshi. 2006. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21:437-43.
  289. Schilsky, M. L., and S. Fink. 2006. Inherited metabolic liver disease. Curr Opin Gastroenterol 22:215-22.
  290. Shin, E. C., U. Seifert, T. Kato, C. M. Rice, S. M. Feinstone, P. M. Kloetzel, and B. Rehermann. 2006. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 116:3006-14.
  291. Sigal, S. H., C. M. Stanca, N. Kontorinis, C. Bodian, and E. Ryan. 2006. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 101:1490-6.
  292. Talal, A. H., R. M. Ribeiro, K. A. Powers, M. Grace, C. Cullen, M. Hussain, M. Markatou, and A. S. Perelson. 2006. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43:943-53.
  293. Tellinghuisen, T. L., M. S. Paulson, and C. M. Rice. 2006. The NS5A protein of bovine viral diarrhea virus contains an essential zinc-binding site similar to that of the hepatitis C virus NS5A protein. J Virol 80:7450-8.
  294. Tscherne, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating, and C. M. Rice. 2006. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80:1734-41.
  295. Verna, E. C., and R. S. Brown, Jr. 2006. Hepatitis C virus and liver transplantation. Clin Liver Dis 10:919-40.
  296. von Hahn, T., B. D. Lindenbach, A. Boullier, O. Quehenberger, M. Paulson, C. M. Rice, and J. A. McKeating. 2006. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43:932-942.
  297. Weitzman, G., and I. M. Jacobson. 2006. Peginterferon alfa 2b in the treatment of hepatitis C. Future Virology 1:279-292.
  298. Wright, T. L., C. Avunduk, J. L. Dienstag, J. W. Freston, I. M. Jacobson, H. J. Nord, and M. Sherman. 2006. Advancing patient care: integrating new data. Am J Gastroenterol 101 Suppl 1:S32-9.
  299. Zeremski, M., and A. H. Talal. 2006. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 43:373-6.
  300. Afdhal, N., B. R. Bacon, and R. S. Brown Jr. 2007. HBV management: The unmet need report from an expert panel discussion. Gastroenterol & Hepatology 3.
  301. Ala, A., A. P. Walker, K. Ashkan, J. S. Dooley, and M. L. Schilsky. 2007. Wilson's disease. Lancet 369:397-408.
  302. Arnon, R., J. F. Calderon, M. Schilsky, S. Emre, and B. L. Shneider. 2007. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr 44:596-602.
  303. Bacchetti, P., P. C. Tien, E. C. Seaberg, T. R. O'Brien, M. H. Augenbraun, A. H. Kral, M. P. Busch, and B. R. Edlin. 2007. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 7:145.
  304. Berg, C. L., B. W. Gillespie, R. M. Merion, R. S. Brown, Jr., M. M. Abecassis, J. F. Trotter, R. A. Fisher, C. E. Freise, R. M. Ghobrial, A. Shaked, J. H. Fair, and J. E. Everhart. 2007. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 133:1806-13.
  305. Biswas, P. S., V. Pedicord, A. Ploss, E. Menet, I. Leiner, and E. G. Pamer. 2007. Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J Immunol 179:4520-8.
  306. Bluthenthal, R. N., D. P. Do, B. Finch, A. Martinez, B. R. Edlin, and A. H. Kral. 2007. Community Characteristics Associated with HIV Risk among Injection Drug Users in the San Francisco Bay Area: A Multilevel Analysis. J Urban Health 84:653-66.
  307. Brau, N., R. K. Fox, P. Xiao, K. Marks, Z. Naqvi, L. E. Taylor, A. Trikha, M. Sherman, M. S. Sulkowski, D. T. Dieterich, M. O. Rigsby, T. L. Wright, M. D. Hernandez, M. K. Jain, G. K. Khatri, R. K. Sterling, M. Bonacini, C. A. Martyn, A. Aytaman, J. M. Llovet, S. T. Brown, and E. J. Bini. 2007. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 47:527-37.
  308. Brown Jr, R. S. 2007. Current and emerging therapies for chronic hepatitis B - Commentary. Gastroenterol & Hepatology 3.
  309. Brown Jr, R. S. 2007. Clinical Roundtable Monograph: Avoiding the development of drug resistance in the treatment of chronic hepatitis B. Gastroenterol & Hepatology 3.
  310. Brown, R., Jr., and J. C. Emond. 2007. Managing access to liver transplantation: implications for gastroenterology practice. Gastroenterology 132:1152-63.
  311. Brown, R. S., Jr. 2007. Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea? J Hepatol 47:741-3.
  312. Brown, R. S., Jr. 2007. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 26 Suppl 1:41-8.
  313. Brown, R. S., Jr. 2007. Customizing treatment to patient populations. Nat Clin Pract Gastroenterol Hepatol 4 Suppl 1:S3-9.
  314. Catanese, M. T., R. Graziani, T. von Hahn, M. Moreau, T. Huby, G. Paonessa, C. Santini, A. Luzzago, C. M. Rice, R. Cortese, A. Vitelli, and A. Nicosia. 2007. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 81:8063-71.
  315. Cheruvu, S., A. B. Beeder, M. R. Carden, and B. R. Edlin. 2007. Strategies to control hepatitis C among injection drug users. Hot Topics in Viral Hepatitis 6:23-30.
  316. Cheruvu, S., K. Marks, and A. H. Talal. 2007. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis 11:917-43, ix-x.
  317. Combet, C., N. Garnier, C. Charavay, D. Grando, D. Crisan, J. Lopez, A. Dehne-Garcia, C. Geourjon, E. Bettler, C. Hulo, P. Le Mercier, R. Bartenschlager, H. Diepolder, D. Moradpour, J. M. Pawlotsky, C. M. Rice, C. Trepo, F. Penin, and G. Deleage. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 35:D363-6.
  318. Dahari, H., M. Markatou, M. Zeremski, I. Haller, R. M. Ribeiro, T. Licholai, A. S. Perelson, and A. H. Talal. 2007. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 47:23-30.
  319. Dahari, H., R. M. Ribeiro, C. M. Rice, and A. S. Perelson. 2007. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 81:750-60.
  320. Decalf, J., S. Fernandes, R. Longman, M. Ahloulay, F. Audat, F. Lefrerre, C. M. Rice, S. Pol, and M. L. Albert. 2007. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 204:2423-37.
  321. Dustin, L. B., and C. M. Rice. 2007. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25:71-99.
  322. Edlin, B. R., M. R. Carden, and S. J. Ferrando. 2007. Managing hepatitis C in illicit drug users. Curr Hepatitis Rep 6:60-67.
  323. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wolk, T. Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-5.
  324. Fink, S., and M. L. Schilsky. 2007. Inherited metabolic disease of the liver. Curr Opin Gastroenterol 23:237-43.
  325. Fisher, R. A., L. M. Kulik, C. E. Freise, A. S. Lok, T. H. Shearon, R. S. Brown, Jr., R. M. Ghobrial, J. H. Fair, K. M. Olthoff, I. Kam, and C. L. Berg. 2007. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7:1601-8.
  326. Gambarin-Gelwan, M. 2007. Hepatitis B in pregnancy. Clin Liver Dis 11:945-63, x.
  327. Gambarin-Gelwan, M., S. V. Kinkhabwala, T. D. Schiano, C. Bodian, H. C. Yeh, and W. Futterweit. 2007. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5:496-501.
  328. Gish, R. G., R. P. Perrillo, and I. M. Jacobson. 2007. Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis 27 Suppl 1:9-17.
  329. Guarrera, J. V., B. J. Alkofer, N. Feirt, R. Sandoval, B. Samstein, E. T. Smith, Jr., D. Marshman, C. Cogswell, J. Vannatta, R. S. Brown, Jr., J. C. Emond, and J. F. Renz. 2007. Discovery of diffuse biliary microhamartomas during liver procurement. Liver Transpl 13:1470-1.
  330. Gulick, R. M., C. M. Lalama, H. J. Ribaudo, C. M. Shikuma, B. R. Schackman, J. Schouten, K. E. Squires, S. L. Koletar, C. D. Pilcher, R. C. Reichman, K. L. Klingman, and D. R. Kuritzkes. 2007. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 21:813-23.
  331. Harris, A., S. Eswaran, B. Bosworth, M. Gambarin-Gelwan, and E. Scherl. 2007. Mesalamine-induced phenmonitis and serum sickness-like reaction. Gastroenterol & Hepatology 3:875-877.
  332. Hassanein, T. I., F. Tofteng, R. S. Brown, Jr., B. McGuire, P. Lynch, R. Mehta, F. S. Larsen, J. Gornbein, J. Stange, and A. T. Blei. 2007. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46:1853-62.
  333. Jacobson, I. M. 2007. Commentary of a review of selected presentations on "Utilizing protease and polymerase inhibitor therapy in the treatment of active hepatitis C". Gastroenterol & Hepatology 3:12-14.
  334. Jacobson, I. M. 2007. Preface. Clin Liver Dis 11:xiii-xv.
  335. Jacobson, I. M., R. S. Brown, Jr., B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, E. Godofsky, R. Strauss, D. Bernstein, S. Flamm, M. P. Pauly, P. Mukhopadhyay, L. H. Griffel, C. A. Brass, and WIN-R Study group. 2007. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46:971-81.
  336. Jacobson, I. M., R. S. Brown, Jr., J. McCone, M. Black, C. Albert, M. S. Dragutsky, F. A. Siddiqui, T. Hargrave, P. Y. Kwo, L. Lambiase, G. W. Galler, V. Araya, B. Freilich, J. Harvey, L. H. Griffel, and C. A. Brass. 2007. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 46:982-90.
  337. Jacobson, I. M., and S. H. Sigal. 2007. Future therapies for hepatitis C: Where do we go from here? Nature Clinical Practice Gastroenterology & Hepatology 4:60-61.
  338. Jakab, S. S., A. B. West, D. M. Meighan, R. S. Brown, Jr., and W. B. Hale. 2007. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol 13:6087-9.
  339. Jhang, J. S., M. L. Schilsky, J. H. Lefkowitch, and J. Schwartz. 2007. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apher 22:10-4.
  340. Jones, C. T., C. L. Murray, D. K. Eastman, J. Tassello, and C. M. Rice. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81:8374-83.
  341. Kadam, J. S., S. A. Gonzalez, F. Ahmed, A. Menezes, and I. M. Jacobson. 2007. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci 52:2525-30.
  342. Kadam, J. S., and A. H. Talal. 2007. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 21:154-68.
  343. Keeffe, E. B., S. Zeuzem, R. S. Koff, D. T. Dieterich, R. Esteban-Mur, E. J. Gane, I. M. Jacobson, S. G. Lim, N. Naoumov, P. Marcellin, T. Piratvisuth, and F. Zoulim. 2007. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5:890-7.
  344. Ko, C., N. Siddaiah, J. Berger, R. Gish, D. Brandhagen, R. K. Sterling, S. J. Cotler, R. J. Fontana, T. M. McCashland, S. H. Han, F. D. Gordon, M. L. Schilsky, and K. V. Kowdley. 2007. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int.
  345. Kulkarni, K., I. M. Jacobson, and B. C. Tennant. 2007. The role of the woodchuck model in the treatment of hepatitis B virus infection. Clin Liver Dis 11:707-25, vii.
  346. Lake-Bakaar, G., L. Dustin, J. McKeating, K. Newton, V. Freeman, and S. D. Frost. 2007. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109:845-6.
  347. Lindenbach, B. D., B. M. Pragai, R. Montserret, R. K. Beran, A. M. Pyle, F. Penin, and C. M. Rice. 2007. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J Virol 81:8905-18.
  348. Longman, R. S., D. Braun, S. Pellegrini, C. M. Rice, R. B. Darnell, and M. L. Albert. 2007. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation. Blood 109:1113-22.
  349. MacDonald, M. R., E. S. Machlin, O. R. Albin, and D. E. Levy. 2007. The zinc finger antiviral protein acts synergistically with an interferon-induced factor for maximal activity against alphaviruses. J Virol 81:13509-18.
  350. Maddrey, W. C., N. H. Afdhal, I. M. Jacobson, and M. S. Sulkowski. 2007. HCV management today and tomorrow: Tailoring therapy by genotype, viral response, and novel targets. Gastroenterol & Hepatology 3:4-14.
  351. McHutchison, J. G., B. R. Bacon, S. C. Gordon, E. Lawitz, M. Shiffman, N. H. Afdhal, I. M. Jacobson, A. Muir, M. Al-Adhami, M. L. Morris, J. A. Lekstrom-Himes, S. M. Efler, and H. L. Davis. 2007. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46:1341-9.
  352. McHutchison, J. G., G. Dusheiko, M. L. Shiffman, M. Rodriguez-Torres, S. Sigal, M. Bourliere, T. Berg, S. C. Gordon, F. M. Campbell, D. Theodore, N. Blackman, J. Jenkins, and N. H. Afdhal. 2007. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227-36.
  353. McHutchison, J. G., M. P. Manns, R. S. Brown, Jr., K. R. Reddy, M. L. Shiffman, and J. B. Wong. 2007. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 102:880-9.
  354. McMullan, L. K., A. Grakoui, M. J. Evans, K. Mihalik, M. Puig, A. D. Branch, S. M. Feinstone, and C. M. Rice. 2007. Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A 104:2879-84.
  355. Moller, H. J., H. Gronbaek, F. V. Schiodt, P. Holland-Fischer, M. Schilsky, S. Munoz, T. Hassanein, and W. M. Lee. 2007. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 47:671-676.
  356. Moradpour, D., F. Penin, and C. M. Rice. 2007. Replication of hepatitis C virus. Nat Rev Microbiol 5:453-63.
  357. Murray, C. L., C. T. Jones, J. Tassello, and C. M. Rice. 2007. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol 81:10220-31.
  358. O'Brien, T. R., K. Kachapati, M. Zhang, J. Bergeron, B. R. Edlin, and M. Dean. 2007. HCV infection clearance with functional or non-functional caspase-12. Scand J Gastroenterol 42:416-7.
  359. Olsen, S. K., and R. S. Brown Jr. 2007. Living donor liver transplantation: Ethically justified, beneficial to all. GI and Hepatology News 1.
  360. Olsen, S. K., and R. S. Brown Jr. 2007. The ethics of living-donor liver transplantation: Safe and life saving. AGA Perspectives 3.
  361. Patkar, C. G., C. T. Jones, Y. H. Chang, R. Warrier, and R. J. Kuhn. 2007. Functional Requirements of the Yellow Fever Virus Capsid Protein. J Virol.
  362. Perrillo, R. P., and I. M. Jacobson. 2007. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis 27 Suppl 1:3-8.
  363. Randall, G., M. Panis, J. D. Cooper, T. L. Tellinghuisen, K. E. Sukhodolets, S. Pfeffer, M. Landthaler, P. Landgraf, S. Kan, B. D. Lindenbach, M. Chien, D. B. Weir, J. J. Russo, J. Ju, M. J. Brownstein, R. Sheridan, C. Sander, M. Zavolan, T. Tuschl, and C. M. Rice. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 104:12884-9.
  364. Schackman, B. R., C. P. Neukermans, S. N. Fontain, C. Nolte, P. Joseph, J. W. Pape, and D. W. Fitzgerald. 2007. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Med 4:e183.
  365. Schackman, B. R., and K. Oneda. 2007. Preventing vertical hepatitis C virus transmission. Clin Infect Dis 45:802.
  366. Schackman, B. R., H. J. Ribaudo, A. Krambrink, V. Hughes, D. R. Kuritzkes, and R. M. Gulick. 2007. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 46:547-54.
  367. Schackman, B. R., E. G. Rojas, J. Gans, M. Falco, and R. B. Millman. 2007. Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs. Subst Abuse Treat Prev Policy 2:23.
  368. Schackman, B. R., C. A. Scott, P. E. Sax, E. Losina, T. J. Wilkin, J. E. McKinnon, S. Swindells, M. C. Weinstein, and K. A. Freedberg. 2007. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 45:1062-70.
  369. Schackman, B. R., P. A. Teixeira, and A. B. Beeder. 2007. Offers of hepatitis C care do not lead to treatment. J Urban Health 84:455-8.
  370. Schilsky, M. L. 2007. Non-invasive testing for Wilson disease: revisiting the d-penicillamine challenge test. J Hepatol 47:172-3.
  371. Shin, E. C., U. Seifert, S. Urban, K. T. Truong, S. M. Feinstone, C. M. Rice, P. M. Kloetzel, and B. Rehermann. 2007. Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver. J Interferon Cytokine Res 27:985-90.
  372. Sigal, S., and I. Jacobson. 2007. Future therapies for hepatitis C: where do we go from here? Nat Clin Pract Gastroenterol Hepatol 4:60-1.
  373. Sigal, S. H., C. M. Stanca, J. Fernandez, V. Arroyo, and M. Navasa. 2007. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 56:597-9.
  374. Stamataki, Z., S. Coates, M. J. Evans, M. Wininger, K. Crawford, C. Dong, Y. L. Fong, D. Chien, S. Abrignani, P. Balfe, C. M. Rice, J. A. McKeating, and M. Houghton. 2007. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25:7773-84.
  375. Tellinghuisen, T. L., M. J. Evans, T. von Hahn, S. You, and C. M. Rice. 2007. Studying hepatitis C virus: making the best of a bad virus. J Virol 81:8853-67.
  376. Terrault, N. A., and I. M. Jacobson. 2007. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 27 Suppl 1:18-24.
  377. Terrault, N. A., M. L. Shiffman, A. S. Lok, S. Saab, L. Tong, R. S. Brown, Jr., G. T. Everson, K. R. Reddy, J. H. Fair, L. M. Kulik, T. L. Pruett, and L. B. Seeff. 2007. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 13:122-9.
  378. Tscherne, D. M., M. J. Evans, T. von Hahn, C. T. Jones, Z. Stamataki, J. A. McKeating, B. D. Lindenbach, and C. M. Rice. 2007. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 81:3693-703.
  379. Tseng, F. C., T. R. O'Brien, M. Zhang, A. H. Kral, B. A. Ortiz-Conde, J. Lorvick, M. P. Busch, and B. R. Edlin. 2007. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 46:666-71.
  380. Vakiani, E., K. K. Hunt, R. M. Mazziotta, J. C. Emond, R. S. Brown, J. H. Lefkowitch, and G. Bhagat. 2007. Hepatitis C-associated granulomas after liver transplantation: morphologic spectrum and clinical implications. Am J Clin Pathol 127:128-34.
  381. von Hahn, T., J. C. Yoon, H. Alter, C. M. Rice, B. Rehermann, P. Balfe, and J. A. McKeating. 2007. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132:667-78.
  382. Wan, D. W., D. Serur, H. C. Bodenheimer, Jr., M. J. Goldstein, and S. H. Sigal. 2007. Remission of aseptic inflammatory ascites after nephrectomy of a failed allograft. Am J Kidney Dis 50:645-8.
  383. Weisberg, I. S., R. S. Brown, Jr., and S. H. Sigal. 2007. Hepatitis B and end-stage liver disease. Clin Liver Dis 11:893-916, ix.
  384. Weisberg, I. S., S. H. Sigal, and I. M. Jacobson. 2007. New treatments for hepatitis C: Life cycle lessons. Current Hepatitis Reports 6:75-82.
  385. Zamor, P., I. M. Jacobson, and E. B. Keeffe. 2007. [In Process Citation]. Rev Gastroenterol Disord 7:167-75.
  386. Zeremski, M., M. Markatou, Q. B. Brown, G. Dorante, S. Cunningham-Rundles, and A. H. Talal. 2007. Interferon gamma-inducible protein 10: A predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 45:262-8.
  387. Zeremski, M., L. M. Petrovic, and A. H. Talal. 2007. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 14:675-87.
  388. Zeremski, M., and A. H. Talal. 2007. Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients. Current Opinion in HIV and AIDS 2:489-495.
  389. Afdhal, N., J. McHutchison, R. Brown, I. Jacobson, M. Manns, F. Poordad, B. Weksler, and R. Esteban. 2008. Thrombocytopenia associated with chronic liver disease. J Hepatol 48:1000-7.
  390. Azhar, A., and I. M. Jacobson. 2008. Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients. Rev Gastroenterol Disord 8:218-21.
  391. Bart, G., P. Piccolo, L. Zhang, I. Jacobson, R. A. Schaefer, and M. J. Kreek. 2008. Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction 103:681-6.
  392. Bottecchia, M., A. Madejon, J. Sheldon, J. Garcia-Samaniego, P. Barreiro, and V. Soriano. 2008. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. J Antimicrob Chemother 62:626-7.
  393. Brown, E. E., M. Zhang, R. Zarin-Pass, T. Bernig, F. C. Tseng, N. Xiao, M. Yeager, B. R. Edlin, S. J. Chanock, and T. R. O'Brien. 2008. MBL2 and hepatitis C virus infection among injection drug users. BMC Infect Dis 8:57.
  394. Brown Jr, R. S. 2008. Antiviral therapy of chronic hepatitis B infection. Gastroenterol & Hepatology 4:13-14.
  395. Brown Jr, R. S., R. Higgins, and T. L. Pruett. 2008. The Evolution and Direction of OPTN Oversight of Live Organ Donation and Transplantation in the United States. Am J Transplant.
  396. Brown, R. S., Jr. 2008. Live donors in liver transplantation. Gastroenterology 134:1802-13.
  397. Bussel, J. B., and K. M. Marks. 2008. How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection? Nat Clin Pract Gastroenterol Hepatol 5:424-5.
  398. Bustamante, J., S. Boisson-Dupuis, E. Jouanguy, C. Picard, A. Puel, L. Abel, and J. L. Casanova. 2008. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol 20:39-48.
  399. Charles, E. D., R. M. Green, S. Marukian, A. H. Talal, G. V. Lake-Bakaar, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2008. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 111:1344-56.
  400. Cox, A. L., K. Page, J. Bruneau, N. H. Shoukry, G. M. Lauer, A. Y. Kim, H. R. Rosen, H. Radziewicz, A. Grakoui, D. S. Fierer, A. D. Branch, D. E. Kaplan, and K. M. Chang. 2008. Rare Birds in North America: Acute Hepatitis C Cohorts. Gastroenterology.
  401. Fallon, M. B., M. J. Krowka, R. S. Brown, J. F. Trotter, S. Zacks, K. E. Roberts, V. H. Shah, N. Kaplowitz, L. Forman, K. Wille, and S. M. Kawut. 2008. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 135:1168-75.
  402. Fierer, D. S., A. J. Uriel, D. C. Carriero, A. Klepper, D. T. Dieterich, M. P. Mullen, S. N. Thung, M. I. Fiel, and A. D. Branch. 2008. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 198:683-6.
  403. Fishman, S. L., J. M. Murray, F. J. Eng, J. L. Walewski, S. Morgello, and A. D. Branch. 2008. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 197:597-607.
  404. Gallego, A., J. Sheldon, J. Garcia-Samaniego, N. Margall, M. Romero, P. Hornillos, V. Soriano, and J. Enrlquez. 2008. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 15:392-8.
  405. Gambarin-Gelwan, M., and I. M. Jacobson. 2008. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. J Viral Hepat 15:623-33.
  406. Gonzalez, S. A., C. Zhang, M. I. Fiel, S. Chung, L. Zhang, I. M. Jacobson, and A. H. Talal. 2008. Hepatic inflammatory cytokine mRNA expression in hepatitis C virus-human immunodeficiency virus co-infection. J Viral Hepat 15:331-338.
  407. Haskal, Z. J., and R. S. Brown, Jr. 2008. Role of biliary stress manometry after biliary stricture dilation in living donor liver transplant recipients. J Vasc Interv Radiol 19:216-9.
  408. Hernandez, L., T. C. Johnson, A. J. Naiyer, D. Kryszak, E. J. Ciaccio, A. Min, H. C. Bodenheimer, Jr., R. S. Brown, Jr., A. Fasano, and P. H. Green. 2008. Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci 53:256-61.
  409. Jacobson, I. M. 2008. Combination therapy for chronic hepatitis B: ready for prime time? J Hepatol 48:687-91.
  410. Jacobson, I. M. 2008. Clinical Roundtable Monograph: The future use of interferon in the treatment of hepatitis C: New formulations, new combinations. Gastroenterol and Hepatology 4:3-5.
  411. Jacobson, I. M., and R. S. Brown, Jr. 2008. WIN-R revisited: Response to editorial. Hepatology 47:1427.
  412. Jacobson, I. M., and S. A. Harrison. 2008. Hepatitis C: Current and future therapies. Current Hepatitis Reports 7:21-92.
  413. Kawut, S. M., M. J. Krowka, J. F. Trotter, K. E. Roberts, R. L. Benza, D. B. Badesch, D. B. Taichman, E. M. Horn, S. Zacks, N. Kaplowitz, R. S. Brown, Jr., and M. B. Fallon. 2008. Clinical risk factors for portopulmonary hypertension. Hepatology 48:196-203.
  414. Keeffe, E. B., D. T. Dieterich, S. H. Han, I. M. Jacobson, P. Martin, E. R. Schiff, and H. Tobias. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6:1315-41; quiz 1286.
  415. Keeffe, E. B., A. T. Duddempudi, and I. M. Jacobson. 2008. Advances in Liver Disease: Highlights from the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Rev Gastroenterol Disord 8:58-70.
  416. Koenig, S. P., C. Riviere, P. Leger, P. Severe, S. Atwood, D. W. Fitzgerald, J. W. Pape, and B. R. Schackman. 2008. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 6:3.
  417. Kuntzen, T., J. Timm, A. Berical, N. Lennon, A. M. Berlin, S. K. Young, B. Lee, D. Heckerman, J. Carlson, L. L. Reyor, M. Kleyman, C. M. McMahon, C. Birch, J. Schulze Zur Wiesch, T. Ledlie, M. Koehrsen, C. Kodira, A. D. Roberts, G. M. Lauer, H. R. Rosen, F. Bihl, A. Cerny, U. Spengler, Z. Liu, A. Y. Kim, Y. Xing, A. Schneidewind, M. A. Madey, J. F. Fleckenstein, V. M. Park, J. E. Galagan, C. Nusbaum, B. D. Walker, G. V. Lake-Bakaar, E. S. Daar, I. M. Jacobson, E. D. Gomperts, B. R. Edlin, S. M. Donfield, R. T. Chung, A. H. Talal, T. Marion, B. W. Birren, M. R. Henn, and T. M. Allen. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-78.
  418. Kuritzkes, D. R., C. M. Lalama, H. J. Ribaudo, M. Marcial, W. A. Meyer, 3rd, C. Shikuma, V. A. Johnson, S. A. Fiscus, R. T. D'Aquila, B. R. Schackman, E. P. Acosta, and R. M. Gulick. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197:867-70.
  419. Kwong, A. D., L. McNair, I. Jacobson, and S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 8:522-31.
  420. Martinez, A., and A. H. Talal. 2008. Noninjection drug use: an under-appreciated risk factor for hepatitis C virus transmission. Liver Int 28:757-60.
  421. Marukian, S., C. T. Jones, L. Andrus, M. J. Evans, K. D. Ritola, E. D. Charles, C. M. Rice, and L. B. Dustin. 2008. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48:1843-50.
  422. Menendez, A., D. A. Calarese, R. L. Stanfield, K. C. Chow, C. N. Scanlan, R. Kunert, H. Katinger, D. R. Burton, I. A. Wilson, and J. K. Scott. 2008. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J 22:1380-92.
  423. Mizukoshi, E., C. Eisenbach, B. R. Edlin, K. P. Newton, S. Raghuraman, C. Weiler-Normann, L. H. Tobler, M. P. Busch, M. Carrington, J. A. McKeating, T. R. O'Brien, and B. Rehermann. 2008. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 198:203-12.
  424. Murray, C. L., C. T. Jones, and C. M. Rice. 2008. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol 6:699-708.
  425. Murray, C. L., J. Marcotrigiano, and C. M. Rice. 2008. Bovine viral diarrhea virus core is an intrinsically disordered protein that binds RNA. J Virol 82:1294-304.
  426. Murray, J., S. L. Fishman, E. Ryan, F. J. Eng, J. L. Walewski, A. D. Branch, and S. Morgello. 2008. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 14:17-27.
  427. Oh, T. S., and C. M. Rice. 2008. Predicting response to hepatitis C therapy. J Clin Invest.
  428. Olsen, S. K., and R. S. Brown, Jr. 2008. Live donor liver transplantation: current status. Curr Gastroenterol Rep 10:36-42.
  429. Page-Shafer, K., B. L. Pappalardo, L. H. Tobler, B. H. Phelps, B. R. Edlin, A. R. Moss, T. L. Wright, D. J. Wright, T. R. O'Brien, S. Caglioti, and M. P. Busch. 2008. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 46:499-506.
  430. Rana, A., M. A. Hardy, K. J. Halazun, D. C. Woodland, L. E. Ratner, B. Samstein, J. V. Guarrera, R. S. Brown, Jr., and J. C. Emond. 2008. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 8:2537-46.
  431. Ribaudo, H. J., D. R. Kuritzkes, C. M. Lalama, J. T. Schouten, B. R. Schackman, E. P. Acosta, and R. M. Gulick. 2008. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 197:1006-10.
  432. Rybak, D., M. B. Fallon, M. J. Krowka, R. S. Brown, Jr., J. Reinen, L. Stadheim, D. Faulk, C. Nielsen, N. Al-Naamani, K. Roberts, S. Zacks, T. Perry, J. Trotter, and S. M. Kawut. 2008. Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. Liver Transpl 14:1357-65.
  433. Sanyal, A. J., T. Boyer, G. Garcia-Tsao, F. Regenstein, L. Rossaro, B. Appenrodt, A. Blei, V. Gulberg, S. Sigal, and P. Teuber. 2008. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360-8.
  434. Schackman, B. R., C. A. Scott, R. P. Walensky, E. Losina, K. A. Freedberg, and P. E. Sax. 2008. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22:2025-33.
  435. Schackman, B. R., P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson. 2008. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making 28:233-42.
  436. Sheldon, J., B. Ramos, C. Toro, P. Rios, J. Martinez-Alarcon, M. Bottecchia, M. Romero, J. Garcia-Samaniego, and V. Soriano. 2008. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 13:97-102.
  437. Sheldon, J., and V. Soriano. 2008. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61:766-8.
  438. Shudo, E., R. M. Ribeiro, A. H. Talal, and A. S. Perelson. 2008. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 13:919-26.
  439. Siegel, A. B., E. I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. J. Knox, H. Chen, S. Clark-Garvey, A. Weinberg, J. Mandeli, P. Christos, M. Mazumdar, E. Popa, R. S. Brown, Jr., S. Rafii, and J. D. Schwartz. 2008. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992-8.
  440. Siegel, A. B., R. B. McBride, H. B. El-Serag, D. Hershman, R. S. Brown, Jr., L. Zablotska, and A. I. Neugut. 2008. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest 26:511-5.
  441. Siegel, A. B., R. B. McBride, H. B. El-Serag, D. L. Hershman, R. S. Brown, Jr., J. F. Renz, J. Emond, and A. I. Neugut. 2008. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 103:120-7.
  442. Soriano, V., A. Madejon, E. Vispo, P. Labarga, J. Garcia-Samaniego, L. Martin-Carbonero, J. Sheldon, M. Bottecchia, P. Tuma, and P. Barreiro. 2008. Emerging drugs for hepatitis C. Expert Opin Emerg Drugs 13:1-19.
  443. Soriano, V., E. Vispo, M. Bottecchia, J. Sheldon, P. Tuma, J. Garcia-Samaniego, and P. Barreiro. 2008. Management of hepatitis B virus co-infection on and off antiretroviral therapy. Curr HIV/AIDS Rep 5:86-93.
  444. Talal, A., K. E. Tanner, R. Billington, and G. J. Pearson. 2008. Effect of ultrasound on the setting characteristics of glass ionomer cements studied by Fourier Transform Infrared Spectroscopy. J Mater Sci Mater Med.
  445. Teixeira, P. A., and B. R. Schackman. 2008. Can urban methadone patients complete health utility assessments? Patient Educ Couns 71:302-7.
  446. Tellinghuisen, T. L., K. L. Foss, J. C. Treadaway, and C. M. Rice. 2008. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 82:1073-83.
  447. Tscherne, D. M., M. J. Evans, M. R. MacDonald, and C. M. Rice. 2008. Transdominant inhibition of bovine viral diarrhea virus entry. J Virol 82:2427-36.
  448. Tseng, F. C., B. R. Edlin, M. Zhang, A. Kral, M. P. Busch, B. A. Ortiz-Conde, T. M. Welzel, and T. R. O'Brien. 2008. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 15:690-8.
  449. Uebelhoer, L., J. H. Han, B. Callendret, G. Mateu, N. H. Shoukry, H. L. Hanson, C. M. Rice, C. M. Walker, and A. Grakoui. 2008. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 4:e1000143.
  450. Verna, E. C., and R. S. Brown, Jr. 2008. Hepatitis C and liver transplantation: Enhancing outcomes and should patients be retransplanted. Clin Liver Dis 12:637-59, ix-x.
  451. von Hahn, T., and C. M. Rice. 2008. Hepatitis C virus entry. J Biol Chem 283:3689-93.
  452. Wan, D. W., D. Serur, H. C. Bodenheimer, Jr., M. J. Goldstein, and S. H. Sigal. 2008. Remission of aseptic inflammatory ascites after nephrectomy of a failed allograft. Am J Kidney Dis 52:626.
  453. Weiss, J. J., L. Bhatti, D. T. Dieterich, B. R. Edlin, D. A. Fishbein, M. B. Goetz, K. Yu, and G. J. Wagner. 2008. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther 28:289-93.
  454. Woelk, B., B. Buchele, D. Moradpour, and C. M. Rice. 2008. A dynamic view of hepatitis C virus replication complexes. J Virol 82:10519-31.
  455. You, S., and C. M. Rice. 2008. 3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U). J Virol 82:184-95.
  456. Zeremski, M., L. M. Petrovic, L. Chiriboga, Q. B. Brown, H. T. Yee, M. Kinkhabwala, I. M. Jacobson, R. Dimova, M. Markatou, and A. H. Talal. 2008. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology.
  457. Zeremski, M., M. A. Shu, Q. Brown, Y. Wu, D. C. Des Jarlais, M. P. Busch, A. H. Talal, and B. R. Edlin. 2008. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 16:10-20.
  458. Amini-Bavil-Olyaee, S., J. Sheldon, T. Lutz, C. Trautwein, and F. Tacke. 2009. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS 23:268-72.
  459. Leege, T., W. Fuchs, H. Granzow, M. Kopp, B. G. Klupp, and T. C. Mettenleiter. 2009. Effects of simultaneous deletion of pUL11 and glycoprotein M on virion maturation of herpes simplex virus type 1. J Virol 83:896-907.
  460. Roberts, K. E., M. B. Fallon, M. J. Krowka, R. L. Benza, J. A. Knowles, D. B. Badesch, R. S. Brown, D. B. Taichman, J. Trotter, S. Zacks, E. M. Horn, and S. M. Kawut. 2009. Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. Chest Epub:1/15/2009.
  461. Witteveldt, J., M. J. Evans, J. Bitzegeio, G. Koutsoudakis, A. M. Owsianka, A. G. Angus, Z. Y. Keck, S. K. Foung, T. Pietschmann, C. M. Rice, and A. H. Patel. 2009. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90:48-58.
  462. Bwanali, J., V. Arandhara, A. W. Tarr, R. J. P. Brown, C. P. McClure, T. P. Hickling, M. T. Catanese, A. Vitelli, A. Nicosia, R. A. Robins, and J. K. Ball. In preparation. Identification of species-specific hepatitis C virus E2 envelope glycoprotein binding determinants on scavenger receptor class B type I.
  463. Kadam, J., K. Jones, R. Peterson, L. Dove, T. Hassanein, J. Aberg, R.-C. Liu, L. Heller, M. Glesby, I. M. Jacobson, and A. H. Talal. In preparation. Dose reduction and growth factor supplementation in HIV/HCV coinfected patients undergoing treatment for hepatitis C virus infection.
  464. Kadam, J. S., K. Jones, R. Peterson, L. Dove, T. Hassanein, J. Aberg, R.-C. Liu, L. Heller, M. Glesby, I. M. Jacobson, and A. H. Talal. In preparation. Dose reduction and growth factor supplementation in HIV/HCV coinfected patients undergoing treatment for hepatitis C virus infection.
  465. Kopp, M., M. T. Catanese, and C. Rice. In preparation. Identification of viral and host cell proteins in purified hepatitis C virus particles.
  466. Kopp, M., and C. Rice. In preparation. Functional analysis of the C-terminus of the core protein of hepatitis C virus.
  467. Martinez, A., M. Zeremski, A. B. Beeder, M. J. Kreek, and A. H. Talal. In preparation. Integration of hepatitis C virus evaluation and treatment between hepatology and methadone maintenance clinics: The embedded addition medicine-hepatology model.
  468. Newton, K. P., D. M. Netski, Z. Stamataki, I. Desombere, T. von Hahn, S. Mehta, A. Talal, G. Leroux-Roels, T. Heller, D. L. Thomas, B. Rehermann, C. M. Rice, P. Balfe, and J. A. McKeating. In preparation. Neutralizing antibodies in acute and chronic HCV infection.
  469. Ploss, A., and (as a member of the Grand Challenges Global Health4 Consortium). In preparation. Humanized mice: Modeling human infectious disease for basic biology and preclinical applications.
  470. Ploss, A., S. K. Khetani, A. J. Syder, C. T. Jones, L. Andrus, C. M. Rice, and S. N. Bhatia. In preparation. A multi-well microscale human liver platform for hepatitis C drug screening applications.
  471. Raison, C. L., A. H. Talal, T. Hassanein, H. C. Bodenheimer, Jr., and W. C. Maddrey. In preparation. Fatigue and its management among patients with chronic hepatitis C.
  472. Zeremski, M., M. Shu, Q. B. Brown, D. C. Des Jarlais, M. P. Busch, B. R. Edlin, and A. H. Talal. In preparation. Chemokines in acute hepatitis C virus infection.
  473. Amini-Bavil-Olyaee, S., U. Herbers, J. Sheldon, T. Leudde, C. Trautwein, and F. Tacke. In press. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-negative hepatitis B virus strains. Hepatology.
  474. Backmund, M., C. Schuetz, K. Meyer, B. R. Edlin, and J. Reimer. In press. The risk of emergency room treatment due to overdose in injection drug users. J Addict Dis.
  475. Bao, Y., E. P. Post, T. R. Ten Have, B. R. Schackman, and M. Bruce. In press. Achieving effective antidepressant pharmacotherapy in primary care: The role of depression care management in treating late-life depression. J Am Geriatr Soc.
  476. de Jong, B. C., M. Antonio, T. Awine, K. Ogungbemi, Y. P. de Jong, S. Gagneux, K. DeReimer, N. Rastogi, M. Borgdoff, P. C. Hill, and R. A. Adegbola. In press. Use of spoligotyping and large-sequence polymorphisms to study the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear positive tuberculosis cases in the Gambia. J Clin Microbiol.
  477. Gonzalez, S. A., M. I. Fiel, J. Sauk, P. W. Canchis, R. C. Liu, L. Chiriboga, H. T. Yee, I. M. Jacobson, and A. H. Talal. In press. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis.
  478. Kreek, M. J., A. H. Talal, and P. Piccolo. In press. Treating chronic hepatitis C in recovering opiate addicts: Yes, we can. Digestive and Liver Disease.
  479. Lai, J. C., E. M. Pichardo, J. C. Emond, and R. S. Brown Jr. In press. Resource utilization of living donor versus deceased donor liver transplantation is similar at an experienced transplant center. American Journal of Transplantation.
  480. Nelson, D., G. L. Davis, I. M. Jacobson, G. T. Everson, M. W. Fried, S. A. Harrison, T. Hassanein, D. M. Jensen, K. L. Lindsay, N. Terrault, and N. Zein. In press. Hepatitis C virus: A critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol.
  481. Paltiel, A. D., K. A. Freedberg, C. A. Scott, B. R. Schackman, E. Losina, B. Wang, G. r. Seage, C. E. Sloan, P. E. Sax, and R. P. Walensky. In press. HIV pre-exposure prophylaxis (PrEP) in the United States: impact on lifetime infection risk clinical outcomes, and cost-effectiveness. Clin Infect Dis.
  482. Pereira, A. A., D. E. Weiner, T. Scott, P. Chandra, R. Bluestein, J. Griffith, and M. J. Sarnak. In press. Subcortical cognitive impairment in dialysis patients. Hemodialysis International.
  483. Ploss, A., M. J. Evans, M. Panis, H. You, Y. P. de Jong, V. Gayinskaya, and C. M. Rice. In press. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature.
  484. Roberts, K. E., M. B. Fallon, M. J. Krowka, R. S. Brown Jr, J. F. Trotter, H. Tighiouart, J. A. Knowles, D. Babinowitz, R. L. Benza, D. B. Badesch, D. B. Taichman, E. M. Horn, S. Zacks, N. Kaplowitz, S. M. Kawut, and for the PVCLD Study Group. In press. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Crit Care Med.
  485. Schackman, B. R., Z. Dastur, D. S. Rubin, J. Berger, E. Camhi, J. Netherland, Q. Ni, and R. Finkelstein. In press. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care.
  486. Wan, D. W., K. R. Marks, R. K. Yantiss, and A. H. Talal. In press. Importance of autoimmune hepatitis in HIV/HCV coinfection. AIDS Patient Care and STDS.
  487. Walters, K.-A., A. J. Syder, S. L. Lederer, D. L. Diamond, B. Paeper, C. M. Rice, and M. G. Katze. In revision. Genomic analysis reveals a potential role for cell cycle dysregulation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog.
  488. Akondy, R. S., N. D. Monson, J. D. Miller, S. Edupuganti, D. Teuwen, H. Wu, F. Quyyumi, S. Garg, J. D. Altman, C. Del Rio, H. L. Keyserling, A. Ploss, C. M. Rice, M. J. Mulligan, W. A. Orenstein, and R. Ahmed. Submitted. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Exp. Med.
  489. Bekker, V., S. J. Chanock, M. Yeager, A. A. Hutchinson, T. von Hahn, S. Chen, N. Xiao, M. Dotrang, B. R. Edlin, C. M. Rice, and T. R. O'Brien. Submitted. Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. Hepatology.
  490. Catanese, M. T., J. K. Ball, M. Moreau, T. Huby, R. Cortese, A. Vitelli, and A. Nicosia. Submitted. Recognition of the hepatitis C virus E2 envelope glycoprotein by scavenger receptor class B type I is an early step of viral infection and correlates with secies permissiveness.
  491. Eng, F. J., J. L. Walewski, A. L. Klepper, S. L. Fishman, S. M. Desai, L. K. McMullan, M. J. Evans, C. M. Rice, and A. D. Branch. Submitted. The hepatitis C virus core gene expresses a family of core protein isoforms through internal initiation. J. Virology.
  492. Gutierrez, J. A., A. L. Klepper, J. Garber, J. L. Walewski, K. Bateman, V. Khaitova, T. D. Schiano, A. J. Syder, D. M. Tscherne, A. Gauthier, C. M. Rice, D. Jefferson, and A. D. Branch. Submitted. Ascitic fluid is a rich source of anti-HCV antibodies and biomarkers.
  493. Hassanein, T., A. T. Blei, T. Perry, R. Hilsabeck, J. Stange, F. S. Larsen, R. S. Brown Jr, S. Caldwell, B. McGuire, F. Nevens, and R. J. Fontana. Submitted. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol.
  494. Hoofnagle, J. H., A. S. Wahed, R. S. Brown Jr, C. D. Howell, S. H. Belle, and for the Virahep-C Study Group. Submitted. Early changes in hepatitis C viral levels in response to peginterferon and ribavirin in African-American and Caucasian-American patients with chronic hepatitis C, genotype1 infection.
  495. Marks, K. M., R. M. A. Clarke, J. B. Bussel, A. H. Talal, and M. J. Glesby. Submitted. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
  496. Strowig, T., C. Gurer, A. Ploss, Y. F. Liu, J. Sashihara, M. Pack, F. Brilot, F. Arrey, C. Rice, J. Young, A. Chadburn, J. I. Cohen, R. Steinman, and C. Munz. Submitted. Priming of protective and tumor specific T cell responses in mice with human immune system components.
  497. Terrault, N. A., T. T. Tran, E. Schiff, B. M. McGuire, R. S. Brown Jr, R. Tupper, S. Ramanathan, J. Enejosa, L. Zhong, J. Zong, and for the Study531 Team. Submitted. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.
  498. Zeremski, M., Q. B. Brown, R. Dimova, I. M. Jacobson, M. Markatou, and A. H. Talal. Submitted. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Books, Book chapters or sections and Electronic media

  1. Blight, K., and C. M. Rice. 2000. Hepatitis C Virus. In T. E. Creighton (ed.), The Encyclopedia of Molecular Medicine. John Wiley and Sons, New York, NY.
  2. Kuemmerer, B. M., and C. M. Rice. 2000. Flaviviruses. In N. Y. John Wiley and Sons, NY (ed.), The Encyclopedia of Molecular Medicine. Creighton, T.E., New York, NY.
  3. Blight, K., A. Grakoui, H. L. Hanson, and C. M. Rice. 2001. The Molecular Biology of Hepatitis C Virus, p. 81-108. In J.-H. J. Ou (ed.), Hepatitis Viruses. Kluwer Academic Publishers, Boston.
  4. Lindenbach, B., and C. M. Rice. 2001. Flaviviridae: The viruses and their replication, p. 991-1041. In B. Fields, D. Knipe, and P. Howley (ed.), Fields Virology, Fourth ed. Raven Press, New York, NY.
  5. Talal, A., and I. Jacobson. 2001. Update on Hepatitis C virus in HIV/HCV coinfection, vol. 2001. National AIDS Treatment Advocacy Program.
  6. (Dr. Jacobson was a member of the Editorial Advisory Board). 2002. The Cornell Illustrated Encyclopedia of Health. Lifeline Press, Washington DC.
  7. Barba, G., and C. M. Rice. 2002. Genus Hepacivirus (Flaviviridae). In C. A. Tidona and G. Darai (ed.), The Springer Index of Viruses. Springer-Verlag, Heidelberg.
  8. Frissora, C. L., and I. M. Jacobson. 2002. Gastrointestinal Manifestations of Diabetes, p. 439-458. In L. Poretsky (ed.), Principles of Diabetes Mellitus. Kluwer, Boston.
  9. Russo, M. W., and I. M. Jacobson. 2002. Hepatocellular Cancer: Screening, Surveillance and Prevention, p. 559-568. In D. P. Kelsen and et al. (ed.), Gastrointestinal Oncology: Principles and Practice. Williams and Wilkins, Philadelphia.
  10. Jacobson, I. M. 2003. Imaging Overview, p. 281-286. In E. R. Schiff, M. F. Sorrell, and W. C. Maddrey (ed.), Schiff's Disease of the Liver, ninth edition. Lippincott, Williams and Wilkins, Philadelphia.
  11. Jacobson, I. M. 2003. Gallstones, p. 772-783. In S. L. Friedman, K. R. McQuaid, and J. H. Grendell (ed.), Current Diagnosis and Treatment in Gastroenterology. Lange, New York.
  12. Rice, C., S. You, G. Randall, J. Zhang, L. K. McMullan, T. Marcello, A. Grakoui, H. L. Hanson, D. Moradpour, B. Lindenbach, and J. McKeating. 2003. Hepatitis C: Unravelling the details of hepatitis C virus replication and immunity, Review of Eleventh International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia.
  13. Ahmed, F., and I. M. Jacobson. 2004. Hepatitis C, p. 118-145. In W. C. Maddrey (ed.), Atlas of the Liver. Current Medicine, Inc., Philadelphia.
  14. Jacobson, I. M. 2004. Evaluation of suitability for therapy. In J. G. McHutchison (ed.), Management issues in hepatitis C infection. Science Press Limited, London.
  15. Jacobson, I. M., and D. B. Purow. 2004. Diseases of the bile ducts, p. 431-445. In L. S. Friedman and E. B. Keeffe (ed.), Handbook of Liver Disease, Second ed. Churchill Livingstone, London.
  16. Kuemmerer, B. M., S. M. Amberg, and C. M. Rice. 2004. Flavivirin. In J. A. Barrett, N. D. Rawlings, and J. F. Woessner (ed.), Handbook of Proteolytic Enzymes. Academic Press, Inc.
  17. Marcotrigiano, J., K. E. Reed, and C. M. Rice. 2004. Hepatitis C Virus Endopeptidase 2. In A. Barrett, N. Rawlings, and J. Woessner (ed.), Handbook of Proteolytic Enzymes, 2nd Edition ed. Academic Press, Inc.
  18. Tellinghuisen, T. L., and C. M. Rice. 2004. The molecular virology of hepatitis C virus, p. 455-495, The Liver in Biology and Disease, Principles of Medical Biology, vol. 15. Elsevier Press.
  19. Thiel, H.-J., M. S. Collett, E. A. Gould, F. X. Heinz, M. Houghton, G. Meyers, R. H. Purcell, and C. M. Rice. 2004. Flaviviridae, ICTV Report. ICTV.
  20. Brown Jr, R. S., and S. A. Fink. 2005. Current indications, contraindications, de-listing criteria and timing for liver transplantation, p. 96-112. In R. Busuttil and G. Klintmalm (ed.), Transplantation of the Liver. Elsevier, St. Louis.
  21. Hietpas, J., L. K. McMullan, D. P. Mindell, H. L. Hanson, and C. M. Rice. 2005. Keeping track of viruses, p. 55-97. In S. Schutzer, R. Breeze, and B. Budowle (ed.), Microbial Forensics. Elsevier Academic Press, St. Louis.
  22. Raynshteyn, E., and S. Sigal. 2005. Hepatitis C, Encyclopedia Krugosvet. Krugosvet, Moscow.
  23. Ahmed, F., and I. M. Jacobson. 2006. Hepatitis C, p. 127-168. In W. C. Maddrey (ed.), Atlas of the Liver, 4th ed. Current Medicine/Springer, Philadelphia.
  24. Calarese, D. A., C. N. Scanlan, H. K. Lee, P. M. Rudd, C. H. Wong, R. A. Dwek, D. R. Burton, and I. A. Wilson. 2006. Towards a carbohydrate-based HIV-1 vaccine. In A. Klyosov (ed.), American Chemical Society Symposium Series: Carbohydrate Drug Design. Oxford University Press, Oxford.
  25. Chung, R. T., and S. A. Fink. 2006. Hereditary hemochromatosis. In R. H. Glew and R. D. Rosenthal (ed.), Clinical Studies in Medical Biochemistry. Oxford University Press, Oxford.
  26. Gaglio, P. J., and R. S. Brown Jr. 2006. Post liver transplantation management and complications, p. 961ff. In T. D. Boyer MD, T. L. Wright MD, and M. P. Manns MD (ed.), Zakim and Boyer's Hepatology, Fifth ed, vol. 2. Elsevier, St Louis.
  27. Moradpour, D., and C. Rice. 2006. Replication and Pathogenesis of Hepatitis C Virus, p. 125-147. In T. D. Boyer MD, T. L. Wright MD, and M. P. Manns MD (ed.), Zakim and Boyer's Hepatology, 5th Edition ed, vol. 1. Saunders Elsevier.
  28. Ribeiro, R. M., K. A. Powers, A. H. Talal, and A. S. Perelson. 2006. Modeling the viral dynamics of HCV in patients treated with pegylated interferon alpha-2b, p. 407-420. In R. Schinazi and E. R. Schiff (ed.), Framing the knowledge of therapeutics for viral hepatitis. IHL Press, Arlington.
  29. Talal, A. 2006. Hepatitis C infection, p. 41-44, Clinical Manual for Management of the HIV-infected Adult. Aids Education and Training Centers, Newark.
  30. 2007. Chronic Hepatitis B, vol. 11. Elsevier Saunders, Philadelphia.
  31. Ahmed, F., D. Coll, and I. M. Jacobson. 2007. Imaging, p. 83-126. In E. R. Schiff, M. F. Sorrell, and W. C. Maddrey (ed.), Schiff's Diseases of the Liver. Lippincott, Williams and Wilkins, Philadelphia.
  32. Cheruvu, S., A. B. Beeder, M. R. Carden, B. R. Edlin, and A. H. Talal. 2007. Interventions to control hepatitis C infection among injection drug users, p. 23-30. In F. Negro (ed.), Hot Topics in Viral Hepatitis 2007, vol. 6. Fb Communications, Modena.
  33. Dove, L. M., and R. S. Brown Jr. 2007. Patient selection for liver transplantation, UpToDate for Patients. UpToDate, Inc.
  34. Jacobson, I. M. 2007. Clinics in Liver Disease: Chronic Hepatitis B, vol. 11. Elsevier Saunders, St. Louis.
  35. Lindenbach, B., H.-J. Thiel, and C. Rice. 2007. Flaviviridae: the viruses and their replication., p. 1101-52. In B. Fields, D. Knipe, and P. Howley (ed.), Fields Virology, 5th Edition ed. Lippincott Williams & Wilkins, Philadelphia.
  36. Olsen, S. K., and R. S. Brown Jr. 2007. Living donor liver transplantation: Outcomes and controversies with lives in the balance. AGA Institute Press, Bethesda.
  37. Voigt, L., S. H. Sigal, and N. A. Halpern. 2007. Perioperative Critical Care in Hepatobiliary Surgery. In L. H. Blumgart (ed.), Blumgart: Surgery of the Liver, Biliary Tract, and Pancreas, 4th ed. Elsevier, New York.
  38. Gaglio, P. J., and R. S. Brown Jr. 2008. Medical care of the liver transplantation recipient, UpToDate for Patients. UptoDate, Inc.
  39. Jacobson, I. M., and S. A. Harrison. 2008. Hepatitis C: Current and Future Therapies, p. 21-92. In B. R. Bacon and K. J. Reddy (ed.), Current Hepatitis Reports 2008, vol. 7.
  40. Renz, J. F., and R. S. Brown Jr. 2008. The dilemma of adult-to-adult living donor liver transplantation. In G. T. Everson and J. Trotter (ed.), Liver Transplantation: Challenging controversies and topics. Humana Press/Springer-Verlag, Totowa.
  41. Russo, M. R., and R. S. Brown Jr. 2008. Liver transplant cost analysis p. 671-677. In R. Gruessner and E. Benedetti (ed.), Living donor organ transplantation. McGraw-Hill, New York.
  42. Sheldon, J., and M. Bottecchia. 2008. Resistencia a lost antivirales en el VHB, p. 125-136. In V. Soriano and J. Gonzalez-Lahoz (ed.), Coinfeccion VIH y haptitis viricas en 2008. Permanyer SL, Madrid.
  43. Sheldon, J., and J. Garcia-Samaneigo. 2008. Mecanismos de seleccion de mutantes resistentes a los farmacos antivirales, p. 97-113. In J. Enrique and P. Balanzo (ed.), Hepatitis B. Marge Medica Books.
  44. Renz, J. F., and R. S. Brown Jr. 2009. The dilemma of adult-to-adult living donor liver transplantation. In G. T. Everson and J. Trotter (ed.), Liver Transplantation. Humana Press, New York.
  45. Sheldon, J. 2009 In press. Resistencias a los antivirales en el VHB. In V. Soriano and J. Gonzalez-Lahoz (ed.), Co-infeccion VIH y Hepatitis B. Permanyer SL, Madrid.
  46. Sheldon, J. 2009, In press. Replicacion in vitro y resistencias en el virus de la hepatitis C. In V. Soriano and J. Gonzalez-Lahoz (ed.), X Curso de Biologia Molecular para clinicos. Permanyer SL.
  47. Weisberg, I. S., S. H. Sigal, and R. S. Brown Jr. In press. Transvenous liver biopsy, Clinical Hepatology, Principles and Practice of Hepatobiliary Disease. Springer.
  48. Brown Jr, R. S., S. H. Sigal, and F. Poordad. In press. Pathophysiologic basis for the medical management of portal hypertension, Expert Opinion on Pharmacotherapy. Informa Healthcare, Cambridge.
  49. Lorenz, I. C., J. McKeating, and C. Rice. In press. Assembly and Entry of HCV, Current Topics in Microbiology and Immunology.
  50. Sheldon, J., and J. Garcia-Samaneigo. In press. Mecanismos de seleccion de mutantes resistentes a los farmacos antivirales. In J. Enrique and P. Balanzo (ed.), Hepatitis B. P. Marge Medica Books, Madrid.
  51. Fink, S. A., and R. S. Brown Jr. In publication. Liver Transplantation. In H. Dancygier (ed.), Textbook of Hepatology. Springer-Verlag, New York.
  52. Gaglio, P., and R. S. Brown Jr. Submitted. Medical care of the liver transplant recipient, UpToDate. UptoDate, Inc. Conference Presentations (oral and poster)
  53. Goldsweig, C., H. Remotti, I. Jacobson, and M. Russo.2000. A case report of multiple myeloma involving the liver, Presented at the American College of Gastroenterology Annual Meeting, New York.
  54. Goldsweig, C. D., R. S. J. Brown, I. M. Jacobson, and M. W. Russo. 2000. A meta-analysis of interferon trials in patients with hepatitis C on demodialysis, Presented at the American College of Gastroenterology Annual Meeting, New York.
  55. Rudow, D., E. Shane, V. Dodd, M. Russo, J. Emond, and R. Brown. 2000. Prevalence of bone disease in patients with cirrhosis, Presented at the Fifty-first Annual Meeting of the American Association for the Study of Liver Diseases, Dallas.
  56. Talal, A., H. Yee, and D. Dieterich. 2000. Effect of Hepatitis C virus and HIV-1 on hepatic parenchymal and mononuclear cell proliferation and apoptosis, Presented at the Digestive Disease Week, San Diego.
  57. Talal, A. H., C. E. Irwin, L. Zhang, D. T. Dieterich, and D. D. Ho. 2000. Effect of HIV-1 on lymphocyte proliferation and apoptosis in gut associated lymphoid tissue, Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, Washington DC.
  58. Anandasabapathy, S., D. Nikolic-Djokic, G. Dorante, S. Flynn, H. Pollack, W. Borkowsky, and A. H. Talal. 2001. Hepatitis C virus (HCV)-specific immune responses and viral load in HIV-1/HCV co-infected individuals before and after interferon-alfa2a therapy, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dallas.
  59. Barritta, D., I. M. Jacobson, S. Esposito, and M. W. Russo. 2001. The effect of milk thistle (Silymarin) on serum alanine aminotransferase and viral levels in patients with chronic hepatitis C, Presented at the American College of Gastroenterology Annual Meeting, Las Vegas.
  60. Bart, G., L. Borg, P. Piccolo, M. Green, A. Wells, A. Ho, L. Zhang, S. Handy, R. Schaefer, I. Jacobson, and M. Kreek. 2001. Current prevalence of hepatitis A, B and C serologic markers, hepatitis C genotype and viral load in former opiate addicts in methadone maintenance treatment, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  61. Brideau-Andersen, A., C. M. Rice, M. Tripodi, and F. V. Chisari. 2001. Inducible expression of the HCV open reading frame in differentiated murine hepatocytes, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  62. Canchis, W., I. Fiel, L. Chiriboga, I. Jacobson, L. Johnson, D. Dieterich, H. Yee, and A. H. Talal. 2001. Hepatocyte and infiltrating hepatic lymphocyte proliferation and apoptosis in HIV/HCV coinfected and HCV monoinfected individuals, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  63. Elazar, M., P. Liu, H. B. Greenberg, C. M. Rice, and J. S. Glenn. 2001. Mechanism of NS5A's membrane association and role in RNA replication, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  64. Fiel, I., N. Reddy, D. Barritta, M. Russo, and I. Jacobson. 2001. The intrazonal distribution of steatosis in chronic hepatitis C and the impact of hepatic steatosis on fibrosis and necroinflammatory activity, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  65. Goldstein, M., S. Kapur, M. Kinkhabwala, P. Harren, D. Rudow, S. Lobritto, M. Russo, R. Brown, A. Weinberg, J. Renz, and J. Emond. 2001. Analysis of failure in living donor liver transplantation (LRT): Differential outcomes in children and adults, Presented at the AST Winter Symposium, Honolulu.
  66. Hardy, R. W., K. Blight, and C. M. Rice. 2001. Characterization of hepatitis C virus RNA replication mediated by the authentic viral replicase in vitro., Presented at the American Society for Virology, 20th meeting, Madison.
  67. Jacobson, I., M. Russo, R. Brown, E. Lebovics, A. Min, S. Esposito, H. Tobias, F. Lion, O. Pizov, C. Brass, and the NY Peg Intro Study Group. 2001. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers, Presented at the Digestive Disease Week, Atlanta.
  68. Jacobson, I. M., M. W. Russo, R. S. Brown Jr, E. Lebovics, A. Min, S. Esposito, H. Tobias, F. Klion, O. Pizov, C. Brass, and NY Peg Intron Study Group. 2001. Pegylated interferon alfa-2B plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases, Dallas.
  69. Kumar, J., M. Russo, S. Esposito, A. Borcz, I. Jacobson, M. Brown, and R. Brown. 2001. Severe pulmonary toxicity of interferon (IFN) and ribavirin (RIBA) therapy in chronic hepatitis C, Presented at the American College of Gastroenterology, Las Vegas.
  70. Lebovic, E., E. Castillo, P. Rampersaud, J. Hirsch, A. Casellas, C. McFarlane, S. Esposito, H. Tobias, J. Geders, I. Jacobson, F. Klion, and D. Wolf. 2001. Comparison of hepatic iron content in African Americans and Caucasians with Hepatitis C, Presented at the Digestive Disease Week, Atlanta.
  71. Lindenbach, B., J. Y. Sgro, and P. Ahlquist. 2001. A long distance base pairing interaction in Flock House virus RNA1 controls subgenomic RNA3 synthesis, Presented at the Sixth International Symposium on Positive Strand RNA Viruses, Paris.
  72. Lindenbach, B., J. Y. Sgro, and P. Ahlquist. 2001. Flock House virus subgenomic RNA3 synthesis is controlled by a long distance base pairing interaction in RNA1, Presented at the Twentieth Annual Meeting of the American Society for Virology, Madison.
  73. Major, M. E., J. Fernandez, D. Taylor, K. Mihalik, A. A. Kolykhalov, C. Rice, and S. M. Feinstone. 2001. Persistence of infection in chimpanzees inoculated with an HCV infectious clone: analysis of the molecular evolution of the circulating HCV genomes, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  74. Major, M. E., K. Mihalik, M. Puig, B. Rehermann, M. Nascimbeni, C. Rice, and S. M. Feinstone. 2001. Previously infected chimpanzees exhibit memory immune responses that rapidly control HCV replication upon rechallenge, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  75. McKeating, J. A. 2001. HCV glycoprotein biogenesis and cellular localization in hepatoma cells supporting full length HCV genome replication, Presented at the Third Annual Midwinter Hepatitis C Virus Symposium, Barbados.
  76. Mizukoshi, E., M. Nascimbeni, J. B. Blaustein, J. Miller, C. Rice, T. J. Liang, S. M. Feinstone, and B. Rehermann. 2001. The repertoire of HCV epitopes and T cell specificities generated in vivo during HCV infection extends across species barriers and can be predicted according to HLA-PATR orthologues, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  77. Morrison, L. A., and L. B. Dustin. 2001. Differential protection of the genital tract from HSV-2 infection promoted by mucosal and parenteral immunization, Presented at the American Society for Virology Annual Meeting, Madison.
  78. Nascimbeni, M., M. E. Major, K. Mihalik, C. Rice, S. M. Feinstone, and B. Rehermann. 2001. Intrahepatic innate and adaptive immune responses in HCV infected chimpanzees, Presented at the Eighth International Symposium on Hepatitis C Virus and Related Viruses, Paris.
  79. Russo, M., S. Esposito, R. Brown, K. Foulger, and I. Jacobson. 2001. Complementary-alternative medicine (CAM) use among patient with chronic hepatitis C infection (HCV), Presented at the Digestive Disease Week, Atlanta.
  80. Sood, A., I. Jacobson, and M. Russo. 2001. A meta-analysis of mortality and encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites, Presented at the Annual Meeting of the American College of Gastroenterology, Las Vegas.
  81. Sood, A., N. Reddy, M. Russo, R. Brown, and I. Jacobson. 2001. Use of granulocyte colony stimulating factor (GCSF) for Interferon-induced neutropenia in patient with chronic Hepatitis C infection, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Dallas.
  82. Sood, A., M. Russo, I. Jacobson, A. Talal, and R. Brown. 2001. A meta-analysis of transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites, Presented at the Digestive Disease Week, Atlanta.
  83. Talal, A., S. Flynn, G. Dorante, G. Soto, J. Jin, R. Ribeiro, and A. Perelson. 2001. Hepatitis C virus dynamics in HIV/HCV co-infection in response to daily, high-dose interferon-a2A, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Dallas.
  84. Vaamonde, C., L. Szczech, and A. Talal. 2001. Renal function in HIV-infected individuals with and without hepatitis C co-infection, Presented at the Fifty-second Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Dallas.
  85. Zhang, L., W. Yu, Y. Guo, J. Yu, A. Kim, T. He, C. Irwin, A. Talal, M. Markowitz, and D. Ho. 2001. Abnormalities in gd T cells persist in HIV-1-infected individuals despite prolonged treatment with HAART (Abstract No. 44), Presented at the The Eighth Conference on Retroviruses and Opportunistic Infections, Washington DC.
  86. Anglade, P., M. W. Russo, A. Talal, and I. M. Jacobson. 2002. Characteristics of patients with chronic hepatitis C and no fibrosis (Stage O), Presented at the Digestive Disease Week, San Francisco.
  87. Balan, V., I. Jacobson, R. Brown, N. Afdhal, R. Rubin, J. Spivey, B. Freilich, D. Bernstein, V. Sharma, C. Brass, and WIN-R Study group. 2002. Regional and racial variation of hepatitis C genotypes in the United States, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  88. Balfe, P., K. Blight, P. Lopez, C. Rice, and J. McKeating. 2002. Interplay between hepatitis C virus and the host cell cycle, Presented at the The Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  89. Bamji, N., M. W. Russo, A. Talal, P. W. Canchis, J. Davila, and I. M. Jacobson. 2002. Therapy with interferon decreases serum a-fetoprotein (AFP) levels in individuals with chronic hepatitis C (HCV), Presented at the Digestive Disease Week, San Francisco.
  90. Bart, G., P. Piccolo, A. Wells, A. Ho, L. Zhang, S. Handy, R. Schaefer, I. Jacobson, and M. Kreek. 2002. Hepatitis C virus and serologically silent hepatitis B virus coinfection in former opiate addicts in methadone maintenance treatment (MMT), Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  91. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for Hepatitis C virus replication, Presented at the The Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  92. Brideau-Andersen, A., A. Althage, J. Chung, C. Rice, and F. V. Chisari. 2002. Inducible expression of the entire HCV polyprotein in transgenic mice, Presented at the Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  93. Brown, R., I. Jacobson, N. Afdhal, R. Rubin, J. Spivey, F. Regenstein, D. Bernstein, C. Brass, and B. Freilich. 2002. Racial/ethnic differences in hematologic toxicity of pegylated interferon and ribavirin therapy: Analysis of the Win-R trial, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  94. Canchis, P. W., J. Davila, M. I. Fiel, I. M. Jacobson, L. Chiriboga, H. T. Yee, and A. H. Talal. 2002. Characterization of intrahepatic lymphocytes and hepatocytes in HIV/HCV coinfected and HCV monoinfected individuals, Presented at the The Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  95. Canchis, P. W., M. I. Fiel, N. Bamji, J. Davila, M. Russo, L. Chiriboga, H. Yee, A. H. Talal, and I. M. Jacobson. 2002. Proliferation and apoptosis in liver biopsies from patients with hepatitis C and elevated alpha-fetoprotein, Presented at the Digestive Disease Week, San Francisco.
  96. Canchis, P. W., I. Jacobson, A. H. Talal, M. Russo, N. Banji, J. Davila, L. Chiriboga, H. Yee, and M. I. Fiel. 2002. Stellate cell activation in NASH, HCV/NASH and normal liver biopsies, Presented at the Digestive Disease Week, San Francisco.
  97. Canchis, P. W., A. H. Talal, I. M. Jacobson, M. W. Russo, J. Davila, A. Teixeira, L. Chiriboga, H. Yee, and I. Fiel. 2002. Hepatic stellate cell activation, hepatic stellate cell and hepatocyte proliferation and apoptosis in liver biopsies from individuals with HCV, steatohepatitis and HCV/steatohepatitis, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  98. Donovan, M., M. W. Russo, P. Y. Kim, M. Kinkhabwala, J. McCarthy, P. J. Gaglio, S. Hafliger, R. S. J. Brown, and J. C. Emond. 2002. Risk factors for neurological complications following liver transplantation, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  99. Dustin, L. B., J. Ni, E. G. Hembrador, T. J. Chambers, A. M. DiBisceglie, G. Dorante, A. H. Talal, I. M. Jacobson, and C. M. Rice. 2002. Peripheral blood B cell expansion in HCV infection is not associated with activation or differentiation, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  100. Evans, M., K. Blight, C. Rice, and S. Goff. 2002. The interaction between NS5A and HVAP-A: requirements for HCV RNA replication, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  101. Flint, M., A. North, K. J. Blight, Z.-Y. Keck, H.-P. Hauri, C. M. Rice, and J. A. McKeating. 2002. Co-localization of Hepatitis C virus structural and non-structural proteins in Huh-7 cells supporting full length RNA replication, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  102. Frolov, I., R. Fayzulin, S. Cook, D. Griffin, and C. Rice. 2002. Role of Sindbis virus NSP2 and IFN in determining outcome of infection, Presented at the The World of Microbes, IUMS, Paris.
  103. Gaglio, P., S. Malireddy, and M. Russo. 2002. Hepatitis C recurrence in recipients of grafts from living vs. cadaveric living donors, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  104. Gordon, S., B. R. Bacon, I. Jacobson, M. Shiffman, N. Afdhal, J. McHutchison, T. J. Kwoh, and F. A. Dorr. 2002. A phase II, 12-week study of Isis 14803, An antisense inhibitor of HCV for the treatment of chronic hepatitis C, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  105. Grakoui, A., N. H. Shoukry, H. L. Hanson, C. M. Rice, and C. M. Walker. 2002. Resolution of acute HCV infection: the role for CD4+ T Cells, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  106. Hellinger, J., M. Glesby, A. Stein, A. Talal, S. Tuscher, T. Greenough, M. Becker, A. Chu, and C. Choen. 2002. Evaluation of oral pancrelipase (Ultrae MT-20) for the symptomatic control of Nelfinavir-associated diarrhea, Presented at the Fourteenth International AIDS Conference, Barcelona.
  107. Jacobson, I., R. Brown, Jr., N. Afdhal, R. Rubin, J. Spivey, B. Freilich, D. Bernstein, C. Bass, and Win-R Study Group. 2002. Effect of weight based ribavirin dosing on hematologic parameters: preliminary safety data from WIN-R, Presented at the Digestive Disease Week, San Francisco.
  108. Jacobson, I., R. Brown, N. Afdhal, R. Rubin, J. Spivey, B. Freilich, F. Regenstein, D. Bernstein, R. Doig, C. Brass, and Win-R Study Group. 2002. Characteristics of HCV infection in African-Americans: Findings from the WIN-R trial, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  109. Jacobson, I., M. Russo, R. Brown, Jr., E. Lebovics, A. Min, S. Esposito, H. Tobias, F. Klion, D. Rovner, C. Brass, and NY Peg Intron Study Group. 2002. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  110. Jacobson, I., M. Russo, E. Lebovics, S. Esposito, H. Tobias, F. Klion, R. Brown, D. Dieterich, C. Brass, and The NY normal ALT Study Group. 2002. Interferon alfa-2b ribavirin for patients with chronic hepatitis C and normal ALT: final results, Presented at the Digestive Disease Week, San Francisco.
  111. Jacobson, I. M., R. Brown, N. Afdhal, R. Rubin, J. Spivey, B. Freilich, F. Regenstein, D. Bernstein, R. Doig, and C. Brass. 2002. Clinical correlates of HCV genotype and viral load: Findings from the WIN-R trial, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  112. Kuemmerer, B. M., E. Agapov, T. M. Myers, C. L. Murray, L. Qu, E. Mendez, I. Frolov, and C. M. Rice. 2002. Nonstructural proteins participate in infectious virus production for members of the flaviviridae, Presented at the IUBMB Symposium on Genome Replication of RNA Viruses, Helsinki.
  113. Kuemmerer, B. M., and C. Rice. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles, Presented at the JahresTagung Gesellschaft fur Virologie, Erlangen.
  114. Major, M. E., K. Mihalik, E. Mizukoshi, B. Rehermann, C. M. Rice, and S. M. Feinstone. 2002. Outcome of HCV infection in chimpanzees is independent of route or dose of inoculation and acute phase responses, Presented at the Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  115. Marcellin, P., T. Chang, S. Lim, S. Hadziyannis, N. Tassopoulos, M. Tong, W. Sievert, M. Shiffman, L. Jeffers, Z. Goodman, M. Wulfsohn, S. Xiong, C. James, J. Fry, C. Brosgart, and The GS-98-437 and GS-98-438 Study Investigators(Jacobson). 2002. Adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B, Presented at the Digestive Disease Week, San Francisco.
  116. Mirani, G., P. Canchis, D. Trost, A. Asch, I. Jacobson, A. Talal, and D. DiMichele. 2002. Transjugular liver biopsy (TJLB) is safe and diagnostic in patients with congenital bleeding disorders and chronic hepatitis C (HCV), Presented at the American Society for Hematology Annual Meeting, Philadelphia.
  117. Nascimbeni, M., M. E. Major, K. Mihalik, C. Rice, S. M. Feinstone, and B. Rehermann. 2002. Intrahepatic T cells in hepatitis C: CD4+ T cells with a distinct cytokine profile contribute to HCV clearance in the absence of liver injury, Presented at the Ninth International Meeting on HCV and Related Viruses, San Diego.
  118. Nascimbeni, M., E. Mizukoshi, M. Bosmann, M. E. Major, K. Mihalik, C. Rice, S. M. Feinstone, and B. Rehermann. 2002. Protective immunity against hepatitis C virus exerted by CD4+ and CD8+ memory T cells, Presented at the Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  119. Nascimbeni, M., E. Mizukoshi, M. Bosmann, M. E. Major, K. Mihalik, C. Rice, S. M. Feinstone, and B. Rehermann. 2002. Differential regulation of CD4++ and CD8+ memory T cells during HCV rechallenge of chimpanzees, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  120. Purow, D., N. Bamji, A. Talal, M. Russo, and J. IM. 2002. Estimated rates of fibrosis progression in patients with chronic hepatitis C do not accurately predict actual fibrosis progression: the importance of liver biopsy in making treatment decisions, Presented at the Digestive Disease Week, San Francisco.
  121. Ribeiro, R., A. Talal, J. Layden, K. Powers, T. Layden, and A. Perelson. 2002. The effect of IFN-based therapies on the short-term dynamics of ALT in HCV-infected patients, Presented at the Thirty-seventh Annual Meeting of the European Association for the Study of the Liver, Madrid.
  122. Rudow, D., M. Russo, and L. Rosenthal. 2002. Impact of living donors on the survival of a cohort of patients listed for OLT, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  123. Rudow, D. L., M. W. Russo, L. Rosenthal, M. Kinkhabwala, J. C. Emond, and R. S. Brown Jr. 2002. Impact of living donors on the survival of a cohort of patients listed for OLT, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  124. Russo, M., A. Teixeira, J. Guarrera, I. M. Jacobson, D. L. Rudow, M. Kinkhabwala, J. C. Emond, and R. S. Brown Jr. 2002. Kinetics of biochemical recovery in adult living donor liver transplantation (ALDT) is prolonged compared to cadaveric (CAD) transplantation, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  125. Russo, M., A. Teixeira, D. Rudow, J. Guerrera, P. J. Gaglio, R. S. Brown Jr., J. Emond, and M. Kinkhabwala. 2002. Return of graft function in donors after living donor liver transplantation, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  126. Russo, M. W., A. Teixeira, J. Guarrera, I. M. Jacobson, D. L. Rudow, M. Kinkhabwala, J. C. Emond, and R. S. J. Brown. 2002. Kinetics of biochemical recovery in adult living donor liver transplantation (ALDT) is prolonged compared to cadaveric (CAD) transplantation, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  127. Russo, M. W., A. Teixeira, D. L. Rudow, J. Guerrera, P. J. Gaglio, and R. S. J. Brown. 2002. Return of graft function in donors after adult living donor liver transplantation, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  128. Shoukry, N. H., A. Grakoui, C. M. Rice, and C. M. Walker. 2002. Role of CD8+ T cells in clearance of HCV infection, Presented at the Ninth International Meeting on Hepatitis C Virus and Related Viruses, San Diego.
  129. Szczech, L. A., A. Talal, and C. M. Vaamonde. 2002. The effect of coinfection with HIV and hepatitis C on the prevalence of proteinuria and loss of renal function, Presented at the 35th Annual Meeting of the American Society for Nephrology, Philadelphia.
  130. Talal, A., M. Shata, S. Flynn, G. Dorante, M. Laughlin, R. Ribeiro, and A. Perelson. 2002. HCV dynamics in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  131. Tong, M., E. Schiff, D. Jensen, I. Jacobson, G. Eversen, J. McHutchison, R. Aitcheson, G. Gordon, S. Babcock, J. Enright, L. Maloney, J. A. Sandberg, and L. Blatt. 2002. Preliminary analysis of a phase II study of heptazyme, A nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA, Presented at the Fifty-third Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston, MA.
  132. You, S., A. Branch, D. Stump, I. Jacobson, and C. M. Rice. 2002. Cis-acting Hepatitis C virus RNA elements required for replicons replication in cell culture, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  133. Zhang, J., S. Pohlmann, F. Baribaud, C. Munz, A. Piperno, R. Steinman, R. Doms, C. M. Rice, and J. A. McKeating. 2002. Hepatitis C virus glycoproteins interact specifically with Dc-SIGN and DC-SIGNR, Presented at the The Ninth International Meeting on HCV and Related Viruses, San Diego.
  134. Ahmed, F., P. W. Canchis, A. H. Talal, L. M. Petrovic, and I. M. Jacobson. 2003. Impact of diabetes on chronic hepatitis C, Presented at the Digestive Disease Week, Orlando.
  135. Ahmed, F., I. M. Jacobson, S. T. Chen, S. Cofrancesco, J. Cooley, M. Demicco, B. Freilich, B. Hudes, J. Jensen, A. Levin, K. Lyche, J. McCone, H. P. Monsour, C. Peine, N. Pimstone, T. Rosenfeld, R. Strauss, K. Stokes, N. Terrault, N. Tsai, R. B. Wasserman, G. M. Woolf, R. S. J. Brown, and C. Brass. 2003. Serious Ophthalmologic events during pegylated interferon and ribavirin therapy for chronic hepatitis C: Observations from the WIN-R Trial., Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  136. Ahmed, F., I. M. Jacobson, and et al. 2003. Clinical significance of pegylated interferon induced neutropenia: Results from the WIN-R trial, Presented at the Digestive Disease Week, Orlando.
  137. Ahmed, F., I. M. Jacobson, T. Hargrave, E. Lawitz, B. Migicovsky, V. Reddy, N. Terrault, R. S. Brown Jr., and C. Brass. 2003. Diabetes mellitus of new onset during pegylated interferon and ribavirin therapy for chronic hepatitis C: Observations from the WIN-R Trial, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  138. Ahmed, F., D. Rovner, I. M. Jacobson, C. Albert, M. Brand, M. E. Cox, A. M. Fixelle, J. Herrera, V. K. Rustgi, R. B. Wasserman, R. S. Brown Jr, and C. Brass. 2003. Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R Trial, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  139. Atkinson, J. O., B. R. Edlin, E. A. Engels, A. H. Kral, K. H. Seal, C. J. Gamache, D. Whitby, and T. R. O'Brien. 2003. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco, Presented at the National Institutes of Health Research Festival, Bethesda.
  140. Azzam, H., F. Ahmed, B. Peterson, D. N. Rovner, N. L. Taylor, and I. M. Jacobson. 2003. Delayed recovery of pegylated interferon and ribavirin induced anemia, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  141. Branch, A., S. You, D. Stump, and C. Rice. 2003. Hepatitis C virus has a cis-acting replication element in the polymerase gene: A new feature of the HCV genome with implications for drug development, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  142. Canchis, P. W., L. Petrovic, F. Ahmed, J. Davila, M. Fiel, S. Y. Kim, A. Teixeira, L. Chiriboga, H. Yee, B. R. Edlin, A. H. Talal, and I. M. Jacobson. 2003. Hepatocyte proliferation in hepatitis C: Correlation with degree of liver injury and serum alpha-fetoprotein, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  143. Evans, M. J., C. M. Rice, and S. P. Goff. 2003. Phosphorylation of hepatitis C virus NS5A regulates it interaction with tSNARE hVAP-A and viral RNA replication, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  144. Golia, P., G. Dorante, S. Cunningham-Rundles, and A. Talal. 2003. Interferon-gamma inducible protein-10 concentration is increased in nonresponders compared to responders in chronic HCV-infected patients, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  145. Golia, P., I. Jacobson, and A. Talal. 2003. A preliminary study of growth factors versus dose reduction for peg-interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infection patients, Presented at the Digestive Disease Week, Orlando.
  146. Golia, P., K. A. Powers, G. Dorante, S. Cunningham-Rundles, R. M. Ribeiro, M. Shata, A. Perelson, and A. Talal. 2003. Pharmacodynamics and pharmacokinetics of hepatitis C virus (HCV) and pegylated interferon-alfa 2b in human immunodeficiency virus (HIV)/HCV co-infected patients, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  147. Gonzalez, S., M. Shata, G. Dorante, I. Jacobson, and A. Talal. 2003. Hepatitis C virus-specific effector cell mediated responses in transient virologic responders, Presented at the Digestive Disease Week, Orlando.
  148. Gonzalez, S. A., M. T. Shata, I. M. Jacobson, and A. H. Talal. 2003. A preliminary study of hepatitis C virus-specific cell mediated responses in transient virologic responders, Presented at the Rogers Annual Competition at Weill Medical College, New York.
  149. Gordon, S. C., B. R. Bacon, I. M. Jacobson, M. Shiffman, N. H. Afdhal, R. Z. Yu, J. G. McHutchison, and J. Kwoh. 2003. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  150. Jacobson, I. M., F. Ahmed, M. D. Russo, R. S. J. Brown, and e. al. 2003. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results, Presented at the Digestive Disease Week, Orlando.
  151. Lake-Bakaar, G., L. Ruffini, and S. D. Frost. 2003. Nonlinear HCV and linear ALT dynamics in serum during high dose interferon, Presented at the Digestive Disease Week, Orlando, FL.
  152. Longman, R. S., I. Jacobson, A. Talal, R. Darnell, M. Albert, and C. Rice. 2003. Understanding the role of dendritic cells in the pathogenesis of chronic HCV infection, Presented at the Days of Molecular Medicine Conference, San Diego.
  153. Major, M. E., H. Dahan, K. Mihalik, M. Puig, C. Rice, A. U. Neumann, and S. M. Feinstone. 2003. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  154. Major, M. E., H. Dahari, X. Zhang, K. Mihalik, C. M. Rice, A. U. Neumann, and S. M. Feinstone. 2003. Modeling immune effects on viral dynamics and outcome of primary hepatitis C infection in chimpanzees, Presented at the Eleventh International Symposium on Viral Hepatitis and Liver Disease, Sydney.
  155. Manigold, T., C. Piccirillo, K. Mihalik, C. M. Rice, S. M. Feinstone, and B. Rehermann. 2003. CD4+ CD25+ regulatory T cells control effector functions of HCV-specific memory CD8+ T cells in HCV-recovered chimpanzees, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  156. Mizukoshi, E., C. Eisenbach, B. R. Edlin, C. Weiler, M. Carrington, C. O'Brien, and B. Rehermann. 2003. HCV-specific cellular immune responses in subjects who are anti-HCV-negative, HCV RNA-negative despite long-term (>15 years) injection drug use, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  157. Moradpour, D., K. A. Evans, R. Gosert, Z. Yuan, H. E. Blum, S. P. Goff, B. Lindenbach, and C. Rice. 2003. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional HCV replication complexes in living cells, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  158. Moradpour, D., M. Evans, R. Gosert, Z. Yuan, H. E. Blum, S. Goff, B. Lindenbach, and C. Rice. 2003. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes in living cells, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  159. Moss, A. R., A. Chandra, P. J. Gaglio, S. Hafliger, L. Dove, S. Lobritto, I. M. Jacobson, and R. Brown, Jr. 2003. Suspicion, not standardized depression scores, increases adherence to pegylated interferon and ribavirin therapy for hepatitis C, Presented at the Digestive Disease Week, Orlando.
  160. Moss, J. L. G., L. E. Senkbeil, P. J. Gaglio, S. Hafliger, L. Dove, S. Lobritto, I. M. Jacobson, and R. S. Brown Jr. 2003. Sustained viral response during HCV treatment is associated with higher depression scale scores, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  161. Raison, C. L., A. S. Borisov, S. D. Broadwell, A. K. Manatunga, B. J. Woolwine, I. M. Jacobson, C. B. Nemeroff, and A. H. Miller. 2003. Depression during IFN-alfa plus ribavirin therapy: prevalence and prediction, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  162. Raison, C. L., S. D. Broadwell, A. S. Borisov, A. K. Manatunga, B. J. Woolwine, I. M. Jacobson, C. B. Nemeroff, and A. H. Miller. 2003. Depressive symptoms during IFN-alpha/ribavirin therapy are associated with reduced viral clearance in patients with hepatitis C, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  163. Randall, G., M. Panis, J. Zhang, J. McKeating, T. L. Tellinghuisen, K. A. Soukhodolets, and C. M. Rice. 2003. Interfering with hepatitis C virus replication, Presented at the New York Academy of Sciences: Frontiers in Science. RNAi-based analysis of gene function., New York.
  164. Riess, T. H., M. Downing, K. Vernon, C. McKnight, D. C. Des Jarlais, and B. R. Edlin. 2003. What's community got to do with it?: Implementation models for community acceptance of syringe exchange programs, Presented at the 131st Annual Meeting of the American Public Health Association, San Francisco.
  165. Seal, K. H., R. Thawley, J. P. Hammond, M. Downing, J. Banberger, D. Ciccarone, A. H. Kral, and B. R. Edlin. 2003. Providing naloxone and resuscitation training to heroin injectors can save lives, Presented at the 131st Annual Meting of the American Public Health Association, San Francisco.
  166. Senkbeil, L. E., J. G. Moss, P. J. Gaglio, L. Dove, S. Lobritto, I. M. Jacobson, and R. S. J. Brown. 2003. Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment, Presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Boston.
  167. Shin, E.-C., U. Protzer, A. Untergasser, H. Dana, C. M. Rice, S. M. Feinstone, and B. Rehermann. 2003. Effect of liver-specific IFN-gamma expression in chronic hepatitis C virus infection, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  168. Talal, A., T. Lee, M. Simm, G. Dorante, T. Shata, and S. Cunningham-Rundles. 2003. NK-T cells are important determinants of HCV RNA levels, Presented at the Digestive Disease Week, Orlando.
  169. Zhang, J., G. Randall, A. Higginbottom, C. Logvinoff, P. Monk, C. Rice, and J. McKeating. 2003. CD81 is essential for hepatitis C virus glycoprotein mediated viral infection, Presented at the Tenth International Meeting on Hepatitis C Virus and Related Viruses, Kyoto.
  170. Afdhal, N., B. Freilich, R. Levine, M. Black, R. S. Brown Jr, H. Monsour, M. O'Brien, and C. A. Brass. 2004. Colchicine versus PegIntron long term (Copilot) Trial: Interim analysis of clinical outcomes at year 2, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  171. Ahmed, F., I. M. Jacobson, R. S. J. Brown, J. Vierling, T. Box, J. L. Cochran, J. B. Gross, H. Matossian, M. Rabinovitz, G. Sahagun, T. Sepe, and C. Brass. 2004. Arrhythmias during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial, Presented at the Digestive Disease Week, New Orleans.
  172. Arora, N., S. Bellemare, P. Gaglio, J. Emond, L. Dove, R. S. Brown Jr, J. Renz, and M. Kinkhabwala. 2004. Fate of livers nobody wants, Presented at the American Transplant Congress, Boston.
  173. Berg, C. L., M. Abecassis, R. S. Brown Jr, J. E. Everhart, B. W. Gillespie, T. E. Hulbert-Shearon, and R. M. Merion. 2004. Living donor liver transplantation reduces the risk of death of transplant candidates, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  174. Butera, D., S. Marukian, I. M. Jacobson, A. M. Di Bisceglie, T. J. Chambers, C. M. Rice, and L. B. Dustin. 2004. Interferon-gamma stimulated chemokines predict treatment outcome in patients with chronic HCV infection, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses, Heidelberg.
  175. Davern II, T. J., M. L. Schilsky, L. S. Hynan, W. M. Lee, and The Acute Liver Failure Study Group. 2004. Prevalence of diabetes mellitus is not increased in acute liver failure, Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston.
  176. Dickson, R. C., N. Terrault, M. Ishitani, R. Reddy, P. Sheiner, C. Soldevila-Pico, V. Luketic, R. Brundage, D. Jensen, M. Fried, R. S. Brown Jr, L. Muenz, G. Horwith, and A. Lok. 2004. The effect of hepatitis B replication status on hepatitis B immunoglobulin does requirements and pharmacokinetics in liver transplantation for hepatitis B virus, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  177. Fasola, C. G., T. G. Heffron, L. Sher, D. D. Douglas, R. S. Brown Jr, J. Ham, L. Teperman, M. Hanaway, D. Eckhoff, K. W. Washburn, M. Millis, J. Roberts, P. Baliga, T. Pruett, B. Koneru, E. Pomfret, M. Abecassis, and G. B. Klintmalm. 2004. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): A 90-day report, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  178. Flamm, S. L., J. Goldman, J. Cahan, G. Nelligan, D. Chua, B. Shapiro, M. Bawani, R. Yapp, E. Jurkovic, R. S. Brown Jr, S. Skahen, and T. Jackson. 2004. PEG-IFN 2B 1.0 G/KG/Wk + Ribavirin is equally effective as PEG-IFN 2B 1.5 G/KG/Wk + Ribavirin: Preliminary SVR results from a prospective, randomized, controlled multi-center trial, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  179. Flint, M., J. Zhang, C. Logvinoff, A. Sibahi, R. Garry, P. Balfe, C. M. Rice, and J. A. McKeating. 2004. The early steps of hepatitis C virus glycoprotein-dependent virus entry, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses, Heidelberg.
  180. Frolov, I. V., R. Gorchakov, E. I. Frolova, B. R. Williams, and C. M. Rice. 2004. PKR-dependent and PKR-independent mechanisms are involved in translational shutoff during Sindbis virus infection, Presented at the Twenty-third Annual Meeting of the American Society for Virology, Montreal.
  181. Gaglio, P., S. Jakab, A. Novogrudsky, J. C. Emond, and R. S. Brown Jr. 2004. Hepatitis C recurrence following liver transplantation: Does histologic severity of inflammation in the explant correlate with recurrence?, Presented at the American Transplant Congress, Boston.
  182. Gaglio, P., E. C. Verna, A. Novogrudsky, J. Lefkowitch, M. Kinkhabwala, J. C. Emond, and R. S. Brown Jr. 2004. HCV associated cholestasis related to biliary complications following deceased and living donor liver transplantation: Poor outcomes despite therapy, Presented at the American Transplant Congress, Boston.
  183. Gaglio, P. J., E. Verna, A. Novogrudsky, J. Lefkowitch, M. Kinkhabwala, J. C. Emond, and R. S. Brown Jr. 2004. Cholestatic hepatitis C in patients with biliary obstruction after deceased and living donor liver transplantation: Poor outcomes despite therapy, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  184. Gonzalez, S. A., and I. M. Jacobson. 2004. Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging, Presented at the Digestive Disease Week, New Orleans.
  185. Hao, L., B. Lindenbach, X. Wang, B. Dye, D. B. Kushner, and P. Ahlquist. 2004. Systematic, genome-wide identification of host genes affecting Nodavirus RNA replication, Presented at the Seventh International Symposium on Positive Strand RNA Viruses, San Francisco.
  186. Harren, P., R. S. Brown Jr, J. C. Emond, and S. J. Lobritto. 2004. Safety and efficacy of liver viral vaccines in post liver transplant recipients on montherapy immunosuppression, Presented at the American Transplant Congress, Boston.
  187. Hassanein, T., T. Flemming, R. S. Brown Jr, B. M. McGuire, P. Lynch, R. Mehta, J. Gornbein, J. Stange, and A. T. Blei. 2004. Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: A prospective, controlled, randomized multicenter trial, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  188. Ho, E., K. Smith, K. Patel, S. Goron, J. M. Pawlotsky, I. M. Jacobson, and J. G. McHutchison. 2004. An improved biomarker panel (FIBROSpectII0 for differentiating mild form more severe liver fibrosis in chronic HCV patients, Presented at the Digestive Disease Week, New Orleans.
  189. Jacobson, I. M., R. S. Brown Jr, J. McCone, M. Black, C. Albert, M. Dragutsky, F. A. Siddiqui, T. Hargrave, P. Kwo, N. Gitlin, L. Lambiasi, G. Galler, V. Araya, B. Freilich, J. Harvey, C. A. Brass, and Win-R Study group. 2004. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-American (AA) compared to flat dose ribavirin with peginterferon alfa-2B combination therapy, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  190. Jakab, S. S., W. Hale, A. B. West, and R. S. Brown Jr. 2004. Mycophenolate Mofetil for drug-induced vanishing bile duct syndrome, Presented at the Digestive Disease Week, New Orleans.
  191. Jones, K., S. Ferrando, A. Talal, C. Truman, and P. Luckett. 2004. High prevalence of fatigue and depression in HIV/Hepatitis C co-infected patients treated with pegylated interferon/ribavirin, Presented at the Fifteenth International AIDS Conference, Bangkok.
  192. Joseph, B., V. Kumaran, I. Volenberg, M. L. Schilsky, and S. Gupta. 2004. Wilson's disease in the LEC rat model is corrected by cell transplantation with hepatic preconditioning using radiation and bile salt administration, Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  193. Kadam, J. S., S. A. Gonzalez, N. L. Taylor, D. N. Rovner, and I. M. Jacobson. 2004. Prognostic significance of positive TMA for HCV RNA wi8th negative PCR after 24 weeks of peginterferon and ribavirin for chronic hepatitis, Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  194. Kral, A. H., J. Lorvick, D. Ciccarone, L. Wenger, L. Gee, A. Martinez, and B. R. Edlin. 2004. HIV prevalence and risk behaviors among men who have sex with men and inject drugs, Presented at the XV International AIDS Conference, Bangkok.
  195. Lai, M., A. Cardenas, J. C. Emond, and R. S. Brown Jr. 2004. Race and payer source are barriers to access to liver transplantation and risk factors for death from cirrhosis in New York state; A statewide analysis, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  196. Lake-Bakaar, G. 2004. Controlled therapy interruption, CTI: A novel approach harnessing memory CD8 T-cell response in chronic HCV therapy, Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  197. Lake-Bakaar, G., V. Freeman, and S. D. Frost. 2004. Interferon-alpha pharmacokinetics and hepatitis C viral dynamics: Possible evidence for early interferon escape, Presented at the Digestive Disease Week, New Orleans.
  198. Lin, A., S. A. Gonzalez, S. Marshall, A. Tignor, C. Ha, G. Dorante, I. Jacobson, S. Cunningham-Rundles, and A. Talal. 2004. Effects of pegylated interferon-a on bright and dim natural killer cell activation in chronic hepatitis C infection, Presented at the Digestive Disease Week, New Orleans.
  199. Lindenbach, B. D., B. M. Pragai, and C. M. Rice. 2004. The C-terminal acidic domain of HCV NS4A is a critical determinant of replication, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses: Molecular Virology, Pathogenesis and Antiviral Therapy, Heidelberg.
  200. Logvinoff, C., D. Netski, M. Major, D. Oldach, S. Heyward, B. Rehermann, P. Balfe, S. M. Feinstone, S. Ray, D. Thomas, H. J. Alter, C. M. Rice, and J. A. McKeating. 2004. The role of neutralizing antibodies in acute and chronic hepatitis C virus infection, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses: Molecular Virology, Pathogenesis and Antiviral Therapy, Heidelberg.
  201. Lok, A. S., A. Regev, E. B. Keeffe, S. H. Han, S. Emre, M. Ishitani, V. Luketic, R. S. Brown Jr, S. K. Fung, and M. Hussain. 2004. Relati8ons between HBV genotypes and HBV variants and indications for liver transplant (LT) in hepatitis B patients in the US, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  202. MacDonald, M. R., and et al. 2004. ZAP is an RNA binding protein and a component of mammalian stress granules, Presented at the American Society for Virology, 23rd Annual Meeting, Montreal.
  203. Marcotrigiano, J., and C. M. Rice. 2004. Structure of the alphavirus nsP3X domain, an RNA-binding protein, Presented at the Seventh International Symposium on positive Strand RNA Viruses, San Francisco.
  204. Marks, K., L. Petrovic, A. Talal, M. Murray, R. Gulick, and M. Glesby. 2004. Hepatic steatosis and associated histological findings in HIV/HCV co-infected patients, Presented at the Eleventh Conference on Retroviruses and Opportunistic Infections, Washington DC.
  205. Marks, K., L. M. Petrovic, A. H. Talal, M. P. Murray, R. M. Gulick, and M. J. Glesby. 2004. Histologic findings and clinical characteristics associated with steatosis in HIV/HCV co-infected patients, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  206. McHutchison, J. G., B. R. Bacon, S. C. Gordon, N. Afdhal, I. M. Jacobson, A. Muir, A. M. Krieg, S. Efler, M. Al-Adhami, H. L. Davis, and T. K. Schmalbach. 2004. Human pharmacologic activity of a new TLR9 agonist antiviral, CPG10101 (Actilon(tm)), Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  207. McMullan, L. K., A. Grakoui, M. Puig, K. Mihalik, A. D. Branch, S. M. Feinstone, and C. M. Rice. 2004. Multiple stop codons in the HCV ARF suggest that expression of F/ARFP is not essential for virus replication but reveal a functional RNA element, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses: Molecular Virology, Pathogenesis and Antiviral Therapy, Heidelberg.
  208. Moss, J. L. G., D. L. Rudow, J. C. Emond, M. Kinkhabwala, D. Marratta, and R. S. Brown Jr. 2004. Obese donors for LDLT do not have an increased rate of serious postoperative complications, Presented at the American Transplant Congress, Boston.
  209. Murray, C. L., J. Marcotrigiano, and C. M. Rice. 2004. Properties of bovine viral diarrhea virus capsid protein, Presented at the Twenty-third Annual Meeting of the American Society for Virology, Montreal.
  210. Nascimbeni, M., E.-C. Shin, E. Mizukoshi, K. Mihalik, C. M. Rice, S. M. Feinstone, and B. Rehermann. 2004. Early incubation phase of acute hepatitis C: T cell differentiation status and cytokine profile correlate with the outcome of infection, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses, Heidelberg.
  211. Paulson, M. S., I. V. Frolov, and C. M. Rice. 2004. Viral determinants of cytopathogenicity in a pestivirus, Presented at the Twenty-third Annual Meeting of the American Society for Virology, Montreal.
  212. Pfeffer, S., M. Zavolan, F. Graesser, G. Randall, B. Lindenbach, C. Rice, V. Simon, D. Ho, D. Marks, B. John, A. Enright, C. Sander, and T. Tuschl. 2004. Small RNA profiles of virus-infected cells, Presented at the Keystone Symposium on siRNAs and miRNAs, Keystone.
  213. Randall, G., M. Panis, T. L. Tellinghuisen, K. A. Soukhodolets, and C. M. Rice. 2004. A systematic RNAi screen of host genes significant for hepatitis C virus replication, Presented at the Keystone Symposium on siRNAs and miRNAs, Keystone.
  214. Renz, J. F., M. Kinkhabwala, D. Jan, S. L. Lobritto, L. M. Dove, D. Lapointe-Rudow, S. Bellemare, R. Varadarajan, R. S. Brown Jr, and J. C. Emond. 2004. Systematic use of liver donor liver transplantation: Differential impact on children and adults, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  215. Rudow, D. L., R. S. Brown Jr, D. Marratta, J. Lee, J. C. Emond, and M. Kinkhabwala. 2004. Asymptomatic thrombocytopenia after donor right hepatectomy: Evidence for occult portal hypertension exists, Presented at the American Transplant Congress, Boston.
  216. Rudow, D. L., M. Kinkhabwala, S. Hafliger, D. Marratta, J. Lee, J. C. Emond, and R. S. Brown Jr. 2004. Declining number of potential living donor candidates for adult LDLT, Presented at the American Transplant Congress, Boston.
  217. Russo, M. W., R. Ghalib, S. H. Sigal, V. Joshi, R. Detwiler, K. Andreoni, and R. Shrestha. 2004. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (Peg-intron) in patients with chronic hepatitis C and end stage kidney disease on dialysis, Presented at the Fifty-fifth Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  218. Tellinghuisen, T. L., J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice. 2004. The NS5A protein of hepatitis C virus is a zinc metallo-protein, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses: Molecular Virology, Pathogenesis and Antiviral Therapy, Heidelberg.
  219. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein, Presented at the Seventh International Symposium on Positive Strand RNA Viruses, San Francisco.
  220. Tscherne, D. M., and C. M. Rice. 2004. Transdominant inhibition of bovine viral diarrhea virus replication, Presented at the Twenty-third Annual Meeting of the American Society for Virology, Montreal.
  221. Wolk, B., B. Buchele, H. Blum, D. Moradpour, and C. M. Rice. 2004. A dynamic view of hepatitis C virus replication complexes, Presented at the Eleventh International Symposium on Hepatitis C Virus and Related Viruses: Molecular Virology, Pathogenesis and Antiviral Therapy, Heidelberg.
  222. Wolk, B., B. Buchele, H. E. Blum, and D. Moradpour. 2004. A dynamic view of hepatitis C virus replication complexes, Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  223. Wolk, B., C. Lemmel, S. Stevanovic, C. Gremion, H. Rammensee, H. E. Blum, A. Cerny, and D. Moradpour. 2004. Identification of naturally processed HCV specific MHC class I ligands, Presented at the Eleventh International Meeting on Hepatitis C Virus and Related Viruses, Heidelberg.
  224. Zhang, C., P. Golia, I. Jacobson, and A. Talal. 2004. Hepatic inflammatory cytokine mRNA expression in hepatitis C virus (HCV) and HCV/human immunodeficiency virus (HIV) co-infected patients, Presented at the Digestive Disease Week, New Orleans.
  225. Brown Jr, R. S., A. S. Lok, R. G. Gish, E. R. Schiff, D. Shouval, Senturk, T. T. Chang, C. Yurdaydin, D. Apelian, L. Fernandes, K. Kleszewski, A. P. Cross, and R. B. Wilber. 2005. Entacavir demonstrates consistent responses among baseline subgroups in the treatment of nucleoside-naive, HbeAg(+) and HbeAg (-) patients with chronic hepatitis B, Presented at the Digestive Disease Week, Chicago.
  226. Carden, M. R., B. R. Edlin, A. H. Talal, E. D. Getter, and M. A. Shu. 2005. Treatment for hepatitis C in active substance users, Presented at the 4th International Conference on Urban Health, Toronto.
  227. Conjeevaram, H. S., M. W. Fried, L. J. Jeffers, N. Terrault, T. E. Wiley-Lucas, N. Afdhal, R. S. Brown Jr, S. H. Belle, P. R. Robuck, and C. D. Howell. 2005. Peginterferon alfa-2A and ribavirin in African American and Caucasian patients with chronic hepatitis C genotype 1, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  228. Dahari, H., R. M. Ribeiro, M. Zeremski, T. Licholai, I. Haller, A. S. Perelson, and A. H. Talal. 2005. Modeling ribavirin pharmacokinetics in HIV-1/HCV-coinfected patients predicts higher intracellular ribavirin concentration in sustained viral responders, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  229. Edlin, B. R. 2005. Five million Americans infected with the hepatitis C virus: A corrected estimate, Presented at the Fifty-sixth Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  230. Edlin, B. R. 2005. Hepatitis C treatment in injection drug users: The NIH consensus conference process, Presented at the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence, Orlando.
  231. Fasola, C. G., T. G. Heffron, L. S. Sher, D. D. Douglas, R. S. Brown Jr, J. Ham, L. Teperman, M. Hanaway, D. E. Eckhoff, K. Washburn, M. Millis, J. P. Roberts, M. R. Charlton, P. Baliga, T. L. Pruett, B. Baliga, E. Pomfret, M. M. Abecassis, and G. Klintmalm. 2005. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): A one year follow up report, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  232. Fasola, C. G., T. G. Heffron, L. S. Sher, D. D. Douglas, R. S. Brown Jr, J. Ham, L. Teperman, M. Hanaway, D. E. Eckhoff, K. W. Washburn, M. Millis, J. P. Roberts, M. R. Charlton, P. Baliga, T. L. Pruett, B. Koneru, E. Pomfret, M. M. Abecassis, and G. Klintmalm. 2005. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): A one year follow up report, Presented at the American Transplant Congress, Seattle.
  233. Flam, S., J. Goldman, J. Cahan, G. Nelligan, D. Chua, B. Shapiro, M. Bawani, R. Yapp, E. Jurkovic, R. S. Brown Jr, S. Skahen, and T. Jackson. 2005. Peg-IFN Alpha 2B (1.5 mcg/kg/wk) + RIB (800-1400 mg daily) is significantly more effective than Peg-IFN Alpha 2B (1.0 mcg/kg/wk) + RIB (800-1400 mg daily) in men with GT 1 and women with GT 2/3: Final results of a prospective, randomized, controlled trial., Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  234. Gaglio, P. J., J. Choi, D. Zimmerman, L. Heller, and R. S. Brown Jr. 2005. Weight based ribavirin in combination with pegylated interferon alpha 2-B does not improve SVR in HCV infected patients who failed prior therapy: Results in 454 patients, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  235. Hassanein, T., F. Tofteng, R. S. Brown Jr, B. M. McGuire, P. Lynch, R. Mehta, F. S. Larsen, J. Stange, D. L. Oliver, and A. Blei. 2005. MELD and SOFA scores as a predictor of transplant free survival time in patients with end stage liver disease complicated by intractable hepatic encephalopathy grades 3 and 4, Presented at the Digestive Disease Week, Chicago.
  236. Jacobson, I. M., R. S. Brown Jr, B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, E. Godofsky, R. Strauss, D. Bernstein, N. Bala, V. Araya, M. Davis, H. Monsour, J. Vierling, F. Regenstein, V. Balan, M. S. Dragutsky, R. W. Herring, R. Rubin, G. W. Galler, M. P. Pauly, L. H. Griffel, C. A. Brass, and WIN-R Study Group. 2005. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R Study, a US community based trial, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  237. Kin, C., J. F. Renz, C. Wang, C. Lin, R. S. Brown Jr, S. Lu, C. Chen, and J. C. Emond. 2005. Hepatocellular carcinoma: A comparative analysis of eastern and western medical practice, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  238. Kin, C. J., J. F. Renz, M. Kinkhabwala, D. Jan, R. Varadarajan, M. J. Goldstein, R. S. Brown Jr, and J. Emond. 2005. Extended donor criteria allografts maximize donor utility and patient access to liver transplantation, Presented at the American Transplant Congress, Seattle.
  239. Kinkhabwala, M., D. Jan, R. Varadarajan, M. J. Goldstein, R. S. Brown Jr, and J. C. Emond. 2005. Cadaver whole organ vs. living donor liver transplantation for hepatocellular carcinoma, Presented at the American Transplant Congress, Seattle.
  240. Lagging, M., J. Romero, J. Westin, L. Dustin, J. M. Pawlotsky, A. U. Neumann, C. Ferrari, G. Missale, B. Haagmans, S. W. Schalm, F. Negro, and K. Hellstrand. 2005. Association with histology, viral kinetics, and outcome during therapy for chronic hepatitis C, Presented at the 12th International Symposium on Hepatitis C and Related Viruses, Montreal.
  241. Lennon, A. M., A. Tan, F. Gleeson, A. Brannigan, J. R. Lennon, J. O'Sullivan, A. White, D. Keegan, H. Mulcahy, J. M. Hyland, K. Sheahan, R. S. Brown Jr, and D. P. O'Donoghue. 2005. Proteomics - A novel method for screening for colorectal cancer?, Presented at the Digestive Disease Week, Chicago.
  242. Marks, K. M., A. H. Talal, and J. B. Bussel. 2005. Experience with Anti-D and IVIG for the treatment of thrombocytopenia in the setting of HCV therapy, Presented at the 12th Annual Symposium on Hepatitis C Virus and Related Viruses, Montreal.
  243. Marukian, S., R. Longman, B. Lindenbach, T. L. Tellinghuisen, C. M. Rice, and L. B. Dustin. 2005. No robust replication of cell culture-produced HCV in lymphoid or moncytoid cells in vitro, Presented at the 12th International Symposium on Hepatitis C and Related Viruses, Montreal.
  244. McHutchison, J., B. R. Bacon, S. C. Gordon, E. Lawitz, M. Shiffman, N. H. Afdhal, I. Jacobson, A. Muir, S. M. Efler, M. Al-Adhami, H. David, and T. Schmalbach. 2005. Relationships of HCV RNA responses to CPG10101, a TLR 9 agonist: pharmacodynamics and patient characteristics, Presented at the Fifty-sixth Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco.
  245. McHutchison, J. G., B. R. Bacon, S. C. Gordon, E. Lawitz, M. Shiffman, N. H. Afdhal, I. M. Jacobson, A. Muir, S. M. Efler, K. Vicari, N. A. Myette, P. P. Murzenok, G. Lipfor, T. K. Schmalbach, A. M. Krieg, and H. L. Davis. 2005. Immunophenotyping profile of CPG10101, a new TLR9 agonist antiviral for hepatitis C, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  246. O'Brien, C., E. Godofsky, M. Rodriguez-Torres, N. Afdhal, S. C. Pappas, P. Pockros, E. Lawitz, N. Bzowej, V. K. Rustgi, M. S. Sulkowski, K. Sherman, I. M. Jacobson, G. Chao, S. Knox, K. Pietropaolo, and N. A. Brown. 2005. Randomized trial of valopicitabine (NM283), alone or with PEG-Interferon, vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: First interim results, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  247. Raison, C. L., C. M. Pariante, L. Capuron, B. Chen, B. J. Woolwine, C. Bruno, I. M. Jacobson, and A. H. Miller. 2005. The association of fatigue with poor virologic response in patients receiving interferon-alpha plus ribavirin for the treatment of hepatitis C, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  248. Ribeiro, R. M., A. H. Talal, K. A. Powers, M. Grace, C. Cullen, M. Hussain, and A. S. Perelson. 2005. Pharmacodynamic effects of pegylated interferon-a differentiate sustained virologic responders from nonresponders in hepatitis C virus/human immunodeficiency virus coinfected patients, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  249. Samstein, B., C. Kin, M. J. Goldstein, J. V. Guarrera, J. Renz, and J. Emond. 2005. parenchymally challenged donor grafts with equivalent outcomes to standard donor grafts or living donor grafts, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  250. Schackman, B. R., P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson. 2005. Quality of Life tradeoffs for hepatitis C treatment: Do patients and health professionals agree?, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  251. Seal, K. H., A. H. Kral, J. Lorvick, L. Gee, J. I. Tsui, and B. R. Edlin. 2005. Among injection drug users, interest is high, but access low to HCV antiviral therapy, Presented at the 28th Annual Meeting of the Society of General Internal Medicine, New Orleans.
  252. Shin, E.-C., U. Seifert, C. Rice, S. M. Feinstone, P. M. Kloetzel, and B. Rehermann. 2005. Proteosomal antigen-processing is regulated by cytokines of the innate immune response in acute HCV infection, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  253. Stange, J., T. I. Hassanein, R. Mehta, P. Lynch, F. S. Larsen, F. Tofteng, R. S. Brown Jr, B. McGuire, J. Gornbein, and A. Blei. 2005. Short-term survival of patients with severe intractable hepatic encephalopathy: The role of albumin dialysis, Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
  254. Tscherne, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating, and C. M. Rice. 2005. Hepatitis C virus is acid-resistant and requires activation prior to low pH-triggered entry, Presented at the Keystone Symposia - Cell Biology of Virus Entry, Replication and Pathogenesis, Santa Fe.
  255. Tscherne, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating, and C. M. Rice. 2005. Hepatitis C virus is acid-resistant but undergoes pH-dependent entry, Presented at the 12th International Meeting on Hepatitis C and Related Viruses, Montreal.
  256. Tseng, F. C., M. Zhang, A. Kral, T. M. Welzel, B. R. Edlin, and T. R. O'Brien. 2005. Relationship of chronic HBV infection, chronic HCV infection and duration of injection drug use, Presented at the Digestive Disease Week, Chicago.
  257. Zeng, S., N. Ippagunta, H. Dun, A. Schmidt, and J. C. Emond. 2005. RAGE-expressing mononuclear phagocyte derived dendritic cells in liver mediate upregulation of proinflammatory signals in massive liver injury, Presented at the 56th Annual Meeting of the American Association for the Study of LIver Disease, San Francisco.
  258. Zeremski, M., Q. Brown, G. Dorante, S. Cunningham-Rundles, and A. H. Talal. 2005. Prognostic value of IP-10 concentration for HCV treatment response in HIV/HCV coinfected patients, Presented at the Hepatitis Single Topic Conference, AASLD, Chicago.
  259. Zeremski, M., L. M. Petrovic, Q. Brown, L. Chiriboga, H. Yee, and A. Talal. 2005. CXCL10: An important determinant of inflammation in chronic HCV infection?, Presented at the 12th International Symposium on Hepatitis C and Related Viruses, Montreal.
  260. Afdhal, N., I. M. Jacobson, R. S. Brown Jr, B. Freilich, J. Santoro, L. H. Griffel, and Win-R Study group. 2006. The effect of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: Results from the WIN-R trial, Presented at the Digestive Disease Week, Los Angeles.
  261. Beeder, A. B., A. Martinez, E. Curet, A. Talal, I. M. Jacobson, and K. Alexander. 2006. Model for translational medicine in viral hepatitis and substance abuse treatment, Presented at the 5th International Conference on Urban Health, Amsterdam.
  262. Berg, C. L., B. W. Gillespie, R. M. Merion, R. S. Brown Jr, M. M. Abecassis, J. E. Everhart, J. H. Fair, R. A. Fisher, C. E. Freise, R. M. Ghobrial, A. Shaked, J. F. Trotter, and The A2ALL Study Group. 2006. Adult living donor liver transplantation reduces transplant candidate mortality, Presented at the World Transplant Congress, Boston.
  263. Brown Jr, R. S., I. M. Jacobson, N. Afdhal, B. Freilich, M. P. Pauly, F. Regenstein, S. Flamm, P. Y. Kwo, M. Becker, L. H. Griffel, and C. A. Brass. 2006. Risk factors for relapse in genotype 3 high viral load patients with hepatitis C in the WIN-R trial, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  264. Brown Jr, R. S., I. M. Jacobson, N. Afdhal, B. Freilich, F. Regenstein, S. Flamm, P. Y. Kwo, M. P. Pauly, L. H. Griffel, and C. Brass. 2006. Differences on treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial, Presented at the Digestive Disease Week, Los Angeles.
  265. Carden, M. R., B. R. Edlin, A. H. Talal, E. D. Getter, and M. Shu. 2006. Treatment for hepatitis C in active substance users, Presented at the 17th International Conference on the Reduction of Drug Related Harm, Vancouver.
  266. Carden, M. R., B. R. Edlin, A. H. Talal, E. V. Getter, and M. A. Shu. 2006. Hepatitis C treatment among community-recruited active drug users: Establishing a collaborative multidisciplinary model of care, Presented at the 6th Annual National Harm Reduction Conference, Oakland.
  267. Chang, K.-M., Y. Li, S. N. Issacs, L. U. Buxbaum, and C. M. Rice. 2006. Rose of hepatitis C virus gene expression on FOXP3-T cell induction in mice infected with recombinant vaccinia viruses, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  268. Conjeevaram, H. S., J. E. Everhart, N. Afdhal, R. S. Brown Jr, M. W. Fried, C. D. Howell, L. J. Jeffers, N. A. Terrault, T. E. Wiley, J. H. Hoofnagle, and A. Wahed. 2006. Changes in body weight and insulin sensitivity during and after peginterferon and ribavirin therapy of chronic hepatitis C, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  269. Everson, G. T., M. J. Tong, I. M. Jacobson, D. M. Jensen, A. A. Haller, G. M. Lauer, J. Parker, J. Ferraro, S. E. Cruickshank, R. C. Duke, D. Apelian, T. C. Rodell, and E. R. Schiff. 2006. Interim results from a randomized, double-blind, placebo-controlled phase 1B study in subjects with chronic HCV after treatment with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  270. Fallon, M. B., M. R. Arguedas, M. J. Krowka, V. H. Shah, R. S. Brown Jr, R. Shrestha, S. Zacks, K. Roberts, S. K. Olsen, D. Faulk, J. Reinen, and S. M. Kawut. 2006. Epidemiologic and clinical features of hepatopulmonary syndrome (HPS): Analysis from a prospective multicenter cross-sectional study of patients evaluated for liver transplantation, Presented at the Digestive Disease Week, Los Angeles.
  271. Fasola, C. G., T. G. Heffron, L. S. Sher, D. Douglas, R. S. Brown Jr, J. Ham, L. Teperman, M. Hanaway, D. E. Eckhoff, K. Washburn, M. Millis, J. Roberts, M. Charlton, P. Baliga, T. Pruett, B. Koneru, E. Pomfret, M. M. Abecassis, and G. B. Klintmalm. 2006. Multicenter randomized hepatitis C (HCV) - three trial post liver transplantation (OLT): Two-year interim report, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  272. Flamm, S. L., I. M. Jacobson, R. S. Brown Jr, B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, J. Harvey, L. H. Griffel, and C. A. Brass. 2006. Pegylated interferon alfa 2 B + ribavirin are equally efficacious and well tolerated in patients >65 years old in comparison to other age groups: Subanalysis of a randomized, controlled study (WIN-R trial), Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  273. Freilich, B., K.-Q. Hu, I. M. Jacobson, R. S. Brown Jr, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, E. Godofsky, R. Strauss, D. Bernstein, S. Flamm, N. Bala, V. Araya, L. H. Griffel, and C. A. Brass. 2006. Prospective analysis of sustained virologic response (SVR) to peg-interferon (Peg IFN) alfa 2-B and ribavirin treatment in Asian and Hispanic patients with chronic hepatitis C: Results from the WIN-R trial, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  274. Freise, C. E., B. W. Gillespie, A. J. Koffron, A. S. Lok, T. L. Pruett, J. C. Emond, J. H. Fair, R. A. Fisher, K. M. Olthoff, J. F. Trotter, R. M. Ghobrial, and The A2ALL Study Group. 2006. Comparison of complication rates in recipients of living donor and deceased donor liver transplants: Findings from the adult to adult living donor liver transplantation cohort study (A2ALL), Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  275. Gaglio, P. J., E. C. Verna, E. DeMartin, D. LaPointe-Rudow, J. Lefkowitch, J. Renz, J. Emond, and R. S. Brown Jr. 2006. Cholestatic hepatitis C in living versus deceased donor liver transplant recipients, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  276. Guarrera, J. V., B. Alkofer, B. Samstein, C. Kin, P. J. Gaglio, L. Dove, D. Jan, S. Lobritto, M. Kinkhabwala, R. S. Brown Jr, J. C. Emond, and J. F. Renz. 2006. Expanded criteria donor liver utilization: Who and when?, Presented at the World Transplant Congress, Boston.
  277. Guarrera, J. V., B. Arrington, M. Donovan, J. F. Renz, and R. S. Brown Jr. 2006. Early results of a phase 1 trial of hypothermic machine preservation in human liver transplantation, Presented at the World Transplant Congress, Boston.
  278. Jacobson, I., R. S. Brown Jr, B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, F. Ahmed, L. H. Griffel, C. A. Brass, and WIN-R Study Group. 2006. Stratification of high viral load: Impact on sustained virologic response in the WIN-R trial, Presented at the Digestive Disease Week, Los Angeles.
  279. Jacobson, I. M., R. S. Brown Jr, B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, A. E. Wakil, D. Pound, J. Harvey, L. H. Griffel, and C. A. Brass. 2006. Response to peginterferon alfa-2B and ribavirin for chronic hepatitis C in patients with body weight > 125 kg: Results from the WIN-R trial, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  280. Jacobson, I. M., R. Ghalib, E. Lawitz, B. Freilich, S. C. Gordon, P. Y. Kwo, T. R. Riley, D. Bright, M. L. Morris, M. Al-Adhami, J. L. Himes, F. E. Massari, and J. G. McHutchison. 2006. Early viral response and on treatment response to CPG10101 (Actilontm), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response., Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  281. Jacobson, I. M., P. Pockros, Y. Benhamou, R. Esteban-Mur, Y. Lurie, R. Flisiak, N. Afdhal, Y. Kim, Y. Xu, and B. Murphy. 2006. Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alfa-2B in the treatment of chronic HCV, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  282. Jones, K., A. Talal, S. Ferrando, and R. Peterson. 2006. High prevalence of fatigue and depression in HIV/Hepatitis C coinfected patients treated with pegylated interferon and ribavirin, Presented at the 2nd International Workshop on HIV & Hepatitis Coinfection, Amsterdam.
  283. Kadam, J. S., K. Jones, R. Peterson, L. Dove, D. Pearce, T. Hassanein, L. Doonquah, M. Glesby, L. Heller, D. Aboulafia, J. Rodriguez, H. Bonilla, J. Galpin, J. Aberg, B. Johnston, R. Liu, I. M. Jacobson, and A. H. Talal. 2006. Growth factors versus dose reduction for pegylated interferon alfa-2b and Ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients, Presented at the Digestive Disease Week, Los Angeles.
  284. Kaplan, T., A. Yee, J. Conry, A. Talal, and B. Merritt. 2006. Screening, diagnosis and treatment of hepatitis among homeless, substance abusing women, Presented at the 134th Annual Meeting of the American Public Health Association, Boston.
  285. Kinkhabwala, M., G. Davidzon, D. Lapointe-Rudow, R. S. Brown Jr, and J. C. Emond. 2006. Morbidity after liver donor hepatectomy based on Clavien scoring, Presented at the World Transplant Congress.
  286. Kinkhabwala, M., A. Mayerfield, C. Kin, J. C. Emond, P. J. Gaglio, and R. S. Brown Jr. 2006. Nonideal liver grafts are associated with higher rates of clinically significant recurrent hepatitis C, Presented at the World Transplant Congress, Boston.
  287. Kwo, P. Y., I. M. Jacobson, R. S. Brown Jr, B. Freilich, N. Afdhal, J. Santoro, S. Becker, A. E. Wakil, D. Pound, E. Godofsky, R. Strauss, D. Bernstein, S. Flamm, N. Bala, V. Arraya, M. Davis, H. Monsour, J. Vierling, F. Regenstein, V. Balan, M. S. Dragutsky, M. Epstein, R. W. Herring, L. H. Griffel, and C. Brass. 2006. Prior HCV treatment experience and its relationship to sustained virologic response (SVR): An analysis of the WIN-R study database, a US academic community based trial, Presented at the Digestive Disease Week, Los Angeles.
  288. Liu, Q., L. Chiriboga, H. Yee, M. Zeremski, A. H. Talal, and L. M. Petrovic. 2006. Increased expression of CXCR3 in acute allograft rejection following liver transplantation, Presented at the Annual Meeting of the American Society for Clinical Pathology, Las Vegas.
  289. Lorenz, I. C., T. G. Dentzer, J. Marcotrigiano, and C. M. Rice. 2006. Nonstructural Protein 2 is a dimer with a pair of composite cysteine protease active sites in mammalian cells, Presented at the 13th International Symposium on Hepatitis C Virus and Related Viruses, Cairns.
  290. Olsen, S. K., J. F. Renz, J. C. Emond, and R. S. Brown Jr. 2006. Lamivudine monotherapy prevents de novo hepatitis B in recipients of HBCAB (+) grafts: A retrospective analysis, Presented at the World Transplant Congress, Boston.
  291. Pauly, M. P., A. J. Sheinbaum, J. L. Szpakowski, J. B. Ready, R. S. Brown Jr, B. Freilich, N. Afdhal, P. Y. Kwo, J. Santoro, S. Becker, I. Jacobson, L. H. Griffel, and C. Brass. 2006. The influence of cigarette smoking on response to treatment with pegylated interferon alfa-2b and Ribavirin in patients with chronic hepatitis C, Presented at the Digestive Disease Week, Los Angeles.
  292. Petrovic, L. M., M. Zeremski, Q. Brown, L. Chiriboga, H. Yee, and A. H. Talal. 2006. CXCL10: An important determinant of inflammation in chronic HCV infection?, Presented at the 95th Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta.
  293. Pockros, P., C. O'Brien, E. Godofsky, M. Rodriguez-Torres, N. Afdhal, S. Pappas, E. Lawitz, N. Bzowej, V. K. Rustgi, M. S. Sulkowski, K. Sherman, I. M. Jacobson, G. Chao, S. Knox, K. Pietropaolo, and N. Brown. 2006. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to pegIFN/RBV: Week 24 results, Presented at the Digestive Disease Week, Los Angeles.
  294. Pruett, T. L., J. R. Freeman, P. S. Appelbaum, B. W. Gillespie, D. R. Armstrong, J. C. Emond, R. M. Weinrieb, D. C. Nixon, and The A2ALL Study Group. 2006. Use of a computerized assessment to measure patient competency to provide informed consent for living liver donation: Findings from the adult to adult living donor liver transplantation cohort study (A2ALL), Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  295. Samstein, B., B. Alkofer, J. V. Guarrera, J. Emond, R. S. Brown Jr, and J. F. Renz. 2006. Acceptances of EDC liver lowers wait list mortality, increases transplant access and decreases length of stay over waiting for standard graft., Presented at the World Transplant Congress, Boston.
  296. Shin, E.-C., K. Mihalik, S. M. Feinstone, C. M. Rice, and B. Rehermann. 2006. CD8 T cells are recruited to the liver in acute hepatitis C by HCV RNA-induced CXCR3- and CCR5 ligands, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  297. Verna, E. C., P. J. Gaglio, L. Dove, M. Kinkhabwala, J. Emond, and R. S. Brown Jr. 2006. Efficacy and safety of prolonged interferon and ribavirin for recurrent hepatitis C following orthotopic liver transplantation, Presented at the World Transplant Congress, Boston.
  298. von Hahn, T., M. J. Evans, A. J. Syder, T. Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2006. Identification of claudin-1 as an essential cellular cell entry factor for hepatitis C virus, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  299. You, S., and C. M. Rice. 2006. Functional characterization of the structural RNA elements in the genome of hepatitis C virus, Presented at the 71st Symposium: Regulatory RNAs, Cold Spring Harbor.
  300. Zeng, S., H. Dun, N. Ippagunta, S.-F. Yan, A. Schmidt, and J. C. Emond. 2006. Early growth response-1 is critical for rage mediated hepatic ischemia and reperfusion, Presented at the 57th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  301. Afdhal, N., C. O'Brien, E. Godofsky, M. Rodriguez-Torres, S. C. Pappas, E. Lawitz, P. Pockros, M. S. Sulkowski, I. M. Jacobson, G. Chao, S. Knox, K. Pietropaolo, N. A. Broan, and Valopiticitabine 04 Study Group. 2007. Valopiticitabine (MN283) alone or with peginterferon, compared to PEG interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: One year results, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  302. Al Sibae, M., I. S. Weisberg, A. H. Talal, and I. M. Jacobson. 2007. Frequency and significance of F-Actin antibodies (FAA) in HIV/HCV co-infected patients, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  303. Bavisotto, L., C. C. Wang, S. Gordon, I. M. Jacobson, P. Marcellin, S. Zeuzem, E. J. Lawitz, M. Lunde, P. Sereni, C. O'Brien, D. W. Oldach, and G. Rhodes. 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a Phase 1 trial in HCV genotype 1 infected subjects, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  304. Bavisotto, L., C. C. Wang, I. M. Jacobson, P. Marcellin, S. Zeuzem, E. J. Lawitz, M. Lunde, P. Sereni, C. O'Brien, D. W. Oldach, and G. Rhodes. 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase 1 trial in HCV genotype 1 infected subjects, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  305. Beeder, A. B., A. Martinez, E. Curet, A. Talal, I. M. Jacobson, and K. Alexander. 2007. Model for translational medicine in viral hepatitis and substance abuse treatment, Presented at the 18th International Confrerence on the Reduction of Drug Related Harm, Warsaw.
  306. Carden, M. R., and B. R. Edlin. 2007. Hepatitis C treatment among active drug users: Establishing a collaborative, multidisciplinary model of care, Presented at the 2nd National Conference on Methamphetamine, HIV and Hepatitis, Salt Lake City.
  307. Catanese, M. T., and et al. 2007. Analysis of functional hepatitis C virus E1 and E2 envelope glycoproteins representative of genotype 1 to 6.
  308. de la Fuente, C., M. J. Evans, and C. M. Rice. 2007. Identification of determinants involved in HCV replication and virus production, Presented at the 14th International Symposium on Hepatitis and Related Viruses, Glasgow.
  309. Dentzer, T. G., and et al. 2007. The role of hepatitis C virus nonstructural protein 2 in virus assembly, Scientific Meetings at CRP-Sante 2007, Luxemboug.
  310. Egorova, N. N., G. Greco, C. Fang, R. Krapf, and R. S. Brown Jr. 2007. Effect of medical errors (MEs) and complications on length of stay (LOS), Presented at the American Transplant Congress, San Francisco.
  311. Eng, F. J., L. K. McMullan, A. Klepper, M. J. Evans, C. M. Rice, S. M. Desai, and A. D. Branch. 2007. A novel IRES in the core-encoding region stimulates production of mini-core, a small protein comprised of the C-terminal portion of the core protein, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  312. Eng, F. J., L. K. McMullan, A. Klepper, M. J. Evans, C. M. Rice, S. M. Desai, and A. D. Branch. 2007. A novel IRES in the core-encoding region stimulates production of mini-core, a small protein comprised of the C-terminal portion of the core protein, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  313. Fallon, M. B., K. Roberts, M. J. Krowka, V. H. Shah, J. Trotter, D. B. Badesch, L. Forman, R. S. Brown Jr, D. Rabinowitz, S. Zacks, and S. M. Kawut. 2007. A multi-center case-control study of genetic predictors for hepatopulmonary syndrome (HPS), Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  314. Fink, S. A., E. C. Verna, P. J. Gaglio, J. F. Renz, J. Emond, and R. S. Brown Jr. 2007. Histologic recurrence of hepatitis C virus infection in Living and deceased donor liver transplant recipients: A protocol biopsy study, Presented at the American Transplant Congress, San Francisco.
  315. Gonda, T. A., S. Marukian, A. E. Iwamaye, E. D. Charles, A. Talal, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2007. Chronic HCV infection causes insulin resistance - A meta-analysis, Presented at the Digestive Disease Week, Washington DC.
  316. Gonda, T. A., S. Marukian, A. E. Iwamaye, E. D. Charles, A. Talal, I. M. Jacobson, C. M. Rice, and L. B. Dustin. 2007. Gene expression profiling of B cells in chronic hepatitis C, Presented at the Digestive Disease Week, Washington DC.
  317. Grossman, E., M. Gambarin-Gelwan, T. Hahambis, R. Yantiss, B. R. Edlin, and I. M. Jacobson. 2007. Inflammation and fibrosis in patients with chronic hepatitis B despite low viral load at the time of liver biopsy, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston.
  318. Guarrera, J. V., M. Kim, J. F. Renz, B. Arrington, Y. Chen, J. Meltzer, B. Samstein, S. Bellemare, L. E. Ratner, R. S. Brown Jr, J. C. Emond, M. Kinkhabwala, and H. T. Lee. 2007. Hypothermic machine preservation of human liver allografts: Markers of reperfusion injury, Presented at the American Transplant Congress, San Francisco.
  319. Gutierrez, J. A., A. Klepper, J. J. Garber, K. M. Bateman, J. L. Walewski, V. Khaitova, D. Jefferson, D. M. Tscherne, A. J. Syder, C. M. Rice, S. M. Desai, D. T. Dieterich, T. D. Schiano, and A. D. Branch. 2007. Selection instead of injection: A new method for producing antibodies for HCV studies, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  320. Harren, P., K. Ventura, M. Martinez, D. Jan, R. S. Brown Jr, and S. Lobritto. 2007. Treatment of hepatitis B using Introl A vs. peginterferon in combination with Lamivudine in children, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  321. Jacobson, I. M., G. T. Everson, S. C. Gordon, R. Kauffman, L. McNair, A. Muir, and J. G. McHutchison. 2007. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  322. Jacobson, I. M., G. T. Everson, S. C. Gordon, R. Kauffman, L. McNair, A. Muir, and J. G. McHutchison. 2007. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  323. Jones, C. T., C. L. Murray, D. K. Eastman, J. Tassello, and C. M. Rice. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus, Presented at the 14th International Symposium on HCV and Related Viruses, Glasgow.
  324. Klintmalm, G., C. G. Fasola, L. Jennings, T. G. Heffron, L. S. Sher, D. C. Mulligan, R. S. Brown Jr, J. Ham, L. Teperman, S. Rudich, D. E. Eckhoff, K. Washburn, M. Millis, J. P. Roberts, M. R. Charlton, P. Baliga, T. L. Pruett, E. Pomfret, B. Koneru, and M. M. Abecassis. 2007. Hepatitis C (HCV)-3 Study: Does immunosuppression (IS) affect the progression of fibrosis of HCV recurrence after liver transplantation (OLT)?, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  325. Kuntzen, T., A. Berical, A. M. Lennon, D. Heckerman, J. Timm, S. Adams, J. C. Schulze zur Wiesch, J. Carlson, S. K. Young, A. Y. Kim, C. Kadie, G. M. Lauer, F. M. Marincola, R. T. Chung, F. K. Bihl, A. Cerny, C. Brander, U. Spengler, B. W. Birren, B. D. Walker, G. Lake-Bakaar, E. S. Daar, I. M. Jacobson, E. D. Gomperts, B. R. Edlin, S. M. Donfield, A. Talal, T. N. Marion, M. R. Henn, and T. M. Allen. 2007. HLA class I associated sequence polymorphisms in HCV reveal reproducible patterns of immune escape - towards a comprehensive map of key residues for vaccine design, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  326. Kuntzen, T., A. Berical, N. Lennon, N. Heckerman, C. McMahon, J. Schulze Zur Wiesch, A. Kim, G. Lauer, The Swiss HCV Study Cohort, F. Bihl, A. Cerny, C. Brander, U. Spengler, Z. Liu, Y. Xing, M. A. Madey, J. F. Fleckenstein, V. M. Park, C. A. Riely, B. Birren, B. D. Walker, G. V. Lake-Bakaar, E. S. Daar, I. M. Jacobson, E. D. Gomperts, B. R. Edlin, S. M. Donfield, A. H. Talal, T. Marion, M. Henn, and T. A. Allen. 2007. HLA class I associated sequence polymorphisms in HCV reveal reproducible patterns of immune escape-towards a comprehensive map of key residues for vaccine design, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  327. Lai, J. C., J. Emond, and R. S. Brown Jr. 2007. Transplant costs of adult living donor liver transplantation at an experienced transplant center are similar to deceased donor liver transplantation, despite increased surgical costs, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  328. Lai, J. C., A. Montero, B. Lebwohl, and R. S. Brown Jr. 2007. Length of stay in patients with decompensated liver disease: Impact of a specialized housestaff hepatology service, Presented at the American Transplant Congress, San Francisco.
  329. Lake-Bakaar, G., I. M. Jacobson, and M. Al Sibae. 2007. Clinical spectrum of chronic hepatitis C virus-related cryoglobulinemia in the US, Presented at the Digestive Disease Week, Washington DC.
  330. Lake-Bakaar, G., A. Lin, P. Tsang, A. Talal, I. M. Jacobson, R. Uppal, and R. Petersen. 2007. B-cell activating factor (baff/blys) and response to interferon based therapy in chronic hepatitis C virus infection, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease Boston.
  331. Law, J., J. W. Carroll, C. M. Rice, and M. R. MacDonald. 2007. Characterization of CCCH domains in Zinc-finger antiviral protein (ZAP) and its effect on Sindbis virus replication, Presented at the 8th International Symposium on Positive Strand RNA Viruses, Washington DC.
  332. McHutchison, J. G., G. T. Everson, S. Gordon, I. M. Jacobson, R. Kauffman, L. McNair, and A. Muir. 2007. Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon alfa-2A and ribavirin in previously untreated subjects with hepatitis C, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  333. McMullan, L. K., M. J. Evans, and C. M. Rice. 2007. A conserved RNA element in the capsid gene impacts hepatitis C virus replication and translation, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  334. Merion, R. M., T. H. Shearon, C. L. Berg, J. E. Everhart, M. M. Abecassis, A. Shaked, R. A. Fisher, J. Trotter, R. S. Brown Jr, N. Terrault, P. H. Hayashi, R. M. Ghobrial, and The A2ALL Study Group. 2007. Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  335. Murray, C. L., C. T. Jones, J. Tassello, and C. M. Rice. 2007. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus, Presented at the 14th International Symposium on HCV and Related Viruses, Glasgow.
  336. Petrovic, L. M., L. Chiriboga, M. Zeremski, Q. Liu, and A. H. Talal. 2007. Expression of CXCR3 and IP-10 in recurrent hepatitis C following liver transplantation, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  337. Schiff, E. R., G. T. Everson, N. Tsai, N. H. Bzowej, R. G. Gish, J. G. McHutchison, I. M. Jacobson, M. J. Tong, D. M. Jensen, G. M. Lauer, S. E. Cruickshank, J. Ferraro, A. Haller, R. Duke, T. Rodell, and D. Apelian. 2007. HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: A randomized, double-blind, placebo controlled phase 1B study, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  338. Shah, M. B., R. S. Brown Jr, T. Barski, B. Freilich, R. A. Levine, and N. Afdhal. 2007. Tolerability of low-dose peginterferon alfa-2B in hepatitis C patient with cirrhosis: Results from the CoPILOT trial, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  339. Shah, M. B., R. S. Brown Jr, I. S. Weisberg, A. H. Talal, and I. M. Jacobson. 2007. Frequency and significance of F-Actin antibodies (FAA) in HIV/HCV coinfected patients, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  340. Shiffman, M. L., R. Ghalib, E. Lawitz, B. Freilich, S. C. Gordon, P. Y. Kwo, R. T. Riley, E. Schiff, S. Flamm, I. M. Jacobson, N. N. Zein, A. Reuben, M. Swim, D. Bright, M. Al-Adhami, J. A. Lekstrom-Himes, F. E. Massari, and J. G. McHutchison. 2007. CPG 10101 (Actilon) in combination with pegylated interferon and/or ribavirin in chronic HCV genotype 1 infected patients with prior relapsed response: Week 48 data, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  341. Siegel, A. B., R. B. McBride, H. B. El-Serag, L. Zablotska, D. Hershman, R. S. Brown Jr, and A. I. Neugut. 2007. The risk of hepatocellular carcinoma in patients with previous malignancy, Presented at the Gastrointestinal Cancers Symposium, American Society of Clinical Oncology.
  342. Verna, E. C., E. DeMartin, P. Burra, P. J. Gaglio, D. Neri, J. C. Emond, and R. S. Brown Jr. 2007. The impact of hepatitis C and extrahepatic biliary obstruction on patient and graft survival following liver transplantation, Presented at the American Transplant Congress, San Francisco.
  343. You, S., and C. M. Rice. 2007. Dissecting the tertiary RNA structure at the 3' end of the hepatitis C virus genome important for RNA replication, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  344. You, S., T. L. Tellinghuisen, J. Marcotrigiano, and C. M. Rice. 2007. Investigation of the RNA binding activity of hepatitis virus nonstructural protein NS5A, Presented at the 14th International Symposium on Hepatitis C and Related Viruses, Glasgow.
  345. Yu-Inductivo, I., D. Dreizin, R. Gish, A. Talal, and M. Bonacini. 2007. Predictive value for low level hepatic fibrosis in chronic hepatitis C (CHC) patients: Comparison of five non-invasive indices, Presented at the 42nd Annual Meeting of the European Association for the Study of Liver, Barcelona.
  346. Yu-Inductivo, I., D. Dreizin, A. Talal, R. Gish, and M. Bonacini. 2007. Predictive value for low-level hepatic fibrosis in chronic hepatitis C (CHC) patients: Comparison of five non-invasive indices, Presented at the Digestive Disease Week, Washington DC.
  347. Zeng, S., H. Dun, N. Ippagunta, R. H. Rosaria, A. Schmidt, and J. C. Emond. 2007. Distinct effects of RAGE and MYD88 signaling in massive hepatectomy, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  348. Zeremski, M., Q. B. Brown, M. A. Shu, B. R. Edlin, and A. H. Talal. 2007. HCV-specific cellular responses in antibody negative, HCV RNA negative injection drug users, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  349. Basu, P. P., K. Rayapudi, J. Estevez, and R. S. Brown Jr. 2008. A pilot study utilizing nitazoxanide for hepatic encephalopathy in chronic liver failure, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  350. Carden, M. R., B. R. Edlin, A. H. Talal, and B. Getter. 2008. Hepatitis C treatment outcomes among persons who use drugs recruited from community based needle exchange programs, Presented at the 7th National Harm Reduction Conference, Miami.
  351. Carden, M. R., B. R. Edlin, A. H. Talal, and E. V. Getter. 2008. Treating hepatitis C in people actively using drugs: Using a collaborative multidisciplinary model of care, Presented at the 19th International Conference on the Reduction of Drug Related Harm, Barcelona.
  352. Charles, E. D., S. Marukian, K. D. Ritola, M. Gambarin-Gelwan, A. H. Talal, and I. M. Jacobson. 2008. Gene expression analysis of IgM+kappa+CD27+ B cells in patients with HCV-associated mixed cryoglobulinemia, Presented at the 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio.
  353. Dentzer, T. G., and et al. 2008. Role of hepatitis C virus non-structural protein 2 in virus assembly, 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio.
  354. Dentzer, T. G., and et al. 2008. Role of hepatitis C virus nonstructural protein 2 in virus assembly, 4th VIRGIL Internaltional Symposium on Antiviral Drug Resistance, Lyon.
  355. Dove, L. M., R. C. Rosen, D. Ramcharran, A. S. Wahed, S. H. Belle, R. S. Brown Jr, and J. H. Hoofnagle. 2008. Decline in sexual desire, function and satisfaction in men during peginterferon and ribavirin therapy for chronic hepatitis C, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  356. Eng, F. J., A. L. Klepper, J. L. Walewski, L. K. McMullan, M. J. Evans, C. M. Rice, S. M. Desai, and A. D. Branch. 2008. Infectious HCV produces a family of minicore proteins, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  357. Everson, G. T., I. M. Jacobson, S. C. Gordon, J. G. McHutchison, R. Kauffman, L. McNair, and A. Nuir. 2008. Prove1: Results from a phase 2 study of telaprevir with peginterferon alfa-2b and ribavirin in the treatment-naive subjects with hepatitis C, Presented at the Digestive Disease Week, San Diego.
  358. Fallon, M. B., R. Tanikella, G. Philips, S. M. Kawut, M. J. Krowka, R. S. Brown Jr, J. F. Trotter, S. Zacks, K. E. Roberts, V. Shah, N. Kaplowitz, L. Forman, K. M. Wille, and M. Mohd. 2008. Health related quality of life predicts survival in liver transplant candidates, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  359. Fink, S. A., E. C. Verna, E. De Martin, P. Burra, P. Gaglio, J. C. Emond, and R. S. Brown Jr. 2008. Impact of weight and body mass index on biliary complications, graft loss, rejection, and survival post orthotopic liver transplantation, Presented at the American Transplant Congress, Toronto.
  360. Gane, E. J., M. Rodriguez-Torres, D. R. Nelson, I. M. Jacobson, J. G. McHutchison, L. Jeffers, A. Beard, S. Walker, N. Shulman, W. T. Symonds, E. Albanis, and M. M. Berrey. 2008. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: Interim results of R7128 1500 mg bid with PEG-IFN and ribavirin for 28 days, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  361. Gillespie, B. W., R. M. Merion, A. O. Ojo, A. Shaked, R. S. Brown Jr, C. A. Nielsen, C. L. Berg, E. Ortiz-Rios, M. M. Abecassis, A. S. Ashworth, C. E. Freise, R. M. Ghobrial, J. F. Trotter, and J. E. Everhart. 2008. Comparison of patient information in the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the scientific registry of transplant recipients (SRTR) database, Presented at the American Transplant Congress, Toronto.
  362. Goldstein, M. J., A. Rana, J. V. Guarrera, B. Samstein, R. S. Brown Jr, and J. C. Emond. 2008. Early access to liver transplantation reduces 5 year mortality despite differences in donor quality, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  363. Guarrera, J. V., B. Arrington, B. Samstein, J. F. Renz, L. E. Ratner, R. S. Brown Jr, H. T. Lee, and J. C. Emond. 2008. Machine preservation of liver allografts for transplantation: Updated results of a phase 1 clinical trial, Presented at the American Transplant Congress, Toronto.
  364. Halazun, K. J., M. A. Hardy, A. A. Rana, D. C. Woodland, A. B. Seigal, R. S. Brown Jr, and J. Emond. 2008. Elevated preoperative neutrophil to lymphocyte ratio predicts outcome in patients with hepatocellular carcinoma (HCC) after liver transplantation (LT), Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  365. Heathcote, E. J., P. Marcellin, I. M. Jacobson, M. L. Schiffman, H. N. Trinh, K. J. Peschell, D. Goodwin, J. Sorbel, E. A. Fagan, and F. Rousseau. 2008. Limited value of single ALT determination for assessing chronic hepatitis B, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  366. Jensen, G. S., N. Terrault, A. T. Blei, R. M. Merion, B. W. Gillespie, J. E. Everhart, R. S. Brown Jr, K. M. Olthoff, P. H. Hayashi, C. L. Berg, R. A. Fisher, and J. F. Trotter. 2008. Long-term follow-up of laboratory values in right hepatic lobe liver donors following donation: The A2ALL experience, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  367. Karkhanis, J., W. M. Lee, and R. S. Brown Jr. 2008. Steroid use in drug induced and cryptogenic causes of acute liver failure, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  368. Klintmalm, G., C. G. Fasola, L. Jennings, T. G. Heffron, L. S. Sher, D. C. Mulligan, D. D. Douglas, R. S. Brown Jr, J. M. Ham, L. W. Teperman, S. M. Rudich, D. E. Eckhoff, K. Washburn, M. Millis, J. P. Roberts, M. R. Charlton, P. Baliga, T. L. Pruett, B. Koneru, E. A. Pomfret, and M. M. Abecassis. 2008. Hepatitis C (HCV) - 3 study: severe HCV recurrence (R) post liver transplantation (OLT) is decreased in patients treated with mycophenolate mofetil (MMF), particularly, in the absence of steroids (PRED), Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  369. Kopp, M., and et al. 2008. Amino acids in the C-terminus of HCV core protein are required for core stability and production of infectious virus, Presented at the 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio.
  370. Kuntzen, T., J. Timm, A. Berical, A. M. Berlin, C. Oniangue-Ndza, B. Lee, D. Heckerman, J. Carlson, H. R. Rosen, F. K. Bihl, A. Cerny, U. Spengler, Z. Liu, Y. Xing, M. A. Madey, J. F. Fleckenstein, V. M. Park, C. A. Riely, G. Lake-Bakaar, E. S. Daar, I. M. Jacobson, E. D. Gomperts, B. R. Edlin, S. M. Donfield, R. T. Chung, A. Talal, T. Marion, B. W. Birren, M. R. Henn, and T. M. Allen. 2008. Naturally occurring STAT-C resistance mutations in treatment-naive HCV infected patients - an international multi-center study, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  371. Kwo, P. Y., E. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, M. David, J. Galati, S. Gordon, N. Ravendhran, L. Rossaro, F. Anderson, I. M. Jacobson, R. Rubin, P. Mukhopadhyay, E. Chaudhri, L. D. Pedicone, and J. K. Albrecht. 2008. Interim results from HCV spring-1: RVR/EVR from phase 2 study of boceprevir plus pegintrontm (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 CHC, Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  372. Kwo, P. Y., E. Lawitz, J. McCone, E. R. Schiff, J. M. Vierling, D. Pound, M. Davis, J. S. Galati, S. C. Gordon, N. Ravendhran, L. Rossaro, F. H. Anderson, I. M. Jacobson, R. Rubin, K. Koury, E. I. Chaudhri, and J. K. Albrecht. 2008. HCV Sprint-1: Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  373. Lake-Bakaar, G., A. Lin, I. M. Jacobson, and A. Talal. 2008. B-cell activating factor (BAFF/BLYS) plays an important role in the natural history of chronic hepatitis C virus infection, Presented at the Digestive Disease Week, San Diego.
  374. Lalezari, J., E. J. Gane, M. Rodriguez-Torres, E. DeJesus, D. B. Nelson, G. T. Everson, I. M. Jacobson, R. Reddy, G. Z. Hill, A. Beard, W. T. Symonds, M. M. Berrey, and J. G. McHutchison. 2008. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: Interim results of R7128 500 mg bid for 28 days, Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  375. Lawitz, E. J., M. S. Sulkowski, I. M. Jacobson, S. Faruqui, W. K. Kraft, B. Maliakkal, M. Al-Ibrahim, R. H. Ghalib, S. C. Gordon, P. Y. Kwo, J. Rockstroh, M. Miller, P. Hwang, J. Gress, and E. Quirk. 2008. Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  376. Lindsay, K. L., M. P. Manns, S. C. Gordon, P. Pockros, D. Haussinger, S. Hadziyannis, W. N. Schmidt, I. M. Jacobson, R. Barcena, E. Schiff, O. S. Shaikh, B. R. Bacon, P. Marcellin, C. I. Smith, J. G. McHutchison, W. Peng, L. D. Pedicone, and J. K. Albrecht. 2008. Clearance of HCV at 5 year follow-up for peginterferon alfa-2b +/- ribavirin is predicted by sustained virologic response at 24 weeks post treatment, Presented at the Digestive Disease Week, San Diego.
  377. Lok, A. S. F., S.-H. B. Han, E. R. Schiff, R. S. Brown Jr, S. Emre, C. Soldevila-Pico, K. R. Reddy, M. Ishitani, E. B. Keeffe, V. Luketic, and B. Degertekin. 2008. HBV recurrence rate post-liver transplantation (OLT) and associated factors: Results of the NIH-HBV-OLT Study, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  378. Mann, M., K. L. Lindsay, S. C. Gordon, P. J. Pockros, D. Haeussinger, S. Hadziyannis, W. N. Schmidt, I. M. Jacobson, R. Barcena, E. Schiff, O. S. Shaikh, B. R. Bacon, P. Marcellin, C. Smith, J. G. McHutchison, W. Deng, L. D. Pedicone, and J. K. Albrecht. 2008. Sustained virologic response after peginterferon alfa-2b and ribavirin treatment predicts long-term clearance of HCV at 5-year follow-up, Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  379. Manns, M. P., D. Hueppe, P. Marotta, S. Mauss, E. Zehnter, I. M. Jacobson, and C. Kambili. 2008. Sustained virologic response and relapse rates with peginterferon alfa-2b plus ribavirin in clinical trails are comparable to those in community-based studies, Presented at the Digestive Disease Week, San Diego.
  380. Marcellin, P., I. M. Jacobson, F. Habersetzer, H. Senturk, P. Andreone, C. D. Moyes, A. Horban, G. Teuber, J. Sorbel, J. Anderson, E. Mondou, J. Quinn, and F. Rousseau. 2008. Tenofovir dispoproxil fumarate (TDF) for the treatment of HBEAG - negative chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102), Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  381. Marcellin, P., I. M. Jacobson, N. Tsai, N. Bzowej, F. Habersetzer, H. Senturk, C. D. Moyes, P. Teuber, J. Sorbel, J. Anderson, E. Mondou, J. Quinn, and F. Rousseau. 2008. Tenofovir disoproxil fumarate (TDF) for the treatment of HBEAG - negative chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102), Presented at the Digestive Disease Week, San Diego.
  382. Marukian, S., K. D. Ritola, E. D. Charles, I. M. Jacobson, A. H. Talal, C. M. Rice, and L. B. Dustin. 2008. Lack of evidence for HCV infection of immune cells in vitro or in vivo, Presented at the 15th International Symposium on Hepatitis C and Related Viruses, San Antonio.
  383. McHutchison, J. G., G. T. Everson, S. C. Gordon, I. M. Jacobson, R. Kauffman, L. McNair, and A. Nuir. 2008. Prove 1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment naive subjects with hepatitis C, Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  384. McHutchison, J. G., E. J. Lawitz, J. M. Vierling, G. T. Everson, I. M. Jacobson, M. L. Shiffman, T. D. Boyer, E. R. Schiff, S. E. Cruickshank, T. C. Rodell, and D. Apelian. 2008. GI5005 Immunotherapy plus PEGIFN/Ribavirin in genotype 1 chronic hepatitis C patients compared to PEGIFN/ribavirin alone in naive and nonresponder patients: Preliminary RVR and viral kinetic analysis from the GI5005-02 phase 2 study, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  385. McHutchison, J. G., M. L. Shiffman, N. Terrault, M. P. Manns, A. M. Di Bisceglie, I. M. Jacobson, N. H. Afdhal, E. J. Heathcote, S. Zeuzem, H. W. Reesink, S. George, N. Adda, and A. J. Muir. 2008. A phase 2B study of telaprevir with peginterferon-alfa 2A and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa 2A/B and ribavirin therapy: Prove3 interim results, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  386. Metz, Y., K. Kulkarni, M. Gambarin-Gelwan, and I. M. Jacobson. 2008. Hepatitis A and B immunization practices among community physicians of chronic hepatitis C patients, Presented at the Digestive Disease Week, San Diego.
  387. Moss, J. L. G., A. Siegel, E. Lim, V. Khungar, L. Feerante, J. Yu, S. Scrudato, D. Lapointe-Rudow, J. Renz, J. Emond, and R. S. Brown Jr. 2008. Selected tumors outside Milan criteria achieve equivalent outcomes regardless of transplant type, Presented at the American Transplant Congress, Toronto.
  388. Muir, A. J., E. J. Lawitz, J. G. McHutchison, S. C. Gordon, I. M. Jacobson, B. S. Adiwijaya, L. Bengtsson, L. McNair, and M. Rodriguez-Torres. 2008. Viral responses in African-Americans, Latinos and Caucasians in the US phase 2 study (Prove 1) of telaprevir with peginterferon alfa - 2A and ribavirin in treatment naive genotype 1 infected subjects with hepatitis C, Presented at the 59th Annual Meeting of the American Association for the Study of LIver Disease, San Francisco.
  389. Pockros, P., I. M. Jacobson, B. R. Bacon, N. H. Afdhal, F. Poordad, E. Chun, and J. Hammond. 2008. Taribavirin exposure analysis from a previous phase 3 trial correlates with phase 2B weight based dosing interim results, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  390. Reinen, J. M., R. S. Brown Jr, M. B. Fallon, J. F. Trotter, M. Krowka, S. Zacks, N. Kaplowitz, and S. M. Kawut. 2008. Predictors of health-related quality of life (HRQOL) in liver transplant candidates with hepatitis C (HCV), Presented at the American Transplant Congress, Toronto.
  391. Ritola, K. D., C. M. Rice, and L. B. Dustin. 2008. Differences in the virus production from HCV specific inhibitor resistant virus, Presented at the 15th International Symposium on Hepatitis C and Related Viruses, San Antonio.
  392. Ritola, K. D., M. D. Sneller, C. M. Rice, and L. B. Dustin. 2008. Convergent and divergent HVR1 evolution following B-cell depletion in HCV patients with mixed cryoglobulinemia, Presented at the 15th International Symposium on Hepatitis C and Related Viruses, San Antonio.
  393. Rodriguez-Torres, M., J. Lalezari, E. J. Gane, E. DeJesus, D. R. Nelson, G. T. Everson, I. M. Jacobson, K. R. Reddy, J. G. McHutchison, A. Beard, S. Walker, W. T. Symonds, and M. M. Berrey. 2008. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: Subanalysis by race/ethnicity, weight and HCV genotype, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  394. Schiff, E., F. Poordad, I. M. Jacobson, S. Flamm, B. R. Bacon, E. Lawitz, S. Gordon, J. McHutchison, R. Ghalib, T. Poynard, M. S. Sulkowski, C. Trepo, M. Rizetto, S. Zeuzem, P. Marcellin, P. Mendez, and C. A. Brass. 2008. Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness, Presented at the 43rd Annual Meeting of the European Association for the Study of Liver, Milan.
  395. Schiff, E., F. Poordad, I. M. Jacobson, S. L. Flamm, B. R. Bacon, E. J. Lawitz, S. R. Gordon, J. G. McHutchison, R. Ghalib, T. Poynard, M. S. Sulkowski, C. Trepo, M. Rizetto, S. Zeuzem, P. Marcellin, T. P. Mendez, and C. A. Brass. 2008. Role of interferon response during retreatment of null responders with boceprevir combination therapy: Results of phase II trial, Presented at the Digestive Disease Week, San Diego.
  396. Sher, L., J. Almeda, G. Netto, L. Teperman, S. Rudich, M. Kinkhabwala, and R. S. Brown Jr. 2008. The impact of liver donor liver transplantation on hepatitis C recurrence, Presented at the American Transplant Congress, Toronto.
  397. Sherman, M., M. Rizetto, C. L. Lai, Y.-F. Liaw, A. Gadano, I. M. Jacobson, E. R. Schiff, J. Yang, R. Colonno, B. Kreter, and R. Hindes. 2008. Long-term follow-up of entecavir treated protocol-defined non-responders in rollover study ETC-901, Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease, Boston.
  398. Tanikella, R., G. Philips, S. M. Kawut, M. J. Krowka, R. S. Brown Jr, J. F. Trotter, S. Zacks, K. E. Roberts, V. Shah, N. Kaplowitz, L. Forman, K. M. Wille, and M. B. Fallon. 2008. Circulating cytokines in hepatopulmonary syndrome (HPS): The pulmonary vascular complications of liver disease study, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  399. Verna, E. C., A. Balducci, E. Pichardo, J. C. Emond, and R. S. Brown Jr. 2008. Basiliximab and delayed calcineurin inhibitor for induction immunosuppression in liver transplants recipients with pos-operative renal insufficiency, Presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco.
  400. Verna, E. C., E. M. Pichardo, J. C. Emond, and R. S. Brown Jr. 2008. Low dose slowly tapered steroids for immunosuppression in hepatitis C virus infected liver transplant recipients, Presented at the American Transplant Congress, Toronto.
  401. You, S., J. Law, M. R. MacDonald, and C. M. Rice. 2008. Factor(s) in microRNA machinery are involved in innate immunity against RNA viruses, 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio.
  402. Zeremski, M., Q. B. Brown, R. Dimova, I. M. Jacobson, M. Markatou, and A. H. Talal. 2008. CXCL10 as biomarker of hepatic fibrosis in HCV infection, Presented at the 15th International Symposium on Hepatitis C and Related Viruses, San Antonio.
  403. Duddempudi, A. T., Y. Metz, M. Gambarin-Gelwan, B. R. Edlin, A. H. Talal, K. M. Marks, T. H. Hahambis, R. Yantiss, and I. M. Jacobson. 2009. Non-invasive hepatic fibrosis assay scores increase with increasing age in patients with chronic hepatitis C, Presented at the Digestive Disease Week, Chicago.
  404. Martinez, A. D., R. Dimova, A. B. Beeder, M. Zeremski, M. J. Kreek, and A. H. Talal. To be presented 2009. The integrated addiction medicine-hepatology model for management of hepatitis C virus infection among individuals in treatment for drug dependency, Presented at the 13th International Symposium on Viral Hepatitis and Liver Disease, Washington DC.
  405. Zeremski, M., R. K. Yantiss, J. S. Kadam, S. Cheruvu, I. M. Jacobson, H. Faruki, and A. H. Talal. To be presented, 2009. Use of fibrosure as a noninvasive marker of inflammation and fibrosis in hepatitis B virus infection, Presented at the 13th International Symposium on Viral Hepatitis and Liver Disease, Washington DC.